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Abstract 
 
The gut bacterial community plays a vital role in human health with a diverse and 
complex composition, sculpted by complex host – microbe interactions. Neonates born 
prematurely are vulnerable to various infections due to their weak immune system and 
the immaturity of the gut. The most significant diseases are necrotising enterocolitis 
(NEC) and sepsis. With the advent of molecular techniques the development of the 
microbial community were better characterised. Leading to better understanding of the 
microbial contribution to preterm diseases and how clinical and dietary interventions can 
be tailored to reduce their incidence. The  aimed was to study the impacts of clinical and 
dietary interventions on the community structure and function of the preterm gut 
microbiota by using high throughput molecular techniques. 
The microbial communities derived from clinical samples that are implicated in 
gastrointestinal disease were explored. By utilising ecological theory, high-throughput 
sequencing, metabolomic profiling, and statistical modelling to identify how the 
assembly, phylogenetic diversity, and overall function of these communities impact on 
disease state. The comparison of archeal and fungal diversity between preterm infants 
diagnosed with NEC and/or sepsis, compared to healthy controls, showed no significant 
differences in the community profiles between health and disease. To study if microbial 
load was associated with NEC, independent of community profiles, total bacterial load 
was quanitified temporally in NEC infants and matched. The results showed no 
significant differences in the bacterial load between NEC samples before or at diagnosis, 
compared to healthy controls, with the only difference occurring following diagnosis, 
with NEC samples showing significant reduced bacterial load 
To better understand clinical intervention in shaping the developing microbial community 
and the resulting contribution to NEC and sepsis disease mechanisms, the commonly 
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administered antibiotics and probiotic supplementation were investigated. The result of 
the findings confirm existing publications, showing probiotic species administered to 
preterm infants significantly reduce the abundance of potentially pathogenic bacteria 
associated with NEC and LOS. In the first study of its kind, the study followed the same 
neonates longitudinally through probiotic administration, including post discharge 
several months after cessation. Crucially, this novel analysis revealed that supplemented 
bifidobacteria was able to colonise the gut long-term, but supplemented Lactobacilli did 
not. As well as changes in the bacterial profiles, further metabolomic profiling of 
functional small molecules confirmed that probiotic supplementation caused functional 
changes in the preterm gut microbiota. Antibiotic administration represents the most 
important element of current clinical practise that causes profound shifts in the gut 
microbiota. To further explore the routinely used antibiotics in neonatal intensive care 
units and to what extent this intervention alters the preterm gut microbiome, the infants 
were followed temporally through different antibiotic courses. This revealed that 
antibiotics differentially affected the preterm gut microbiome, with no single combination 
found to cause consistent changes between individuals. At a time when antibiotic use is 
under scrutiny, the outcomes show that much greater understanding of the short and long-
term effects on the developing microbiome is necessary. 
This thesis has combined a range of molecular methods to explore the microbial 
community in the developing preterm gut microbiota, including bacteria, fungi, and 
archaea, finding no association in pathogenesis of NEC. Metabolite profiling was also 
performed, determining how changes in the gut microbiota cause functional changes in 
the gut. Combining the data from these powerful analyses revealed probiotics help to 
modulate a healthy gut microbiome, but antibiotics may disturb the developing bacterial 
community. Ultimately, better understanding of the consequences of clinical intervention 
will lead to more refined and personalised care.  
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1 CHAPTER ONE:  Introduction 
 
“Molecular biology has shown that even the simplest of all living systems on the earth 
today, bacterial cells, are exceedingly complex objects. Although the tiniest bacterial 
cells are incredibly small, weighing less than 10-12 gms, each is in effect a veritable 
micro-miniaturized factory containing thousands of exquisitely designed pieces of 
intricate molecular machinery, made up altogether of one hundred thousand million 
atoms, far more complicated than any machine built by man and absolutely without 
parallel in the non-living world.”  
― Michael Denton, Evolution: A Theory in Crisis 
 
 Preterm/prematurity 
 
Neonates born at less than 37 weeks gestational age (GA) are said to be ‘preterm’ or 
exhibit the condition known as ‘prematurity’ (Goldenberg et al. 2009; Yeast & Lu 2007; 
Tucker & McGuire 2004). Preterm infants can be considered as early preterm (when born 
at less than 34 weeks GA) and late preterm (when born at 34 – 36 weeks GA) (Engle et 
al. 2007; Shapiro-Mendoza & Lackritz 2012). Preterm delivery is one of the leading 
causes of morbidity and mortality among the neonates in most developed countries 
(Goldenberg et al. 2009). 
The possible causes of preterm delivery include: eclampsia and intrauterine growth 
restriction; Preterm premature rupture of the membrane (PPRM) (which accounts for 24% 
- 30% of such births) , delivery for maternal or fetal indications (30% -35% of the births) 
(Goldenberg et al. 2008; Ransom & Murtha 2012), and spontaneous preterm labour with 
intact membranes (40% - 45% of births) (Goldenberg & Mcclure 2010; Goldenberg et al. 
2009). However, preterm labour can also be triggered by other factors including 
infections, haemorrhage, stress and immunological conditions (Sayres 2010).  The 
number is higher in black women, those with previous preterm births, low maternal body-
mass index and periodontal diseases can also be considered among the risk factors 
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responsible for spontaneous preterm delivery (Goldenberg et al. 2008; Goldenberg & 
Mcclure 2010). Additionally, poor nutritional status, low socio-economic status, multiple 
deliveries preceding infertility treatment can also increase risk factor  (Van Den Broek et 
al. 2014; Behrman & Butler 2007; Goldenberg & Mcclure 2010), vaginal bleeding have 
also been reported as important risk factors resulting in prematurity (Goldenberg & 
Mcclure 2010; Sayres 2010; Behrman & Butler 2007). Severe illness from gut bacteria 
has also been associated to prematurity (Warner et al. 2016). 
The cost implications to parents, social and health services for caring the neonates born 
prematurely also contribute toward the economics importance in prematurity (Blencowe 
et al. 2013; Tucker & McGuire 2004). Many interventions have been demonstrated to 
improve the health and reduce the incidence of preterm birth including ; smoking 
termination, progesterone therapy and cervical cerclage as well as other postnatal 
intervention (Simmons et al. 2010; Sayres 2010; Ransom & Murtha 2012; 
Wisanskoonwong et al. 2011). 
   
  Preterm infant infections 
 
There are many infections related to prematurity including urogenital infections (Agger 
et al. 2014) and acute respiratory infections that account for most of the clinical disorders 
among the neonates born prematurely (Altman et al. 2013). 
Neonates borne prematurely are vulnerable to infections due to their immature immune 
system  (Groer et al. 2014) and other factors associated with their physiological 
environment (Sim et al. 2014). Necrotising enterocolitis (NEC) and sepsis are the most 
significant causes of morbidity and mortality among the preterm (Grishin et al. 2016; Ng 
et al. 2007). The sepsis has been classified in to two diseases states with different 
aetiological causes; these are: early onset infection and late on-set infection (QiLi et al. 
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2014). There are many factors that can influence the onset of neonatal infections among 
the preterm including: diet, age and other physiological functions (Lafeber et al. 2008). 
Moreover, a recent research shows that beneficial microbes were not fully established in 
the gut of preterm infants as such exposed them to infections (Singh, Brian Firek, et al. 
2015). 
 Necrotising enterocolitis (NEC) 
 
Necrotising enterocolitis is a life threatening infection that occurs when intestinal tissue 
becomes damaged and starts to die. NEC normally affects the premature babies within 
two weeks of delivery (Remon et al. 2014). In a serious case, a hole may appear in the 
intestinal wall enables bacteria to pass in to the abdomen to spread the infection (Jakaitis 
& Denning 2014; Fox & Godavitarne 2012). The timing of the onset of NEC is inversely 
proportional to the gestational age of the infants at birth (Russell & R. 2011). NEC has 
been associated with sequelae including severe neurodevelopmental delay, poor growth, 
intestinal obstruction due to scarring, short bowel syndrome, and potential liver failure 
due to prolonged hyperalimentation (Embleton & Yates 2008).  The common symptoms 
of NEC include: swelling in the abdomen, bloody stool, diarrhoea, inflammation, 
presence of intestinal fluid and intestinal perforation (Hunter et al. 2008). 
Necrotising enterocolitis is one of the catastrophic diseases affecting neonates and 
contributes to high morbidity and mortality rates among preterm infant globally 
(Berrington et al. 2014). NEC affects approximately 6–10% of VLBW babies, with a 
fatality rate as high as 20–40% (Meinzen-Derr et al. 2009). Infants of extremely 
LBW(less than 1000g) or very premature [<28 weeks gestational age (GA)] are at greater 
risk of NEC than those born closer to term (Wiedmeier et al. 2011). NEC only occurs 
following development of the gut microbiota, it has, therefore, been hypothesised that the 
disease is caused by inappropriate colonisation and dysbiosis of the premature intestine 
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(Fox & Godavitarne 2012; Claud & Walker 2001). NEC is uncommon in term infants 
(where it usually appears within 2-3 days after birth). In some studies, the 
pathophysiology of NEC was reported as multifactorial and since premature infants are 
at greatest risk, the immaturity of the intestine and abnormal bacterial colonisation are 
regarded as important contributing factor  (Lin et al. 2008; Julia et al. 2010). 
 Pathogenesis of NEC 
 
 To date, no single causative pathogen has been identified accountable for NEC 
pathogenesis (McMurtry et al. 2015; Brower-Sinning et al. 2014; Leach et al. 2015; 
Carlisle et al. 2011). This is due to an inability to identify a single organism that is found 
in patients with NEC and not found among patients without the disease, thus fulfilling 
Koch’s postulates of causality for microbial disease (Falkow 2004; Singh, Brian Firek, et 
al. 2015), but there are significant population of strict anaerobes found predominantly in 
the gut of preterm infants associated with NEC cases and a reduction in community 
diversity (McMurtry et al. 2015; Brower-Sinning et al. 2014).  Another research 
demonstrated that certain infectious microbiota may be accountable for the NEC among 
the preterm infants (Singh, Brian Firek, et al. 2015). Viruses have also been associated 
with pathogenesis of NEC  although their actual role in the aetiology of NEC have not 
been established (Torrazza & Neu 2013; Resta et al. 1985).  
A recent study demonstrated that Clostridium perfringens and Klebsiella  spp. of 
Enterobacteriacaea  were experimentally examined using high through-put techniques to 
look at their relationship with NEC. After robust analysis comparing between NEC and 
control cases; Clostridium and Klebsiella  spp. were found associated with NEC cases and 
absence in control cases, therefore, the researchers concluded that Clostridium 
perfringens has been regarded as a putative etiological pathogen associated with NEC 
(Sim et al. 2014) . Similarly, Clostridium butyricum is specifically associated with NEC 
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in preterm infant (Cassir et al. 2015).  Klebsiella pneumoniae  has been associated with 
the development of NEC (Torrazza et al. 2013). Moreover, a study demonstrated that 
Clostridium perfringens and Bacteroides dorei are associated with NEC. Whereas, 
Staphylococci are negatively associated with NEC in post-meconium sample (Heida et 
al. 2016). Another recent study showed that Gammaproteobacteria  (GPB) has been 
positively associated with NEC. Whereas, a strict anaerobic bacteria specifically 
Negativicutes is negatively associated with NEC in very low birth weight preterm infants 
(Warner et al. 2016). 
 Sepsis 
 
Neonatal sepsis is a major cause of morbidity and mortality during the early days of a 
preterm infant’s life (Camacho-Gonzalez et al. 2013). It is usually occur as a result of 
direct bacterial translocation from the gut into the bloodstream (Mai et al. 2013). Sepsis 
can be associated with subsequent sequelae including prolonged ventilation and need for 
intravascular access, bronchopulmonary dysplasia, NEC, and an increased length of 
hospital stay (Satar & Özlü 2012). Different microorganisms are responsible for the 
neonatal sepsis depending on the age at onset (Satar & Özlü 2012; Paolucci et al. 2012).  
It can cause long-term complications to the new-born and premature infants during their 
stay at intensive care unit (Tappero & Johnson 2010). 
 The initial sign and symptoms are non-specific and can easily be confused with the other 
conditions from the infants (Tappero & Johnson 2010). The prevalence  of the disease is 
attributed to various factors including geographical region, maternal and neonatal risk 
factors (Shane & Stoll 2014). The smaller preterm infants are at higher  risk of sepsis 
(Russell & R. 2011). Similarly, preterms with very low birth weight are prone to sepsis 
due to their immature organs and compromised of immune system (Shane & Stoll 2014). 
Almost 20% - 30% of all very-low-birth-weight (VLBW; <1500g) that have been 
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hospitalised in NICU will suffer from sepsis at some stage; however, the risk will 
increases up to 35% in preterm of extremely-low-birth-weight (ELBW; <1000g) and to 
closely to 50% in infants of less than 750g (Stoll et al. 2004). 
The gut flora of preterm infants diagnosed with sepsis is quite different from that of 
healthy infants, with an increased incidence of Proteobacteria  and Firmicutes (Russell & 
R. 2011). Unlike in the case of predominant organism in NEC, Staphylococcus spp. are 
regarded as the most serious bacterial species in the pathogenesis of sepsis globally 
(Venkatesh & Abrams 2010).  
 
 Types of sepsis 
 
The neonatal sepsis can be classified in to two types depending on the onset of symptoms 
(Stefanovic 2011), with different aetiological causes; these are: early onset infection and 
late on-set infection (Samuelsson et al. 2014; QiLi et al. 2014).  
 Early on-set sepsis (EOS) 
 
Early on-set sepsis (EOS) normally occur during the first 1-3 days of life (Vergnano & 
Heath 2013). They are associated with very low birth weights of <1500g and are usually 
caused by pathogens which across the placenta and infect the baby (Zuhair 2012). The 
major pathogens responsible for EOS infections are the Group B Streptococci and 
Escherichia coli (Hornik et al. 2012; Simonsen et al. 2014).  In addition, other organisms 
have been reported to cause the sepsis depending on the region and environment 
especially Klebsiella pneumonia , coagulase negative Staphylococcus, Pseudomonas spp., 
Micrococcus spp., and Alcaligenes faecalis , but however, Group B Streptococci and E. 
coli which are the common pathogens causing  EOS in the western countries were not 
detected (Ananthakrishnan & Gunasekaran 2009; Samuelsson et al. 2014). Transmission 
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of the pathogens occurs mostly during labour ( Juretić. 2010), and EOS infection is 
characterised by symptoms of respiratory disorder or fever during the early hours of life 
(Samuelsson et al. 2014; Chacko & Sohi 2001). Sometimes the symptoms are delayed 
more especially if the mother has been treated with antibiotics (Cortese et al. 2015; John 
et al. 2006).  
 Late on-set sepsis (LOS) 
 
Late onset sepsis (LOS) occur between 48 hrs to 90 days after birth (Cortese et al. 2015). 
They are most common in very low birth weight (VLBW) preterm infants, or term infants 
that require prolonged neonatal intensive care (Inna et al. 2010). Late on-set infections 
are usually associated with nosocomial infections (Samuelsson et al. 2014), and studies 
shows that preterm infants are more susceptible than full term babies and the mortality 
rate is greatest in infections that occur soon after birth (Cortese et al. 2015). However, the 
outcomes depend on the duration of exposure and virulence of the causative organism 
(Ananthakrishnan & Gunasekaran 2009). Gram positive organisms are the principal 
pathogens responsible for LOS (Hornik et al. 2012; Zuhair 2012). The most frequently 
encountered pathogens include: coagulase negative Staphylococci which are responsible 
for majority of the infection (Ananthakrishnan & Gunasekaran 2009) and 
Enterobacteriaceae such as Escherichia coli, Klebsiella pneumoniae and Acinetobacter 
baumannii (Inna et al. 2010). Many factors may contribute to increased LOS incidence 
including complications during birth, prolonged labour, ventilation, exposure to 
antibiotics and parenteral nutrition among others (Hornik et al. 2012; Cortese et al. 2015).  
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 Invasive fungal infection 
 
Invasive fungal infections are usually caused by pathogenic fungi most commonly 
Candida Species (Koh 2013; Kaufman et al. 2014). Some studies demonstrated that 
fungal  infections accounts for almost 30% of infections in preterm infants with very low 
birth weight that result in mortality (Iliev & Underhill 2013; Koh 2013).  
The incidence of invasive fungal sepsis is rapidly increasing and becoming common 
among preterm babies receiving neonatal care (Cetinkaya et al. 2014). This is due to the 
ability of fungi to colonize the skin surface, mucosal membrane and vascular catheters 
associated with VLBW (Aydemir et al. 2011). Preterm infants that are immunosuppressed 
or who  require invasive therapies, are exposed to parenteral feeding and broad spectrum 
antibiotics are vulnerable to fungal infection (Kaufman et al. 2014). In some healthcare 
systems, prophylactic antifungal and topical prophylaxis are routinely prescribed to 
reduce the risk of invasive fungal infections  (Kaufman et al. 2014; Al Tawil et al. 2010). 
 Development of gut microbial communities 
 
 Gut Microbiome 
 
Gut microbiomes are the collection of microorganisms including bacteria, archaea, virus 
and fungi found within the gastrointestinal tract (GIT) together with their complete 
genetic material (Actis 2014; Galland 2014). It is estimated that the GIT comprises of 
70% of most of the microbes found in the human body, this makes it complex 
environment with a large population of microorganisms (Brown & Allen-Vercoe 2011). 
It plays a significant role in health as well as affecting the physiological functions and 
psychological changes in our lives (Actis 2014; Christian et al. 2015). However, the 
advent of modern molecular techniques has helped to expand our knowledge and 
understanding of the composition of gut microbiome and its impact on health and disease 
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(Mulle et al. 2013; Icaza-Chávez 2013). A recent report demonstrated that the human gut 
colonisation may be initiated in utero by a distinct microbial communities already present 
in placenta and amniotic fluid (Collado et al. 2016). It has been reported recently that, 
Streptococcus spp. found to be dominant in the gut microbiota of maternal antibiotic 
treatment mothers while Enterococcus faecalis dominated the GIT microbiota of maternal 
antibiotic infant (Gonzalez-Perez et al. 2016). 
 Colonisation and composition of gut microbiomes 
 
The microbial colonization from our cohort study could be classified in to: Beneficial 
Microbes- specifically Bifidobacteria  and Lactobacilli as the key bacteria of our research 
study, potentially pathogenic microbes- mainly Enterobacteriaceae, Escherichia, 
Enterococcus, Bacteriodes, Streptococcus, and Pathogenic microbes which include 
Staphylococcus and Clostridia  (Westerbeek et al. 2006). It is worth mention that the 
bacterial colonization occurs during birth through inoculation from maternal microbiota, 
environment, and other factors (de Almada et al. 2015; Barrett & Guinane 2013; Nyangale 
et al. 2012).  
 Many environmental factors influence the composition and colonisation of the GIT by 
microorganisms including: geography, medication and general life style (Davenport et al. 
2014). The gut microbial colonisation by vaginal and faecal bacteria starts during and 
immediately after delivery such that the early gut microbiome resembles that of the 
maternal microbiota (Rigon et al. 2012). It has been reported recently that the composition 
of infants gut microbiota begins to resemble that found in colostrum (Collado et al. 2016). 
In infants delivery by caesarean section, the microbiome is significantly influenced by 
maternal skin contact and from the environment (Nyangale et al. 2012; Mshvildadze et 
al. 2010). In particular, some work shows that the colonisation of the preterm gut 
microbiome differs over time and between hospital environments which could be relevant 
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to patients outcomes (Taft et al. 2014). Interestingly, after weaning, the composition of 
the gut microbiota becomes almost identical to that of adults and remains relatively stable 
throughout life depending on other environmental factors (Thompson-Chagoyán et al. 
2007). 
Factors associated with premature delivery can affect the composition of gut microbiota 
(Stewart et al. 2012). There is limited information related to the microbial communities 
and their subsequent evolution and dynamics from meconium during the early life of 
preterm infants (Moles et al. 2013). 
However, work on term infants indicates microbial colonization is dominated by 
facultative anaerobes during the first day(s) of life, subsequently as oxygen is depleted in 
the GIT; obligate anaerobic bacterial isolates are observed (Ventura et al. 2012). Bacterial 
communities are found to colonize the human gut more than archaeal and fungal 
communities, however, other biological components such bacteriophage are present in 
very high titres and may exert significant ecological effects on the gut microbial 
communities in ways that are still not clear (Brown & Allen-Vercoe 2011). 
 Microbiome and preterm gut 
 
The gut of an unborn child is regarded as sterile (Rigon et al. 2012) and the recent research 
shows that colonization begins as soon as the unborn child swallows amniotic fluid 
containing microbes from the gut of the mother (Rodrı et al. 2015), this is evidenced by 
meconium samples that are not sterile but harbour diverse microbial communities (Rodrı 
et al. 2015; Ardissone et al. 2014; Moles et al. 2013). However, antibiotic treatment in 
pregnant mothers affects the colonisation of their infants gut microbiota (Gonzalez-Perez 
et al. 2016). 
 Implication of gut microbiome in health and diseases 
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The Microbial community of the human gastrointestinal tract (GIT) plays a vital role in 
human health due to its significance in digestion, nutrition and maintenance of host 
physiology (Brown & Allen-Vercoe 2011).  Preterm gut microbiome has been reported 
to have a short term health effects immediately after birth at NICU and long-term effects 
during post discharge (Stewart et al. 2015). 
The gut microbiome has significant impacts on the health by stimulating the bacterial 
proteins to interact with human antigens to affect the responses of the adaptive immune 
system and production of neurotoxic metabolites (D-lactic acid & ammonia) by bacterial 
enzymes (Galland 2014; Cong et al. 2015). However, it has been recently reported that 
the GIT microbiota play a vital role in regulating adaptive immune functions, but its role 
against systemic viral infections is not clear (Gonzalez-Perez et al. 2016). Additionally, 
the gut microbiome produce hormones that influence microbial growth and virulence 
(Galland 2014), it also stimulate afferent neurones of the enteric nervous system to send 
a signals to the brain through different mechanisms which help to shape the psychological 
behaviour of the host (sleep, stress, mood and cognition) (Cong et al. 2015; Christian et 
al. 2015). 
On the other hand, the GI flora has also been implicated in the pathogenesis of disease  
(Claud et al. 2013; Magne et al. 2005). Premature infants are particularly vulnerable to 
infections and other neonatal sepsis (Cortese et al. 2015) due to the fact that, they have 
low immune system and yet fully matured organs as well as having small number of 
beneficial microbes (Singh, Brian Firek, et al. 2015).  
 Factors affecting the preterm gut microbiome 
 
Preterm infants are normally cared for in neonatal intensive care units (NICU), As a 
result, they are exposed to a different bacterial community compared to full term healthy 
infants in a general ward who are rapidly discharged in to a domestic environment 
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(Berrington et al. 2013). The factors that affect an infant’s microbiota include: mode of 
delivery, delayed enteral feedings, exposure to pathogens in the hospital, exposure to their 
mother’s oral and skin microbiota as well as breast milk (Rigon et al. 2012), antibiotics, 
type of feeding and the function of the host immune system (Berrington et al. 2013; 
Ventura et al. 2012). It has also been shown that long exposure to a NICU is another 
factor contributing to the vulnerability of preterm infants to pathogenic bacteria (Beken 
2015).  
1.8.5.1 Delivery mode 
 
Delivery mode affects the gut microbiome and level of colonisation in preterm infants, it 
determines the initial gut microbiome (Actis 2014). Premature babies born via vaginal 
canal will always harbour a bacterial community resembling that of mother’s vaginal 
environment (Dominguez-Bello et al. 2010).  In contrast, those borne via Caesarean 
section have microbial community derived from the maternal skin with Clostridium, 
Escherichia, Streptococcus and Staphylococcus  predominating (Thompson-Chagoyan et 
al. 2007). Lactobacillus and Bifidobacterium are the dominant bacteria found to colonize 
the gut of preterm infants who were delivered vaginally in the early days of life 
(Dominguez-Bello et al. 2010; Ventura et al. 2012). Nevertheless, a study reported by co-
researchers who compared the mode of delivery among the infants and observed that there 
is no significant difference in microbial diversity between Caesarean and Vaginal 
delivery (Mshvildadze and Neu, 2010). 
Moreover, a comparative study on delivery mode was conducted  among the infants and 
observed that there is no significant difference in microbial diversity between Caesarean 
and Vaginal delivery (P=  0.5) (Mshvildadze & Neu 2010).  Another previous work also 
shows no significant difference between the bacterial diversity and mode of delivery (P= 
0.14) (Mshvildadze et al. 2010). 
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1.8.5.2 Nutrition 
 
The nutrition given to preterm infants has significant impacts on the composition and 
level of colonisation of the gut microbiome (Galland 2014). It has been reported that, 
there is a high abundance of Lactobacilli and Bifidobacteria  in the gut of preterm infants 
in tandem with low numbers of Clostridium spp. In infants fed with maternal breast milk 
compared to preterm infants who receive formula feeding (Penders et al. 2005). Formula 
fed infants usually demonstrate higher microbial diversity with an increase in facultative 
anaerobes, specifically Bacteroides, Clostridium, and Enterococcus. However, feeding 
the preterm with artificial formula rather than expressed maternal breast milk (EBM) 
exposed them to the risk of infections. Remarkably, the gut flora of breast fed babies 
changes to resemble that of formula fed infants after weaning period (Adlerberth & Wold 
2009). 
 The duration of complete enteral feeding and using nutritional supplements (pro and 
prebiotics) may stimulate the gut of preterm infants to function, and influence the 
colonization of beneficial bacteria (Actis 2014; David et al. 2014). 
 
 Microbiology of breast milk 
 
Breast milk is an essential nutrient to all new born neonates. The use of breast milk to 
preterm during their early days of life helped to: reduce the incidence of NEC, faster 
tolerance of enteral feeding and reduced the need of parenteral diet  (Lindemann et al. 
2004). Breast milk microbiota is composed of viable skin and non-skin bacteria and some 
of them plays a vital role in enhancing immunity and liberating the nutrient contents 
(LaTuga et al. 2014), they also influence the establishment and stability of the gut 
bacterial community (Ward et al. 2013). Bifidobacterium species has been shown to be 
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effective in preventing certain disease associated with breast milk (Breast milk Jaundice) 
(Tuzun et al. 2013). 
It has been reported that breast milk contains a reasonable amount of Lactobacilli in the 
gut of an infant, and that new born babies acquire Lactobacilli through oral contamination 
from vaginal strains during delivery and later to transmit such bacteria to the maternal 
breast during breast feeding (Martin et al., 2007). Breast milk can sometimes transmit 
viral and bacterial pathogens leading to the cause of morbidity and mortality to preterm 
infants (Widger et al. 2010). However, there is a strong correlation between the 
concentration of Bifidobacterium bifidum in breast milk and faecal samples of infants 
(Tuzun et al. 2013). Moreover, a current study demonstrated that the microbial 
relationship between the mother and new born baby is continue immediately after 
delivery by microbes found in breast milk (Collado et al. 2016). 
 Management of neonatal infections/sepsis 
 
 NEC 
 Clinical diagnosis of NEC 
 
NEC diagnosis is done by careful observations from clinicians to look for swelling, pain 
and tenderness as well as conducting abdominal X-ray, radiography and ultrasound for 
the symptoms of inflammation (Bohnhorst 2013; Santos & Tristram 2015). Laboratory 
stool tests can be conducted to see the presence of blood (Ng et al. 2015).  Blood test for 
measuring the white blood cells and platelets level can also be helpful in the diagnosis of 
NEC (Ng 2013).  
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 Treatment 
 
As the exact pathogenesis of NEC is yet to be confirmed, its treatment and prevention 
remains challenging (Lin & Stoll 2006; Lin et al. 2008). NEC treatment depends on the 
following factors: the severity of the infection, the gestational age of infants and the 
general health condition of the baby (Harpavat et al. 2012). The treatment can include 
dietary interventions (antibiotics & probiotics), intravenous fluids or sometimes surgery 
in severe cases (Bozeman et al. 2013). Moreover, cessation or delaying in enteral feeds, 
gastric decomposition with intermittent suction and prompt antibiotic therapy can be 
effective in treating the NEC cases (Morgan et al. 2014). Administering oral feeds with 
human milk and probiotics supplementation has also been reported to be effective in the  
prevention of NEC (Torrazza et al. 2013). 
Furthermore, the maternal breast milk is one of the important key factor considered as a 
natural prevention of NEC and facilitating the healthy gut microbiome (Martín et al. 2009; 
Roger et al. 2010), this is because it composed of many immuno-protective and growth 
factors, prebiotics oligosaccharides, bioactive immune-modulatory cells and other 
‘immunonutrients’ including amino acids, fatty acids, lysozyme, lactoferrin, minerals and 
metals such as zinc (Hall 2013; Bhatia 2010). It has been previously reported that oral 
lactoferrin can be used in the prevention of NEC in preterm infants (Pammi & Sa 2011; 
Venkatesh & Abrams 2010). Arginine supplementation also been reported to be helpful 
in prevention of NEC (Shah & Shah 2007).  NEC can also be treated by administering of 
broad-spectrum antibiotics after diagnosis for a minimum of 5 days. If the symptoms 
continue, surgery is an option to remove the dead tissue or necrotic bowel segments 
(Bhatia 2010; Pierro 2005). 
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 Sepsis 
 Clinical diagnosis and treatment of neonatal sepsis 
 
Diagnostic approach mostly focuses on the review of suspected symptoms and patient 
history during the onset (Stefanovic 2011). However, diagnosis is based on blood culture 
techniques (Satar & Özlü 2012), but the advent of molecular techniques, enable 
identification of the possible pathogens to become more accurate and rapid (Camacho-
Gonzalez et al. 2013; E. 2010; Tappero & Johnson 2010). LOS is diagnosed by the 
manifestation of various clinical symptoms including hyperglycaemia, abnormal white 
blood count, feeding intolerance among others (Samuelsson et al. 2014). Sepsis is 
managed by antibiotic treatment for a minimum of 5 days (Tappero & Johnson 2010). 
Empirical antibiotics therapy remain an effective treatment for suspected cases of LOS 
(Dong & Speer 2015). They are usually prescribed to a preterm who show signs of 
infections and may help in reducing the incidence and severity of the infections (Cortese 
et al. 2015). Intrapartum antibiotic prophylaxis is very effective against Group B 
Streptococci (Stefanovic 2011; E. 2010). Sepsis can also be treated using antifungal 
prophylaxis for at least 5 days for the management of fungal mediated sepsis. In cases of 
negative blood culture with the evidence of symptomatic infection, treatment is around 5 
±3 days (Cordero & Ayers 2003; Paolucci et al. 2012). Oral lactoferrin has also been used 
in the prevention of neonatal sepsis (Venkatesh & Abrams 2010). 
 Dietary intervention in preterm infections/sepsis 
 
For effective management of neonatal infections/sepsis,  intervention  including the 
administration of probiotics and the use of antibiotic is reported to play a role in the 
management of neonatal sepsis (Angelakis et al. 2013). The following measures were 
reported in the management of neonatal sepsis: to attack and prevent the spread of  
pathogenic microbes, to enhance and improve the immune response to the host, and to 
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adapt the use of supplementary live microbes and dietary  intervention (probiotics) 
(Robinson 2014). 
 Probiotics 
 
Probiotics are the live microbial supplements that when given in an appropriate amount 
exert a beneficial health impact to the host (Costeloe et al. 2015). Lactobacillus spp., 
Bifidobacterium spp. and Staphylococcus spp. are the most common types of microbes 
used as probiotics, though certain yeasts and bacilli can also be used (Julia et al. 2010). 
Probiotics compete with pathogenic bacteria for host binding sites and nutrients while 
also stimulating host defence mechanisms and enhancing intestinal maturation (Jakaitis 
& Denning 2014; Liu et al. 2015). They may also protect against systemic bacterial 
invasion by decreasing permeability of the GI wall (Klaenhammer et al. 2012; Julia et al. 
2010).  
Lactobacillus and Bifidobacterium spp. are the main probiotic groups (Abdulkadir et al. 
2016). However, the probiotic potentialities of Pediococcus, Lactococcus, Bacillus and 
Yeasts has been reported (Soccol et al. 2010) and that some probiotics strains exhibit anti-
inflammatory and anti-allergic properties (Soccol et al. 2013). The potentiality of 
probiotics as a drug agent in pharmaceutical industries has also been reported (Sarkar 
2013).  
The safety of routinely used probiotics has been extensively reviewed and four safety 
areas were highlighted: i- pathogenicity and infectivity, ii- deleterious metabolic 
activities, iii- excessive immune response and iv- potential gene transfer  (Zhang et al. 
2008).  
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 Current scientific dilemma in ǲprobiotic conceptǳ  
 
The ‘Probiotics concept’ is presently in a scientific dilemma, this is due to the initial 
definition of probiotics given by FAO/WHO in 2001 as “Live microorganisms which 
when administered in adequate amounts confer a health benefit on the host”. Since then, 
this concept was widely used and accepted globally in the clinical and industrial field 
(Hill et al. 2014). However, there is a discussion on the misuse of the term ‘probiotic’ by 
many nutritional products without properly fulfilling the criteria of that concept. The 
debate is based on the position that the term ‘probiotic’ can be considered as a “Health 
claim” or “Nutritional claim”. According to EFSA (European Food Safety Authority),  
claims of effects on immunity, pathogen, suppression and gastrointestinal functions, has 
led to scientific studies that fail to establish links to reducing the risk factors of disease 
(Sanz 2016). As a consequence of this debate by various scientific research groups and 
other organisations with an interest in advocating the benefits, to health and nutrition of 
probiotics, guidelines have been published in 2011 and recently updated by a EFSA and 
NDA (Dietary products, Nutrition and Allergies) panel that address: i- functional claims 
related to the role of food in maintenance/improvement of a physiological function and 
ii- disease risk reduction claims related to the role of a food in reducing a risk factor for 
disease. Specific claims addressed in the guidance include those on functions of the 
immune system (based on the essentiality of nutrients), functions of the gastro-intestinal 
tract (discomfort, gas accumulation, normal defecation and digestion and /or absorption 
of nutrients), defences against pathogens and reduction of risk factor for infections. 
Claims evaluated by the panel with a favourable opinion have been used to provide 
guidance to applicants on the scientific requirements for the substantiation, whereas those 
evaluated with an unfavourable opinion have been used to illustrate the shortcomings that 
prevented their substantiation (Sanz 2016). 
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Furthermore, a series of discussions were organised between interested parties related to 
the ‘probiotic concept’ such as ISAPP (International Scientific Association for Probiotic 
and Prebiotic), gastroenterologist, microbiologist, etc. with expertise from WHO/FAO. 
Currently, the dialogue is ongoing between the EU (European Union) and EFSA 
(European Food Safety Authority) to resolve the issue at stake. Nevertheless, some useful 
guidelines to clinicians and consumers on the appropriate use and scope of the term 
probiotics were drafted and reach a consensus agreement (Hill et al. 2014). 
Within the European Union there is a de facto ban on the use of the word ‘probiotic’ when 
presenting, labelling or advertising probiotic foods. This has led the industry and some 
member states to reflect on a Europe-wide solution and to consider the future design of 
the probiotic food industry. However, efforts have been made in collaboration with IPA-
Europe (International Probiotics Association- Europe) to resolve Europe’s probiotics 
issues and create a stable framework for its probiotic industry. The following solutions 
were outlined to end the ban and explain how the probiotic industry is working to restore 
trust in its products. 
 The source of the problem – why the European Commission decided ‘contains 
probiotics’ constituted a health claim 
 A step towards a solution – the legal options now under consideration and 
lessons from beyond the EU 
 The state of play – signs that some member states and the commission want 
to find a solution and re-launch innovation 
 Next steps – the industry’s commitment to prevent misuse of the word 
‘probiotic’ and introduce conditions for its use (Lambert 2016). 
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 Prebiotics  
 
Prebiotics are selective ingredients that induce the growth and activity of beneficial 
microorganisms that exert health benefit to the host (Drakoularakou et al. 2011). 
Typically, they are carbohydrates, indigestible and non-fermented food substances found 
in the GIT and usually fermented by colonic bacteria but not in the upper part of GIT 
(Bronsky. 2011). They are selectively used to support the growth of some beneficial 
bacteria and influence the health status of the host (Quigley 2010). 
Prebiotics can alter the composition of the gut microbiome and prevent intestinal 
infections (Licht et al. 2012). The most common type of prebiotic is from soluble dietary 
fibre inulin found in plant material and frequently consumed in vegetables (Bultosa 
2016). Roots and tuber flours of some plant have also been shown to be source of prebiotic 
compounds (Sousa et al. 2015).  
Prebiotics and probiotics play a significant role in brain functions (Saulnier et al. 2013), 
and have been shown to impact on mucosal immunity and serve as a biomarkers for 
measuring the human immune responses (Klaenhammer et al. 2012). The role of pre and 
probiotics is in modulating the activity of the gut microbiota and how it interacts with the 
enteric and central nervous system (Saulnier et al. 2013; Madsen 2011; Vieira et al. 2013; 
Scaldaferri et al. 2013; Chen & Sears 2014; Shukla et al. 2011; Quigley 2010; Vyas & 
Ranganathan 2012). Prebiotics have been applied in inflammatory skin conditions by 
reducing the incidence of atopic dermatitis in infants (Nole et al. 2014).  
The prebiotics, have a great impact on gut microbiota and gene expressions (Paturi et al. 
2015), and it influenced the gut microbiota to maintained the signal communication that 
exist between the GIT and brain (Mayer et al. 2015). However, the neurological behaviour 
(anxiety, stress, autism, learning, mood and memory) have also been modulated by 
prebiotics and nutritional diets (Burokas et al. 2015; Liu et al. 2015). The prebiotics have 
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also been reported to be effective in treating chronic inflammatory diseases and 
maintaining the gastrointestinal health such as celiac disease, vasculitis lupus, COPD etc 
(Patel & Dupont 2015). 
 Application of probiotics to preterm infants 
 
Many reports show how routinely used probiotic supplements  reduced NEC and other 
sepsis without serious adverse effect to the neonates (Janvier et al. 2014; Neu 2014; Gaul 
2008).  Some reports also demonstrated the effect of prebiotics alone or when combining 
it with probiotics intervention to reduce the incidence of NEC among preterm infants 
(Partty et al. 2013; Szajewska 2010; Beken 2015). 
Probiotics help to reduce morbidity and mortality rate of infection in preterm infants, by 
improving nutrients utilization; in animal models, they increase short term growth. In 
addition, some strains of probiotics have a significant impact on gut microbial 
compositions that are related to obesity and overweight (de Almada et al. 2015; Picaud 
2013b). Low diversity of gut microbiota may increase the risk of bacterial translocation 
across the gut wall, probiotic administration helps to increase the diversity of gut 
microbiota which in turn prevents translocation (Picaud 2013a).  Furthermore, a recent 
study demonstrated how the probiotics can alter the gut microbiota in restoring the 
balance of intestinal flora and its effectiveness in prevention of NEC in VLBW infants 
and treatment of various chronic neurological disorders; this can be achieved by either 
direct antimicrobial effects, enhancement of mucosal barrier integrity or through immune 
modulation (Patel & Dupont 2015). 
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 Antibiotics 
 
Antibiotics are the compound molecules derived from natural, synthetic or semi synthetic 
origin that can kill or inhibit the growth of microorganisms without toxic effect to the 
host. They can either be bacteriostatic or bactericidal and those with bactericidal actions 
are usually preferred in the treatment of immunocompromised patients including preterm 
infants (Alexander Mankin 2011). 
Prophylactic antibiotics are normally prescribed and given to the preterm infants during 
their stay in neonatal care units (Greenwood et al. 2014). Furthermore, the intake of 
enteral feeding and prophylactic antibiotics by some mothers during delivery influence 
the health of the baby (Torrazza et al. 2013). Antibiotics were reported to have short and 
long term impact to the gastrointestinal microbiota, the course of antibiotics administered 
may vary based on clinical experience and other physiological factors (Jernberg et al. 
2010; Jernberg et al. 2007).  
 Impacts of antibiotics on gut flora 
 
 A recent report shows that the composition of the intestinal microbiota is relatively stable 
throughout life but it can be changed due to number of factors including antibiotics 
therapy, dietary intervention and microbial infections (Rodrı et al. 2015). The gut flora 
has been recognised as an important reservoir host of antibiotics resistance genes of the 
human infants (Gosalbes et al. 2016). The routine use of antibiotics in preterm infants is 
one of the factors influencing the colonisation of microbial flora in the early days of life 
and affects their composition (Ward etal., 2014). Exposure to antibiotics also affects the 
microbial diversity and affect the rate of colonization in the preterm gut (Torrazza & and 
Josef Neu 2012). It has been reported recently that maternal antibiotic treatment during 
pregnancy affects the composition of gut micro flora in both mothers and infants 
(Gonzalez-Perez et al. 2016). 
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Antibiotics are either intended to target selected pathogenic bacteria or to provide a broad 
spectrum of antibacterial activity. When administered, they can inhibit the growth of 
beneficial bacteria long after the treatment is stopped which may alter the host- microbial 
relationship (Willing et al. 2011). Important antibiotic factors that are reported to 
influence the composition of gut flora include the combination of drugs, time and number 
of doses (Jernberg et al. 2010). Antibiotic therapy can cause shift in gut microbial flora 
and may predispose preterm to infection later on (Beken 2015), they may also affect the 
chemical composition of faeces (Antunes et al. 2011).  
 The PCR-DGGE Analysis for Archaeal and Fungal Microbial 
communities  
 
Archaea are prokaryotic microorganisms that are genetically distinct from bacteria and 
eukaryote (Breu et al. 2008). Some archaeal taxa are found in the GIT of humans and 
other animals (Matarazzo et al. 2012; Cavicchioli et al. 2003). The archaeal communities 
that colonise the human gastro intestinal tract are limited to few groups, particularly 
methane-producing archaea (Matarazzo et al. 2012; Eme & Doolittle 2015). Despite their 
unique characteristics, the potentiality of archaea as a pathogens is questionable, based 
on how well to addressed and achieved the following assumptions: the diversity nature of 
archaea and its pathogenicity, its relation to eukaryotes, immune response to archaea, 
possession of molecular fingerprints of a known pathogens by archaea and the evidences 
to prove the known disease caused by archaea (Cavicchioli et al. 2003). The presence and 
absence of methanogenic archaea in the human gut determines the level of health and 
dysbiosis of intestinal microbiota respectively (Berrington et al. 2014). 
It has been demonstrated that archaea are widely distributed and there is the interaction 
relationship with eukaryotes (Reed & Hicks 2011; Cavicchioli et al. 2003). Archaea found 
to be present in human gastrointestinal tract (Hoffmann et al. 2013) and human vaginal 
environment (Finster 2008; Belay et al. 1990). It is well established that anaerobic 
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methanogens inhabits eukaryotic hosts, including humans and high numbers have been 
found in the gastrointestinal tract  (Pikuta 2011; Cavicchioli et al. 2003), which might 
cause some dysbiosis in that environment 
Fungi are a diverse group of eukaryotic single-celled or multi nucleated organisms that 
live by decomposing and absorbing the organic materials. They are numerous in the 
environment and appear in different structural forms. Fungi play a vital role as part of the 
normal human gut microbiota (Cui et al. 2013; Ott et al. 2008) and can be commensal or 
pathogenic (Cui et al. 2013; Koh 2013; Huffnagle & Noverr 2013; Iliev & Underhill 2013; 
Lukes et al. 2015; Luan et al. 2015).The diversity of fungal microbiota in the human gut 
is less than that of bacteria (Huffnagle & Noverr 2013; Parfrey et al. 2014). The fungal 
community has been associated with human gastrointestinal tract infections (Koh 2013) 
and other related infections in health and diseases (Cui et al. 2013). The knowledge of 
advanced molecular techniques helps to identified various species of fungi to cause some 
diseases (Candida albicans, Aspergillus fumigatus and dimorphic fungi).  Specific organs 
are also known to harbour different fungi example lung, other species of fungi 
(Penicillium, Aspergillus Species) are found to be useful in pharmaceutical industries.  
The diverse nature of fungal communities from the human gut has been analysed by using 
PCR-DGGE fingerprints (Gouba et al. 2013; Walker et al. 2011; Scanlan & Marchesi 
2008; Luan et al. 2015) and other high throughput techniques that help to revolutionised 
the understanding, the phylogenetic and functional diversity of fungi (Cui et al. 2013; 
Koh 2013; Iliev & Underhill 2013). Though, there is wide range of literature on gut 
microbial communities, the number of studies investigating specifically fungal 
microbiota is quite limited (Ott et al. 2008; Koh 2013) and was not intensely studied (Koh 
2013; Iliev & Underhill 2013; Caporaso et al. 2012), this drawback resulted to the limited 
fungal profiles from the intestinal samples (Luan et al. 2015). 
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Analyses of the microbial communities using PCR-DGGE techniques have been widely 
used to determine their diversity and molecular identification from different habitat 
(Zhongtang et al. 2008; Ranjard et al. 2000),  including stool samples (Brown & Allen-
Vercoe 2011). The analysis of stool samples by PCR-DGGE for assessing fungal and 
bacterial in the preterm gut associated with NEC or sepsis has been undertaken. This 
study showed the viable and total bacterial and fungal communities to differ in preterm 
infants and may contribute to better understanding of NEC and sepsis (Christopher James 
Stewart et al. 2013).   
During our cohort study, the DGGE community profile analysis was used, PCR of 16S / 
28S rRNA genes for the both archaeal and fungal community respectively as well as 
analysis of microbial DGGE products. A previous study illustrated different set of primers 
with many variable regions and found that the V3 region of Archaea using GC-ARC-
344F/519R produced highest and clear DGGE bands (Zhongtang et al. 2008).    
Moreover, low abundance of fungal communities from the gut of preterm infants during 
our cohort study was observed; this could be attributed to the fact that, there is limited 
data and little molecular research conducted on this group more especially with regards 
to the intestinal fungi associated with diseases. This assumption has been confirmed by 
some recent studies (Huffnagle & Noverr 2013; Iliev & Underhill 2013; Luan et al. 2015). 
Though, a different study conducted on fungal DGGE profiles showed a higher fungal 
diversity in patients with Crohn’s disease in comparison with their control (Ott et al. 
2008). Another work demonstrated a low microbial diversity of archaea and fungal 
communities compared to that of bacterial community using PCR-DGGE finger prints 
(Brown & Allen-Vercoe 2011).  
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 The trend in the study of gut microbiota 
 
The methods for the study of gut microbiomes among the preterm infants were classified 
as: culture based techniques or culture independent techniques. Historically, studies relied 
on culture based techniques to cultivate and identify the bacteria present in the gut of 
preterm (de Almada et al. 2015; Singh, Brian Firek, et al. 2015; Rougé et al. 2010). 
Recently, culture independent techniques have helped to reveal the interaction and 
ecology of the GIT bacterial community (Mshvildadze et al. 2010; Zdzislawa Libudzisz 
2010). For the purpose of these studies, focussed was made only on the culture 
independent techniques with different molecular finger print to analyse the association of 
gut microbial communities and relation to preterm infant infections. 
 High throughput-techniques and its application to gut microbiome 
 
The advent of modern technology using advanced molecular techniques have contributed 
immensely toward the understanding of gut microbial communities (Johnson & 
Versalovic 2012). Such culture independent techniques include: metabolomics profiling, 
next generation sequencing (NGS), denaturing gradient gel electrophoresis (DGGE), 
polymerase chain reaction (PCR) and real time PCR to mentioned but a few (Rougé et al. 
2010; Brower-Sinning et al. 2014; Mshvildadze et al. 2010).  
Molecular techniques as a modern research tool have been utilised clinically in the gut 
microbiome and have radically altered our understanding of these communities to that of 
culture based techniques (Petrosino et al. 2009). These techniques allow the microbial 
community to be identified and observed without prior knowledge of its structure or 
composition. The foundation of these techniques is the DNA amplification (DNA and/or 
RNA) processed from stool samples (Nechvatal 2008). DNA analysis is more common 
as a result of the added difficultly and potential for degradation when working with RNA. 
It is feasible that an microorganism is present in a dormant state and so not metabolically 
 
27 
 
active, but when environmental conditions shift they can become active and play a part 
in the community function (Prosser et al. 2007). Likewise, to achieve full coverage and 
understanding of the viral communities, the DNA and RNA need to be thoroughly 
investigated. However, in order to gain the most comprehensive insight into the 
pathogenesis of infectious diseases such as NEC, analysis of both DNA and RNA is 
required. 
After DNA extraction from biological samples, subsequent diversity studies require 
amplification by polymerase chain reaction (PCR), typically based on the 16S ribosomal 
RNA (rRNA) gene. These amplified regions (amplicons) are then further differentiated 
into different regions that take part in to a pre-defined similarity to one another called as 
operational taxonomic units (OTUs). The 16S rRNA gene codes for the small subunit in 
the prokaryotic ribosome (Kang et al. 2010). This ribosomal gene is functionally 
conserved and it is ubiquitously expressed in bacteria. It represents a rational target for 
comparative studies between bacterial communities and is also the most extensively used 
gene for bacterial classification and identification (Isenbarger et al. 2008). The gene 
contains nine different regions known as ‘hypervariable regions’ with substantial 
sequence diversity, this is then fringed by ‘conserved regions’ of homologous sequence 
(Chakravorty et al. 2007). Furthermore, it allows universal PCR primers that become 
complimentary to conserved regions, to be designed, facilitating the amplification of the 
intervening hypervariable regions. Bacterial classification can then be determined by 
comparing the amplicons to homologous 16S rRNA sequences from characterised 
bacteria within open access sequence databases (Brookman-Amissah et al. 2012) 
It is worth mentioning that the multiple copies of the same target gene in PCR analysis 
are not restricted to the bacteria. The linking of cell abundance and PCR amplicons 
abundance is also limited by the multiple copy nature and intragenomic variability of the 
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common molecular marker of fungi; the ITS region of the rRNA gene from the 28S 
subunit (Amend et al. 2010).  
 Denaturing gradient gel electrophoresis (DGGE) 
 
 Denaturing gradient gel electrophoresis (DGGE) was one of the first generation molecular 
fingerprinting techniques that have the ability to separate amplified DNA products not 
exceeding 500 bp (Strathdee & Free 2013; Temmerman & Masco 2003). DGGE is widely 
used as a fingerprint techniques in studying microbial communities from different 
environments (Sakai 2008; Ying et al. 2005). The polymerase chain reaction of environmental 
DNA can generate templates of differing DNA sequence that represent many of the dominant 
bacterial organisms (Enwall & Hallin 2009; Toledo 2004). DGGE is a rapid and sensitive 
technique for easy detection of nucleotide sequence variation using differential melting 
activities (Strathdee & Free 2013; Miller et al. 1999). Therefore, the variable 3 (V3) region 
within the 16S rRNA gene is ideally suited to this analysis with primers targeting the 
conserved regions at positions 341 to 518 (E. coli 16S rDNA position) (Sakai 2008; 
Muyzer G et al. 1993). Molecular fingerprinting approaches exploit the different number 
of intermolecular hydrogen bonds between G-C and A-T base pairs. G-C base pairs have 
three hydrogen bonds and A-T have two, thus G-C base pairs require greater denaturant 
concentration to dissociate the extra hydrogen bond. Following electrophoresis, 
fragments with a higher G-C content will travel further through a denaturing gel, 
separating amplicons on the basis of their base pair content (Strathdee & Free 2013; 
Muyzer G et al. 1993). The gels can be further stained with relevant staining solutions 
and viewed under UV to see the position of the amplicons, which look as bands. DGGE 
is a semi-quantitative technique so the intensity of the band positively correlates with the 
abundance of the OTU in the sample (Scanlan & Marchesi 2008). 
However, the technique is capable of separating amplicons with a single base pair 
difference. Nevertheless, there are some limitations with regards to the use of DGGE 
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technique. The first is multiple sequences migrating to the same position on a gel and as 
a result only one band is detected. This leads to an underrepresentation of the actual 
number of unique OTUs in a mixed population sample, masking the true diversity (Enwall 
& Hallin 2009; Muyzer & Smalla 1998; Papen et al. 1998). A single band which 
incorporates mixed sequences will also lead to false classification of abundance, 
potentially leading to the assumption of a highly abundant OTU. A second limitation 
includes the involvement of a single organism with a multiple copies of the target gene. 
If the multiple copies are homogenous then this may lead to an overestimation of the true 
abundance of an organism, as described above. Also, if the multiple copies of the target 
gene are heterogeneous then multiple bands from the same organism will appear on the 
gel at different positions (Kang et al. 2010). This will lead to an over representation of 
the true diversity of samples. Additionally, if sequence information is required for 
taxonomic classification from the molecular fingerprint then individual bands need to be 
excised and sequenced (Sakai 2008). This process can be time consuming and the added 
expense can be relatively high. Furthermore, the hypervariable regions utilised typically 
generate short amplicons of around 200 bp which limits the resolution of taxonomic 
identification (Strathdee & Free 2013; Temmerman & Masco 2003). It is worth 
mentioning that, the protocols of DGGE finger print is the same as that for bacteria and 
fungi organisms with the exception of the electrophoresis conditions (Seiya Tsushima 
2010). 
 Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) is a technique used to amplify a single copy of 
DNA over different orders of magnitude; leading to produce millions copies of a specific 
DNA fragment. 
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PCR amplifies a specific region of a DNA strand (the DNA target). Most PCR methods typically 
amplify DNA fragments of between 0.1 and 10 (kbp), although some techniques allow for 
amplification of fragments up to 40 kbp in size.  The amount of amplified product is determined 
by the available substrates in the reaction, which become limiting as the reaction progresses (Agne 
et al. 2009). PCR technology is widely used to aid in quantifying DNA because the 
amplification of the target sequence allows for greater sensitivity of detection than could 
otherwise be achieved. In an optimized reaction, the target DNA quantity will 
approximately double during each amplification cycle (Brookman-Amissah et al. 2012). 
PCR has some shortcomings as DNA polymerase is prone to error, which in turn causes mutations 
in the PCR fragments that are made. Additionally, the specificity of the PCR fragments can mutate 
to the template DNA, due to nonspecific binding of primers. Furthermore prior information on 
the sequence is necessary in order to generate the primers, Bias is introduced by universal 
primers through differential annealing in the amplification of a heterogeneous template, 
affecting the amplification efficiency of some OTUs (Wang & Qian 2009).  
 Real time PCR (qPCR) 
 
Quantitative real-time PCR (qPCR) has become the most precise and accurate method for 
analysing gene expression. Before the advent of  qPCR, the most common methods for 
determining expression levels were northern blotting, RNase protection assays, or 
traditional, endpoint reverse transcription (RT) PCR. Endpoint RT-PCR was an 
improvement over the older methods due to its ease of use and the much smaller amounts 
of RNA needed for the reaction (Smith & Osborn 2009). However, with this method, 
expression levels can only be observed by performing agarose gel electrophoresis on a 
sample of the product at the end of the entire reaction. While traditional RT-PCR can be 
useful for determining the presence or absence of a particular gene product, qPCR has the 
advantage of measuring the starting copy number and detecting small differences in 
expression levels between samples (Palmer et al. 2007; Bucher et al. 2011). Additionally, 
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qPCR quantifies the PCR products while the amplification is in progress. Fluorescent 
reagents allow amplification to be measured while the reaction is occurring through use 
of a fluorescence detector in conjunction with the thermal cycler. This allows analysis of 
the entire amplification curve rather than only the end point (Smith & Osborn 2009). 
In real-time PCR (QPCR), the amount of amplified product is linked to fluorescence 
intensity using a fluorescent reporter molecule. The point at which the fluorescent signal 
is measured in order to calculate the initial template quantity can either be at the end of 
the reaction (endpoint semi- quantitative PCR) or while the amplification is still 
progressing (real- time QPCR). The technique relies on the detection of fluorescence, 
where the signal intensity is relative to the number of amplicons generated on completion 
of each cycle in the PCR. The concentration of target DNA in the sample is then 
calculated based on the exponential phase of the PCR when reaction components are in 
abundance by calculating the threshold cycle (Smith & Osborn 2009). 
Moreover, real-time PCR has the following benefits: easiness during the quantification 
of amplified DNA, greater sensitivity, rapid and quick analysis, accuracy, precision and 
reproducibility, maintenance of quality during the process and less risk of contamination 
of the products (Agne et al. 2009). 
  Next Generation Sequencing (NGS) 
 
Different NGS platforms are available to amplify single fragments and perform 
sequencing reactions on the amplified fragments (Siqueira et al. 2012). In NGS, the DNA 
fragments are ligated to platform-specific oligonucleotide adapters needed to perform the 
sequencing biochemistry, requiring as little as 90 minutes to complete (Claesson et al. 
2010; Illumina 2012). 
One of the common amplicon applications in NGS is sequencing the bacterial 16S rRNA 
gene across a number of species, a widely used method for studying phylogeny and 
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taxonomy, particularly in diverse metagenomic samples. This method has been used to 
evaluate bacterial diversity in a number of environments, allowing researchers to 
characterize microbiomes from samples that are otherwise difficult or impossible to 
study. An overwhelming majority of the world’s microorganisms have evaded 
cultivation, but sequencing-based metagenomic analyses are finally making it possible to 
investigate their ecological, medical, and industrial relevance (Illumina 2012). 
The knowledge of 16S sequencing techniques plays a vital role in discovering new 
microbial communities within GIT and beyond. A Scientist called Carl Woese initially 
proposed the three Domain of life as:  Archaea, Bacteria, and Eukarya – and he founded 
his work based on sequence information. The rRNA gene is the least variable DNA 
among all the other cells. There is similarity of rDNA sequence from microorganisms that 
are closely related to each other as such the sequence can be aligned for easy 
identification. This is why; genes that encode the rRNA have been used widely to 
determine nomenclature, phylogeny and help to estimate the differences among the 
bacterial species (Woese 2007).  
One challenge associated with sequencing small genomes is the lack of reference 
genomes available for most species (Claesson et al. 2010). To overcome this challenge, 
some NGS platforms offer paired-end (PE) sequencing protocols, where both ends of a 
DNA fragment are sequenced, as opposed to single-read sequencing where only one end 
is sequenced (Wang et al. 2010). 
Presently, one of the problems facing NGS is the bioinformatics processing of the raw 
sequencing reads. As large amounts of data can be generated in relatively short period of 
time, the computing power needed to analyses the data can be a bottleneck in the process. 
A number of bioinformatics software platforms for the processing and analysis of data 
are now available, for instance, Mothur and QIIME (quantitative insights into microbial 
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ecology) are the leading software packages in microbial ecology (Kozich et al. 2013; 
Schloss et al. 2011; Caporaso et al. 2010; Siqueira et al. 2012) 
 Metabolomics 
 
The advent of metabolomics is another ‘omic’ discipline that has revolutionised the field 
of molecular analyses. Metabolomics is the analysis of  functional metabolites found in 
biological samples (Ganna et al. 2014; Antonucci et al. 2009; V.V. Tolstikov 2002). 
Metabolome analysis is commonly used to detect the detail of chemical and molecular 
substances from biological system (Inna et al. 2010; Gomase et al. 2008; Villas-Bôas, 
Rasmussen & Lane 2005). The word ‘metabolome’ was first recommended by British 
scientist called Stephen Oliver in 1998, to designate the set of low-molecular-mass 
compound substances that have been synthesized by a microorganisms (Morrow et al. 
2013; Villas-Bôas, Rasmussen, Lane, et al. 2005). Subsequently, detailed work on 
metabolomics profiling was published , offering new terminologies and  protocols for the 
better understanding of metabolomics as well as proposing the process for quantification 
and identification of metabolites from different group of organism (Xie et al. 2013; Fiehn 
2002). 
 After undergoing robust validation, it has become clear that developing a metabolomics 
finger print is not an easy task due to the complex chemical nature and diversity of even 
biological systems (Lagomarcino et al. 2013; Idle & Gonzalez 2007; Fiehn 2002). Some 
researches maintain the view that metabolomics should regarded in a broader sense as a 
new phase of scientific research rather than considering it an analytical approach only 
(Antonucci et al. 2009; Villas-Bôas, Rasmussen & Lane 2005). They therefore, give a 
comprehensive definition of metabolomics as  “ The characterization of metabolic 
phenotypes (the metabolome) under specific sets of conditions (i.e. developmental stages, 
environmental conditions, genetic modifications) and the linking of these phenotypes to 
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their correspondent genotypes (integrating or not with gene expression and protein 
patterns)” (Ganna et al. 2014; Gomase et al. 2008; Villas-Bôas, Rasmussen & Lane 2005). 
However, currently the metabolome is further characterised analytically narrowing its 
scope for better understanding. A metabolite profile in that sense is a set of known or 
unknown derivatives that where identified by analysing a biological sample using a 
specific analytical procedure (Marincola et al. 2012; Xie et al. 2013; Roessner et al. 2000; 
Villas-Boas et al. 2005). 
Metabolite profiling was applied in the field of pharmaceutical sciences when discovering 
new drugs and its efficacy, microbial physiology, cytology and its pathogenesis, clinical 
diagnosis and other taxonomic studies (Villas-Bôas, Rasmussen & Lane 2005; Becker et 
al. 2012). There are different analytical platforms used in the study of metabolomics 
profiling which include: nuclear magnetic resonance (NMR) spectroscopy, mass 
spectrometry (MS),  Gas column chromatography - mass spectrometry(GC-MS), Liquid 
chromatography- mass spectrometry (LC-MS) alongside chemometric software that 
provide a simultaneous identification of different compound substances from biological 
samples (Zhou et al. 2013; Idle & Gonzalez 2007; Xie et al. 2013; V.V. Tolstikov 2002). 
The most widely established platform is the GC-MS technique (Ogura & Sakamoto 2007) 
more especially in plant materials. However, LC-MS techniques have been developed 
exploring soft ionization methods like electro spray (ESI) or photo ionization (APPI) and, 
simultaneously, mass spectrometers have become more robust and  sophisticated for daily 
routine use (Ganna et al. 2014; Zhou et al. 2013). 
The interactive relationship between gut microbial communities and their systemic 
function with other metabolic pathways using metabolomics signalling has significant 
potential for increasing and deciphering useful information in clinical applications 
(Becker et al. 2012; Xie et al. 2013).  
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Aims and objectives of the research  
 
The aim and objectives of this research are: 
1- To study the impacts of clinical and dietary interventions, on the community 
structure and function of the preterm gut microbiota by using high throughput 
molecular techniques. 
2-   To study the microbial communities derived from clinical samples that are 
implicated in gastrointestinal disease. 
3- Using ecological theory, high-throughput sequencing and statistical modelling to 
identify the assembly, functional and phylogenetic diversity and contribution 
these communities make to the disease state. 
4- Using molecular methodology including: PCR-DGGE, Real-Time PCR (qPCR), 
16S /28S rRNA gene amplification and next generation sequencing. To compare 
the results obtained within phylogenetic communities and to observe the increase 
in bacterial load from the samples collated. 
5- Determine if the onset of NEC is associated with alterations in the structure of the 
gut microbial community by analysing stool before and after the onset on NEC. 
6- Examine the quantitative changes in the microbial community pre and post onset 
of infections compared to healthy controls. 
7- Observe the impact of archaeal and fungal community and whether it has any 
significance effect to the gut microbiota of preterm infants. 
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2 CHAPTER TWO: General Methods  
 
 Sample collection and patient cohort study 
 
 Faecal samples were collected from a preterm cohort with <32 weeks gestation admitted 
to the neonatal intensive care unit (NICU) of the RVI. Stool samples were collected 
directly from the nappy and immersed in RNA later (Ambion) as soon as possible. RNA 
later is a bacteriostatic agent offering immediate RNA stabilisation and protection. After 
collecting the samples, were transferred to Department of Microbiology at the Freeman 
Hospital Newcastle upon-Tyne where they were kept at -20°C.  
The ethical approval was duly obtained from NHS via National Research Ethics Service, 
County Durham and Tees Valley Research Ethics Committee (Research ethics project 
number: RE-HLS-13-140303-53143b935c9f8) and informed parental consent on behalf 
of the babies.  
Furthermore, clinical characteristics of preterm demographic data were obtained 
concurrently with the new stool samples. The demographic data covers the clinical 
characteristics of the patient in the study cohort including: full names, gender, mode of 
delivery (caesarean or vaginal birth), gestational ages, birth weight, patient’s day of life 
(DOL), pathogenic organisms, incidence of NEC or Sepsis, antibiotics courses and 
administration, antifungal prophylaxis, mortality, and whether the clinicians (Janet 
Berrington and Nicholas Embleton) independently classified the NEC status and other 
clinical diagnosis. Sepsis was also confirmed by obtaining positive blood culture 
laboratory diagnosis. 
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 Comparison of the experimental technique 
 
 Archaeal and Fungal DGGE preliminary study 
 
The stool samples already collated stored at -80oC were sorted in to a total of 43 (25 NEC, 
8 Sepsis and 10 Nec/Sepsis) samples and 24 Controls (NEC and Sepsis). The DNA 
samples were identified from the demographic data and subsequently analysed by PCR-
DGGE for assessment of the total archaeal and fungal communities.  
 Probiotic and non- probiotic diversity: DGGE 
 
A total of 10 patients contributing 85 stool samples contributed to probiotics and non-
probiotic diversity analysis. 7 patients (57 stool samples) were all probiotics babies and 
3 patients contributing 28 samples serve as matched control babies. All the stool samples 
were further analysed using DGGE analysis for bacterial diversity. 
 Stool bacterial load study 
 
In 10 NEC babies (37 samples) and 10 healthy controls (35 samples) samples were 
studied to determine stool bacterial load. The total 72 stool samples were classified by t 
time interval as (i) prior, (ii) during and (iii) after NEC diagnosis and further analysed for 
qPCR technique. 
 Metabolomics profiling and molecular analysis of probiotic studies 
 
A total of 10 preterm infants were enrolled in the study contributing a total of 88 
samples for sequencing, 75 samples for qPCR and 40 stool samples for metabolomics 
analysis. Patients were split into two groups; 7 who received probiotics and 3 matched 
controls. All the babies involved in this cohort were breast-fed with maternal milk. 
The samples were further divided in to four groups: (i) before (ii) during and (iii) after 
probiotic supplementation and (iv) post-discharge samples.  
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 Antibiotics course study 
 
A total of 38 patients contributing 141 stool samples were involved in the antibiotics 
cohort study. All infants were less than 30 weeks gestational age and less than 1500g birth 
weight. The commonly prescribed antibiotic courses identified are: Vancomycin, 
Ceftazidine and Metronidazole (VCM) received by 12 patients contributing 41 samples,, 
Vancomycin and Ceftazidine (VC) given to 13 patients producing 51 samples and 
Amoxicillin, Flucloxacillin, and Gentamicin (AFG) having 13 patients with the total of 
49 stool samples. All the samples were collected at different time intervals and analysed 
using 16S rRNA gene profiling. 
There are two regimes treatment added to cover for what the clinicians know are the most 
likely infections after the first few days of delivery, but the babies  get different things if 
they were infected before delivery versus after (usually). Furthermore, penicillin and 
gentamicin are been used for the first days after delivery, but after that AFG regime is 
been used if the babies are unwell without a lot of medical 'plastic' (such as umbilical or 
long lines for drugs or feed solutions) or VC regime if they are unwell and have a lot of 
plastic in. The Vancomycin (V) covers the CONS (coagulase negative Staphylococcus) 
which is most commonly seen with lots of plastic in the baby. Metronidazole is been 
added to either regime if there are specific concerns about the abdomen, in case there is 
an anaerobic element - so if there is worried about NEC then the patient get 
metronidazole. 
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  Analysis of Faecal microbiota composition by NGS during probiotic 
study 
 
In order to ensure and to accurately determine the probiotics diversity of preterm babies 
compare with the control group. The entire extracted DNA was processed and sequenced 
using the benchtop MiSeq (Illumina) platform. Extracted DNA from the samples was 
aliquot into 96 well plates and was vortexed briefly and span down before being placed 
in the thermocycler (BioRad CFX96 Touch). PCR was carried out using the following 
cycling conditions; initial step at 95 °C for 2 min, then 30 cycles of 95 °C for 20 seconds, 
55°C for 15 seconds, extension at 72 °C for 5 min, and a final extension at 72 °C for 10 
min. Successful PCR was confirmed using an agarose gel (1%) on a subset of 12 samples 
per plate. The details of the PCR reaction was briefly described below (2.5).  However, 
the preparation of 1% agarose gel, its running buffer and dye as well as visualisation of 
band is given on next pages under 2.6 (confirmation of successful DNA and PCR). 
Normalisation was performed by transferring 18 μL of PCR product to the corresponding 
well on a normalisation plate. Library quality control was carried out using a Bioanalyser 
(Agilent bioanalyser 2100) and qPCR using KAPA SYBR FAST qPCR Master Mix 
(Anachem Ltd.).  qPCR was carried out using the following cycling conditions; initial 
activation step at 95 °C for 5 min, then 35 cycles of denaturation at 95 °C for 30 seconds 
and annealing at 60°C for 45 seconds. 
Raw data generated using next generation sequencing technology was processed to 
reduce the error rate and removing reads with a poor quality score using different steps 
of Mothur sequence reads-fastq files as contained in the Illumina Miseq SOP (available 
at - http://www.mothur.org/wiki/MiSeq_SOP), (Kozich et al. 2013). The protocol 
involves; the stability files are processed through set of files and making contigs to read 
a forward & reverse fastq file, this will generate MG-RAST & extract the contiged by 
running to split in to stability trim contig fast groups. The quality of the sequences will 
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be summarised in an aligned/unaligned fast files following the screening of the sequence, 
this will remove any sequences with ambiguous bases and anything longer than 275 bp. 
From there it would lead to the unique sequences found in a fast formatted files and will 
indicate the identical sequences to the reference sequence. At this time, it will calculate 
the distance and cluster each of the sequence. The count sequence will count the number 
of sequence represented by reference sequence.  
The columns that are not included in calculating distances will be filters and remove from 
the alignments. Pre-cluster will also remove sequences that are likely due to 
pyrosequencing errors and remove large number of sequences making the distance 
calculation much faster. This can be achieved through using a special version of 
algorithm. Afterward, chimeric sequences followed via uchime command to remove it 
from the count file. The above removed sequences will take the list of sequence names 
and fastq group in to a new file that does not contain the sequences in the list and further 
classify the sequences through different methods in order to assign their sequences to the 
taxonomy outline page. Later the remove lineage will generates a new file that contains 
only the sequences not containing that taxon and the Mothur will generate those files in 
to distance matrix and use cluster command to assign sequences in to OTUs at certain 
distance from all other sequences within the OTU. A shared file will be created for each 
group and classify the out to get consensus taxonomy for an out (Kozich et al. 2013). The 
protocol for miseq data analysis was presented in detail in the next pages under 2.17 (next 
generation sequencing) and 2.19 (Analysis of data). 
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  DNA extraction of faecal specimen 
 
Microbial DNA was extracted from 100 mg of faecal sample for analysis of the total 
bacterial load using the PowerLyzer™ PowerSoil® DNA Isolation Kit (MoBio). Faecal 
samples were added directly into glass bead tubes (0.1 ml), followed by the addition of 
750 µL of bead solution and gently vortexed to disperse the sample in the bead solution. 
Solution C1 was heated at 60°C to dissolved the precipitation before 60 µL of it was 
added into the sample (Solution C1 helps in cell lysis as its contain SDS and other 
disruption agents that will break down fatty acids and lipids associated with the cell 
membrane of many organisms).The bead tubes were shaken horizontally using the MoBio 
vortex adapter at the maximum speed for 10 minutes for complete homogenization and 
mechanical breakdown of the microbial cells. Then, the glass beads were centrifuged for 
2 minutes at 10,000 x g and 400-500 µL of supernatant was aseptically transferred into a 
sterile 2ml collection tube. 250 µL of solution C2 was added and shaken to mix briefly 
before being incubated at 4oC for 5 minutes (This will precipitate organic and in-organic 
particles including humic substances, cell debris and proteins that may inhibit 
downstream DNA analyses and reduce its purity). The tubes were centrifuged for 1 
minute at 10,000 x g at room temperature. To obtain high quality DNA, transferring any 
pellet was avoided as it still contains some non-DNA organic and inorganic material. 600 
µL of clear supernatant was transferred into another sterile 2 ml collection tube, then 200 
µL of solution C3 was added and briefly vortexed to mix, it was then incubated at 4oC for 
5 minutes to further remove contaminants including leftover humic acid, cell debris and 
proteins. It was then centrifuged at room temperature for 1 minute at 10,000 x g before 
750 µL of the clear supernatant was transferred into another new sterile 2ml collection 
tube. Solution C4 was mixed before 100 µL (1.2ml) was added to the supernatant and 
vortexed briefly, this solution has a high concentration of salt that will allow DNA to bind 
to the silica membrane on to the spin filters. 675 µL of supernatant mixture was loaded 
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on to a spin filter and centrifuged at 10,000 x g for 1 minute at room temperature. The 
flow through was discarded carefully and the whole process was repeated. As there is the 
need to further clean the DNA and remove residual salt, humic acid and other 
contaminants from the silica membrane leaving only DNA, solution C5 an ethanol based 
wash solution (500 µL) was added and centrifuged at 10,000 x g for 30 seconds at room 
temperature, the flow through was discarded and centrifuged again for an additional 1 
minute with same condition to remove all the traces of ethanol which can interfere with 
downstream DNA applications. The spin filter was carefully placed onto a new clean 
sterile 2ml collection tube before 100 µL of solution C6 was added to the centre of the 
filter membrane to release the bound DNA. Solution C6 is an elution buffer which 
contains no EDTA and salt and then it was centrifuged at 10,000 x g for 30 seconds at 
room temperature and the flow through containing eluted DNA was kept frozen at -20oC 
for further downstream application. 
 Polymerase chain reaction (PCR) 
 
All PCR was carried out aseptically in a PCR Workstation™ (C.B.S. Scientific) to control 
the risk of contamination. The C1000 Touch™ thermal cycler (Bio-Rad) was used in all 
analyses to make sure there was no variation during the amplification when using 
different instruments. 
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 Archaeal 16S rRNA amplification 
 
PCR amplification of the V3 region of the archaeal 16S rRNA gene profiling was 
conducted to analyse the archeal community from the gut of preterm infants. Different 
forward and reverse primers with clamp and without clamp before were optimised which 
yielded clear bands. For the forward primers used:  
YUArch344FC(5'CGCCCGCCGCGCCGCGGCGGGCGGGGCGGGGGCACGGGGG
GACGGGGYGCAGCAGGCGCGA), YU-ARCH 344 (ACGGGGYGCAGGCGCGA 
3'), RC Arc 344 f (5'-TCGCGCCTGCTGCRCCCCGT 3') andCS-Arc344FGC (5'-
CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCACGGGGCGCAGCAGGCG
CGA-3') and for the reverse primers: RC519RGC(5'-
CGCCCGCCGCGCGCGGCGGGCGGGGCGGGGGCACGGGGGGCAGCMGCCGC
GGTAATWC 3') and CS 519 R (5'-GWATTACCGCGGCKGCTG 3')   (Zhongtang et 
al. 2008). In order to run the PCR product on DGGE gel the forward primer contained a 
40 bp GC-clamp attached to the 5' end. The reaction was performed with 0.5 mM each 
primer 1x EX-Taq buffer, 0.3 mM each dNTP, 1 mM of MgCl2, 500 mg BSA, 1.25 U 
Ex-Taq (Takara) and 1 μL of gDNA or cDNA template made up to 50 μL with sterile 
18.2 MΩ H20.  
The thermo cycler conditions used for Archeal 16S rRNA DNA amplification included 
initial denaturation for 5 min at 95 ˚C followed by 10 cycles of denaturation at 95 °C for 
30 s, annealing at 61 °C for 30 s, elongation at 72 °C for 1 min and another 25 cycles of 
94 °C denaturation for 30 s, annealing at 56 °C for 30 s and elongation at 72 °C for 1 min 
with a final extension at 72 °C for 10 min. The final extension step was included in all 
PCR cycles that were to be analysed by DGGE to prevent visualisation of spurious double 
bands which would obstruct accurate analysis of the gel images and make excision of 
bands difficult (Janse et al. 2004). 
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 Bacterial 16S rRNA amplification 
 
PCR amplification of the V3 region of the bacterial 16S rRNA gene was performed with 
the following primers (V3FC (5'- CGC CCG CCG CGC GCG GCG GGC GGG GCG 
GGG GCA CGG GGG GCC TAC GGG AGG CAG CAG -3') with a 40 bp GC clamp 
attached to the 5' end and V3R (5'- ATT ACC GCG GCT GCT GG -3') (Muyzer  et al. 
1993). The reaction was performed with 0.5 mM each primer 1x EX-Taq buffer, 0.3 mM 
each dNTP, 1 mM of MgCl2, 500 mg BSA, 1.25 U Ex-Taq (Takara) and 1 μL of gDNA 
or cDNA template made up to 50 μL with sterile 18.2 MΩ H20. The cycling conditions 
include initial denaturation for 5 min at 95 ˚C followed by 20 cycles of 95 °C for 1 min, 
65 °C for 1 min and 72 °C for 30 s followed by 15 cycles of 95 °C for 1 min, 55 °C for 1 
min and 72 °C for 3 min with a final extension at 72 °C for 30 min. The 30 minute final 
extension step was included in all PCR cycles that were to be analysed by DGGE to 
prevent visualisation of spurious double bands which would hinder accurate analysis of 
the gel images and make excision of bands difficult (Janse et al. 2004).  
 Fungal 28S rRNA amplification 
 
The fungal community 28S rRNA amplification was performed with the following 
primers (5'- GTG AAA TTG TTG AAA GGG AA -3') with a 40bp GC clamp at the  5' 
end and 28SRC (5'- CGC CCG CCG CGC GCG CGG CGG GCG GGG CGG GGG CAC 
GGG GGG GAC TCC TTG GTC CGT GTT -3') (Sandhu et al. 1995). The reaction was 
performed with 0.5 μM each primer 1x Ex Taq buffer, 0.3 mM each dNTP, 1 mM of 
MgCl2, 500 mg BSA, 1.25 U Ex Taq (Takara) and 1 μL of cDNA template, the reaction 
was made up to make the final volume of 50 μL with sterile 18.2 MΩ H20. The cycling 
conditions used were an initial denaturation for 5 min at 95 ˚C followed by 10 cycles of 
95 °C for 1 min, 60 °C (-1 °C per cycle) for 1 min and 72 °C for 30s followed by 25 
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cycles of 95 °C for 1 min, 50 °C for 1 min and 72 °C for 30 s with a final extension at 72 
°C for 30 min (Janse et al. 2004). 
 Confirmation of successful DNA extraction and PCR 
 
A 1% (w/v) agarose gel was prepared to confirm that nucleic acid extraction had been 
successful. Briefly,  The agarose gel was submerged in 1× TAE and a 5 μL aliquot of 
nucleic acid was added to 1 μL of 6× bromophenol blue (Appendix 1), mixed by pipetting, 
and then loaded into the wells of the agarose gel alongside 5 μL of Hyperladder 1 
(Bioline). The electrophoresis tank was run at a constant current of 120 mA for 24 
minutes. For DNA staining, 5 μL of SYBR Safe (Invitrogen; 10,000×) was added to the 
molten agarose prior to it setting. The gel was stained in the dark for 30 minutes at room 
temperate with gentle agitation. Gels were viewed under U.V. light using the Gel Doc 
2000 gel documentation system (Bio-Rad) and quantity one™ software (v4.1.1.) to 
confirm the presence of nucleic acid product of correct size by comparison with fragments 
from the standard ladder. 
 Denaturing gradient gel electrophoresis (DGGE) 
 
The DGGE technique involves the following stages: 
 Culture of common stool isolates used for DGGE ladder 
 
In order to create a “ladder”, some common bacterial isolates from the gut of preterm 
infants were cultured that could be used for loading on to a DGGE gel alongside with 
samples to allow alignment across multiple gels (Tourlomousis & Kemsley 2010). The 
isolates used are shown in Table 2.1. Cultured isolates were obtained from the Freeman 
hospital.
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Table 2-1:  Organisms used to generate DGGE ladder 
 
Bacterial speciesa Fungal speciesb 
Enterobacter cloacae  Candida parapsilosis 
Serratia marcescens  Candida dubliniensis 
Citrobacter freundii  Candida albicans 
Staphylococcus epidermidis  Candida glabrata 
Clostridium perfringens  Aspergillus fumigatus 
Bacteroides fragilis  Exophiala dermatitidis 
Sercina ventriculi  Scedosporium apiospermum 
aLadder used only for alignment of multiple gels. Sequencing of bands was carried out 
for identification. 
bLadder used for alignment and identification. 
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 Preparation of the stock solution for DGGE 
 
The details of the stock solution and other electrophoresis conditions for DGGE were 
given in Table 2.1 and 2.2. The other protocols for the preparation of DGGE reagents are 
presented in the appendix 1. 
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Table 2-2: Electrophoresis conditions for DGGE 
 
The following are the protocols for making up a 12% acrylamide denaturing solution 
(200ml) 
Condition  For bacteria  For fungi  
Denaturing concentration 
gradient  
35%  - 55%  40%  - 60%  
Temperature  60°C  60°C  
Voltage  200 V  70 V  
Time  4.5 hrs  17 hrs  
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Table: 2-3  Composition of the gel stock solution for DGGE 
 
Reagent 
For bacteria  For fungi  
35% 
denaturing 
solution  
55% 
denaturing 
solution  
40% 
denaturing 
solution  
60% 
denaturing 
solution  
40% acrylamide 
(37.5:1)  
60 ml  60 ml  60 ml  60 ml  
50× TAE  4 ml  4 ml  4 ml  4 ml  
Formamide 
(deionized)  
28 ml  44 ml  32 ml  48 ml  
Urea(electrophoresi
s grade) 
29.4 g  463.2 g  33.6 g  50.4 g  
Distilled water  Fill up to 200 
ml  
Fill up to 200 
ml 
Fill up to 200 
ml 
Fill up to 200 
ml 
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 Assembly of Gel cast 
  
The (Bio-Rad) protocol was used to cast and run the DGGE gels were placed in the centre 
of the flat plane. Glass plates were first cleaned using ethanol before use to remove any 
residue and static that may interfere with the gel casting. A thin layer of silicon grease 
was applied to the 1mm spacers and the sponge in the casting stand to prevent leakage of 
the denaturant during casting and running  (Brinkhoff & Hannen 2001). The alignment 
card was inserted between the glass plates and the sandwich clamps were tightened to 
each side of the glass plates. The alignment card was then removed and the gel cast was 
securely fixed in the casting stand ensuring the base of the glass plates was sealed. The 
sandwich clamps on the long and short plates were fitted into the notches in the clamps. 
The screws were tightened.  
 Casting Gels  
 
To cast DGGE gels, a 19 gauge needle fitted with a tube and Y-fitting was attached to the 
centre of the plates. Two plastic 50 mL tubes, labelled high and low, were placed upright 
in a rack and the denaturant solutions described below were added to the tubes 
accordingly, the lids were secured, and inverted to mix. Bacterial DGGE analysis utilised 
a denaturant gradient of 34 – 55% denaturant, whereas fungal DGGE employed a 
denaturant gradient of 40 – 60% denaturant (with 100% denaturant corresponding to 7 
mol l-1 urea plus 40% v/v formamide). In all cases 12% polyacrylamide gels were used 
(See Table 1.2 for the composition of DGGE gel stock solutions).  
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Table 2-4:  DGGE reagents 
 
Reagent High 
DCODE dye (Appendix 1) 100 μL 
Denaturing solution (Appendix 3) 25 mL 
APS (10% w/v) 216 μL 
TEMED 21.6 μL 
 
 
  
 
52 
 
The high and low denaturing solutions were each drawn up into a separate 25 mL syringe 
with rubber tubing. Each syringe was then attached to the Y-fitting before being secured 
in a Model 475 gradient former (Bio-Rad) and the cam wheel turned to dispense the 
solutions into the gel cast. The solution was injected until it reached the upper edge of the 
plate. Once the solutions had been dispensed into the cast, the needle was removed and a 
well comb was placed between the two glass plates, ensuring no bubbles existed in the 
gel. The gel was left for a minimum of 1.5 hours to polymerise. 
 Running the DGGE Gel 
 
The control module was placed on the electrophoresis tank, the heater was turned on to 
set up the temperature to 60 ºC at least 5 ºC higher than the electrophoresing temperature 
and the stirrer was switched on. The comb was carefully pulled out from the polymerized 
gel. The gel was attached to the core of the DCode. A 15 μL aliquot of sample was mixed 
with an equal volume of 2x DGGE loading buffer (Appendix 1) and loaded onto gel. The 
control module was replaced and once the temperature had returned to 60 ºC the power 
pack was set to 200 V for 4.5 hours for bacterial community analysis or 70 V for 17 hours 
for fungal community analysis. 
 Staining 
 
A 25 μL aliquot of SYBR gold (Invitrogen, 10,000x) was diluted in 250 mL of 1x TAE 
in a staining container. The gel was removed from the glass plates and submerged in the 
staining solution in the dark for 30 minutes at room temperate with gentle agitation. The 
gel was de-stained in distilled water to remove any excess stain and viewed under U.V. 
light using the Gel Doc 2000 gel documentation system (Bio-Rad) and quantity one™ 
software (v4.1.1.).  
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 Preparation of the DGGE Ladder 
 
The denaturing gradient used for loading the fungal DGGE ladder is 40% - 60% and that 
of archaeal ladder was 35% - 55% which gives desire result as contained in Table 1.1 & 
1.2. The organisms used to generate the ladder were known common isolates for both 
bacterial and fungal species (Table 2.1). The organisms were pulled together, vortexed 
properly and loaded approximately 30 μl each on the three different wells, two wells from 
the both ends and one at the middle, the prepared gels was run accordingly. Clear bands 
were observed and saved. 
 Statistical analysis of DGGE gels (TotalLab Phoretix 1D) 
 
Images captured using quantity one™ software (v4.1.1.) were exported in tagged image 
file format (.TIFF) at 276 dots per inch (DPI) into a new experiment folder. The lanes of 
the gels were created using the automatic lane creation function and the frames manually 
adjusted so that all bands were central in the lanes. The background from the lanes was 
subtracted using a rolling ball method with a radius of 100 pixels. The band detection 
setting was applied to the gels using a minimum slope of 100, noise reduction of 4, and a 
% max peak of 2, then bands were added / removed and the band width adjusted manually. 
As explained previously, a ladder of known organisms was loaded to the outside and 
middle lanes on each DGGE gel in the experiment so that successful gel alignment could 
be achieved (Tourlomousis & Kemsley 2010). Bands from the DGGE ladder were 
assigned standard retention factor (Rf) values based upon the distance they had migrated 
through the gel, each corresponding band from all gels in the experiment was given the 
same value. A minimum of five bands per standard has been suggested for accurate 
interpolation of multiple gels which was exceeded for both the bacterial and fungal bands 
analysis (Tourlomousis & Kemsley 2010). 
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A new database was created in Phoretix 1D Pro based on the analysed gels. The successful 
alignment of the gels was confirmed by matching all lanes in the database then creating 
a dendrogram based on the Dice coefficient. Alignment of multiple gels was deemed 
successful if the ladders clustered together. An OTU matrix was then created by the 
software using the Rf values of all bands and the relative intensities, which was exported 
to Microsoft Excel 2010 to be used for subsequent analysis.  
 PCR-DGGE Analysis for Archeal microbial communities 
 
 Primers trial test 
 
For a robust analysis of archeal community different sets of primers were compared in 
our cohort (all the primers used were ordered). Initially, two new archeal primers were 
ordered for both forward andbackward:CS-
Arc344FGC(5'CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCACGGGGCGC
AGCAGGCGCGA-
3')and:RC519RGC(5'CGCCCGCCGCGCGCGGCGGGCGGGGCGGGGGCACGGGG
GGCAGCMGCCGCGGTAATWC 3'). After conducting normal PCR (as described 
previously) alongside with eight different DNA samples selected from demographic data 
by using the above set of primers; there was no any band observed in all the samples 
including the negative control. Same samples, thermo cycler conditions and other 
protocol maintained to carry out another PCR using new forward primer: YUArch344FC 
(5'CGCCCGCCGCGCCGCGGCGGGCGGGGCGGGGGCACGGGGGGACGGGGY
GCAGCAGGCGCGA). After running the agarose gel for this new primer, same result 
was observed. 
To optimise the above primers, the DGGE was set up and used the two set of PCR 
products from the above set of primers, they were arranged serially and loaded in the 
wells by alternating the samples bearing same numbers i.e. 1 & 1 loaded in the first and 
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second well from the first and second primers respectively, 2 & 2….8 & 8. The DGGE 
was run accordingly. After gel was viewed, clear bands were observed from the second 
wells bearing the second primer (YUArch344FC) indicating that it seems to be better than 
the first primer (CS-Arc344FGC) as such it was maintained and used for subsequent 
archeal studies. 
 Preparation of Archeal Ladder 
Because common archeal isolates were unavailable to be used in generating ladder, an 
improvised ladder was used for subsequent analysis. Therefore, the desired bands 
obtained from known bacterial isolates were cut off and processed accordingly, a normal 
PCR was performed using the prepared products above, after agarose gel was ran, some 
clear bands appeared. Another gel was prepared, a  ladder was made by aliquoting 2μl of 
each PCR products mixed with 15μl of 2X loading dye, vortexed properly and loaded 
30μl on to the first lane as a ladder, then 10 selected PCR products were prepared as DNA 
templates (3 μl DNA+ 2 μl sterile 18.2 MΩ H2O+ 5 sterile 18.2 MΩ H2l of 2X loading 
dye) then 10 μl of the PCR product was loaded on each well and ran the electrophoresis 
for 4.5hrs at 200 volts, after run finished , it was viewed, focussed and saved.  Clear 
desired bands were observed. Furthermore, the DNA samples of the three corresponding 
PCR products above that produced good bands were selected and prepared another PCR 
in quadrant to increase the volume of the ladder (all the other conditions and working 
solutions were maintained). Agarose gel was performed; one amplified DNA was selected 
to represents each set up products, clear bands were seen. Therefore, all the PCR products 
were pooled together and vortexed properly as our desired archeal ladder for subsequent 
used in DGGE analysis. 
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 Sequencing excised Bands from DGGE Gels 
 
  Gel storage 
 
Excess moisture was removed carefully before the gel was placed between two A4 sheets 
of acetate, which was then wrapped in cling film. The gel was then placed in a labelled 
A4 plastic sleeve and stored in a folder at -80 °C. 
  Band excision 
 
The desired bands were excised from previously stored or freshly run DGGE gels. Whilst 
exposed to U.V. light, bands of interest were excised from the gels using a sterile blue (1 
mL) pipette tip and placed in a sterile 1.5 mL microfuge tube. The bands were immersed 
in 10 μL of 18.2 MΩ H20 and vortexed for 1 minute. The tubes were stored at 4 ºC 
overnight to allow DNA to elute from the gel.  
  Amplification and clean-up of excised band 
 
After overnight incubation, the tubes containing the excised band were thoroughly mixed 
and centrifuged prior to the full 10 μL aliquot of the eluate being used as the template for 
PCR. The PCR was conducted following the normal protocols as described previously 
with the exception of the primer containing the 40 bp GC-clamp which was replaced by 
the unclamped primer. Once confirmation of successful PCR was carried out, the PCR 
product was subject to ExoSAP-IT PCR clean-up (Affymetrix). Briefly, 5 μL of PCR 
product was mixed with 2 μL of ExoSAP-IT and incubated in a c1000 Touch™ thermal 
cycler (Bio-Rad) at 37 °C for 15 minutes to degrade unused primers and nucleotides. The 
reaction was then heated to 80 °C for 15 minutes to inactivate the ExoSAP-IT. 
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 Cloning 
  Preparation of Top 10 competent cells 
 
The TOP10 chemically competent E. coli cells are prepared in series of steps over number 
of days. A sterile 30 mL glass universal containing 10 mL LB media was inoculated with 
a single fresh colony of TOP10 E. coli cells (Invitogen). The culture was incubated at 200 
rpm for 2 – 3 hours at 37°C. When the OD600 reached 0.35 – 0.4 nm, the cells were then 
transferred aseptically into two sterile ice cold universals and incubated on ice for 10 
minutes. The cells were then centrifuged for 10 min at 2,700 x g, 4 °C. The supernatant 
was discarded and the each of the pelleted cells were re-suspended in 7.5 ml sterile ice 
cold MgCl2 by gentle mixing. The cells were pelleted again by centrifugation (10 min at 
2,700 x g, 4°C). The supernatant was discarded and each of the cell pellets were re-
suspended in 0.5 mL of sterilised ice cold CaCl2 and incubated on ice for at least 1.5 h to 
become competent. For long term storage the appropriate volume of sterile 50% (v/v) 
glycerol was added to give a final concentration of 15% (v/v). Since transformation 
required the cells at 50 µL per reaction, 65 µL of cells (in 50% (v/v) glycerol at a final 
concentration of 15% (v/v)) was aliquoted into individual sterilised 1.5 mL micro 
centrifuge tubes and stored at -80°C for downstream application. 
  Ligation 
The ligation was carried out following the reaction set up as in the Table (2.2) below. 
ExoSAP-IT treated PCR product was cloned using the pGEM-T® Easy Vector and the 
2X Rapid Ligation Buffer (Promega). Tubes were centrifuged to collect the contents at 
the bottom. The ligation reaction was mixed by pipetting and incubated overnight at 4 °C 
to increase number of transformants after the process. 
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Table 2-5: Ligation reaction set up 
 
Reaction Component Standard Reaction Positive 
Control 
2X Rapid Ligation Buffer,  5 μL 5 μL 
pGEM®-T Easy Vector (50 ng) 1 μL 1 μL 
PCR product 3 μL   - 
Control Insert DNA   - 2 μL 
T4 DNA Ligase (3 Weiss units/μL) 1 μL 1 μL 
18.2 MΩ H20   - 1 μL 
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 Transformation 
 
Aliquots of previously prepared TOP10 competent cells were removed from storage (-80 
°C) and thawed on ice for approximately 5 minutes. Meanwhile, 2 μL of ligation reaction 
were added to a sterile 1.5 mL microfuge tube on ice. The 65 μL aliquot of TOP10 
competent cells were carefully added to the ligation reaction and mixed by gentle flicking. 
The tubes were incubated on ice for 20 minutes and then heat-shocked at 42 °C for 50 
seconds and immediately returned to ice for a further 2 minutes. 950 μL of room 
temperature SOC medium (Appendix 4) was then added and the tubes were incubated for 
1.5 hours at 37 °C in an orbital incubator with shaking at 150 rpm. Duplicate 
LB/ampicillin/IPTG/X-Gal plates (Appendix 5) were warmed in an incubator at 37 °C 
for 30 minutes prior to spreading a lawn from 100 μL of the ligation reaction onto each 
of the two plates which were incubated at 37 °C overnight (16-24 hours). The presence 
of white colonies (Blue-white screening technique) was an indicator of successful 
incorporation of the PCR product in to the plasmid but this must be confirmed by carrying 
restriction enzyme digest. 
  Inoculation and confirmation of successful incorporation of insert 
 
 When the white colony was successfully obtained, most of them were inoculated into an 
LB/ampicillin broth (Appendix 5) which was incubated at 37 °C overnight. PCR 
amplification was performed to confirm successful incorporation of the insert. The 
primers used were M13 Forward (5'- CGC CAG GGT TTT CCC AGT CAC GAC -3') 
and M13 Reverse (5'- TCA CAC AGG AAA CAG CTA TGA C -3'). An initial PCR was 
set up containing 0.5 mM each primer 1x EX-Taq buffer, 0.3 mM each dNTP, 1 mM of 
MgCl2, 500 mg BSA, made up to 49.75 μL with sterile 18.2 MΩ H20 in the absence of 
template DNA and 1.25 U Ex-Taq (Takara). Using a sterile pipette tip, the remainder of 
the white colony was transferred to the PCR reaction before the Ex-Taq was added and 
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the PCR was initiated. The cycling conditions used were an initial denaturation for 5 min 
at 95 ˚C followed by 35 cycles of 95 °C for 30 s, 65 °C for 30 s and 72 °C for 3 min and 
72 °C for 3 min with a final extension at 72 °C for 10 min. An agarose gel was carried 
out following the previous protocols; successful visualisation of a band corresponding to 
the correct fragment length was used to confirm successful incorporation of the insert. 
  Plasmid DNA purification (PureYield™ Plasmid Miniprep kit) 
 
Plasmid DNA was purified using the PureYield™ Plasmid Miniprep kit (Promega). 
Antibiotic selection broth (5 ml) was prepared and individual broths were inoculated with 
a single white colony from the transformation stage and incubated overnight at 37 ˚C.  
Prior to beginning of the experiment, the cell lysis buffer was warmed to 37 ˚C and 
inverted to dissolve any precipitate. Briefly, A 1.5 mL of the LB/ampicillin overnight 
bacterial culture was added to a 2 mL microfuge tube and centrifuged at 13,000 × g for 
30 seconds and the supernatant discarded, this step was repeated once to process a total 
volume of 3 mL. The cell pellet was re-suspended in 600 μL of sterile 18.2 MΩ H20 and 
100 μL of cell lysis buffer was added before the tube was inverted 6 times until the 
solution changed from opaque to clear blue. The cell lysis buffer contains SDS to lyse 
cell membrane and sodium hydroxide which breaks down the cell wall but also causes 
DNA to depolymerise by breaking hydrogen bonds. Within 2 minutes, 350 μL of cold 
neutralization solution was added and the solution was mixed by inversion causing a 
precipitate to form. The neutralisation solution contains potassium acetate which reduces 
the alkalinity of the solution causing renaturation of the plasmid DNA but leaving gDNA 
linearised allowing it to be separated from the plasmid DNA by centrifugation. The 
solution was centrifuged at 13,000 × g for 3 minutes to pellet the precipitate and the 
supernatant (~900 μL) was transferred to a PureYield™ Mini-column. The column was 
centrifuged at 13,000 × g for 15 seconds and the flow through discarded. 200 μL of 
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Endotoxin removal wash was added to the column and centrifuged for 15 seconds, 
followed by addition of 400 μL of column wash solution to the column and a 30 second 
centrifugation at 13,000 × g. The column was transferred to a 1.5 mL micro centrifuge 
tube and 30 μL of elution buffer was added to the column membrane which was incubated 
at room temperature for 1 minute. The column was centrifuged at 13,000 × g for 15 
seconds and the eluted DNA was stored at -20 ˚C for further downstream applications. 
  DNA quantification (NanoDrop 1000) 
 
 The plasmid DNA is required in a concentration of 50 - 100 ng/μL in a total volume of 
15 μL, to calculate the amount needed for an appropriate standard curve for the qPCR 
reaction. To quantify the plasmid DNA a NanoDrop 1000 Spectrophotometer (Thermo 
Scientific) was used. The purified plasmid DNA diluted by 50% and 1 μL was applied to 
the pedestal and readings were measured in triplicate and recorded. An average of the 
triplicates was calculated and the concentration adjusted as appropriate for sequencing. 
Samples were either diluted in sterile 18.2 MΩ H20 or concentrated using a RVC 2-18 
rotational vacuum concentrator at 60 °C.  
 Restriction enzyme (RE) digest 
 
An analytical scale restriction enzyme digest is usually performed in a volume of 20 μl 
between 0.2 – 1.5 μg of substrate DNA. The reaction was set up in the following order: 
Sterile deionized water 12.3 μl, 2.0 μl of RE 10X Buffer, 0.2 μl Acetylated BSA (10 μg/ 
μl), DNA 1 μl/ μl, the above reaction mixture was gently mixed by pipetting and 0.5 μl 
of restriction enzyme was added up to make the final volume of 20 μl. The reaction 
mixture was gently mixed by pipetting and centrifuged; it was then incubated at 37 °C for 
90 minutes followed by a heat inactivation step at 65 °C for 10 minutes. After the 
experiment digestion products were visualised on an agarose gel (1% w/v). 
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 Quantitative Polymerase Chain Reaction (QPCR) 
 Preparation of   qPCR standard curve 
 
 To generate the plasmid DNA standard of the total microbial load from the samples, 
conventional end point PCR was performed on the extracted DNA using 5 μL of X10 
EX-Taq Buffer, 2.5 μL each primer, 4 μL each dNTPs, 0.25 μL each Ex-Taq, 2.0 μL each 
mgcl2, 2.5 μL BSA, 0.5 μL DNA template and 30.75 μL sterile 18.2 MΩ H2O to made 
up to 50 μL. The PCR conditions were as follows: 1 cycle at 95 °C for 3 minutes, followed 
by 34 cycles of 95 °C, denaturation for 30 secs, primer annealing at 65 °C for 30 secs, 
and DNA extension at 72 °C for another 30 secs, then a final extension cycle step at 72 
°C for 6 minutes. The PCR products were cleaned to remove unincorporated dNTPs and 
primers using Exo-SAP-IT and cloned using the p-GEMT easy vector cloning kit 
(Promega). Plasmid DNA was purified using the PureYield™ Plasmid Miniprep kit 
(Promega). The purified plasmids were then pooled into a single micro centrifuge tube. 
Concentration and quality of extracted plasmid DNA was determined using a NanoDrop 
1000 Spectrophotometer (Thermo Scientific). An average of the triplicates was calculated 
and the concentration adjusted as appropriate for Real –Time PCR and sequencing. 
To achieve absolute quantification of the total microbial load of faecal samples, 
quantitative real-time polymerase chain-reactions (qPCR) was conducted on the extracted 
DNA from the samples from NEC and control specimens. The quantification was done 
using SYBR green methodology as described in qPCR protocol Guide (Illumina), with 
universal 16S primers (forward 5’- ACTCCTACGGGAGGCAGCAG-3’ and reverse 5’- 
ATTACCGCGGCTGCTGG-3’). A standard curve with a 3 fold dilution series was 
generated. This requires the calculation of plasmid DNA which is needed to generate the 
standards. The relative fluorescence units (RFU) and then relative Ct values (∆Ct) as well 
as cycle threshold (Ct) were obtained, relative to NEC and control samples. Values were 
normalized by the mass of faecal material used for DNA extraction. Data was then 
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multiplied by a constant 0.1 gram of stool (1000) (Appendix 7 Table for qPCR raw data 
for total bacterial load). 
A standard curve with 10 fold dilutions was generated. This requires the calculation of 
plasmid DNA which is needed to generate the standards. Firstly, the size of the plasmid 
DNA in base pairs (bp) was calculated based on the combined length of the PCR amplicon 
and the plasmid (p-GEMT easy vector is 3015 bp).  
The mass of the plasmid was then calculated by multiplying the size of the plasmid (bp) 
by the average weight of one bp which is 1.096 × 10-21 (g/bp). The average weight of one 
bp was calculated by dividing the average molecular weight of a double stranded DNA 
molecule (660 g) by Avogadro’s number (6.023 × 1023). The mass of plasmid containing 
the copy number needed to achieve a suitable standard curve was then calculated based 
on a standard curve quantifying between 3 × 106 and 30 copies/g in 10-fold dilutions. 
Therefore, to calculate what mass of plasmid will contain the copy number of interest, the 
previously calculated mass of the plasmid was multiplied by the desired copy number for 
the standard curve.  
The figure produced by this calculation could then be divided by the required volume in 
the final PCR reaction mix to give the final concentration of the plasmid DNA (g/µL). It 
was then possible to prepare a standard curve by rearranging the formula V1C1 = V2C2 to 
V1 = C2 X V2 / C1. Where V1 is the initial volume required to achieve the concentration 
(unknown), C1 is the initial concentration of the plasmid which was calculated in the 
previous step, C2 is the final concentration of the stock plasmid, and V2 is the final 
volume in which the plasmid will be diluted. This protocol was maintained throughout 
when calculating the plasmid DNA needed in preparing qPCR standard during the cohort 
studies. 
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Table 2-6 Primers used in qPCR assay for probiotics study 
 
 
Species Name of 
Primer 
Sequence (5'-3') Target 
sequence 
Annealing 
Temp (°C) 
Product 
Size (bp) 
Reference 
B. bifidum BiBIf- 1 CCACATGATCGCATGTGATT
G 
16S rDNA 62 278 (Maria et al. 2003) 
BiBIF- 2 CCGAAGGCTTGCTCCCAAA 
L. acidophilus Acidfor AGCGAGCTGAACCAACAGAT 16S rDNA 60 227 (Tabasco et al. 2007) 
Acidrev AGGCCGTTACCCTACCAACT 
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Table 2-7 Primers used in qPCR assay for the quantification of total bacterial loads  
  
 
Name of 
Primer 
Target 
species 
Sequence (5'-3')       Target 
sequence 
Annealing 
Temp (°C) 
Product 
Size (bp) 
Reference 
EUB517R All 
bacteria 
ATTACCGCGGCTGCTGG 16S rDNA 65 180 Muyzer et al., 1993 
  
EUB338 All 
bacteria 
ACTCCTACGGGAGGCAGCAG 16S rDNA 65 180 J Lane, 1991) 
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 Setup qPCR reaction mix 
 
When the standard curve had been properly prepared, the reaction mix for the standard 
curve and reaction could be setup. All preparation was carried out aseptically in a PCR 
Workstation.  Pipette filter tips (Fisher) and pipettes designated solely for qPCR setup 
were used to reduce the possible contamination and errors during the reaction. No 
template controls (NTCs) were included in every reaction to check for contamination of 
all the reagents, plastics and pipettes used in preparing the reaction. Each reaction was 
performed in triplicate to ensure accuracy. The qPCR protocol was based on the one 
previously described (Baxter & Cummings 2008). The unknown DNA samples were 
diluted 1:20, dilutions were performed in micro centrifuge tubes using sterile 18.2 MΩ 
PCR grade water. These diluted samples and an aliquot of the plasmid DNA stock was 
heated at 95 °C for 10 minutes to ensure any tertiary structures which may have formed 
had been eliminated so that efficient amplification was possible. The plasmid DNA was 
then used to prepare the serial dilutions as calculated previously. The unknown samples 
(diluted 1:20) were further diluted 1:5 and the equivalent volume of sterile 18.2 MΩ water 
was used as the NTC. Once the dilutions of the standard curve and unknown samples was 
complete and the NTC was prepared, the reaction mix was setup ensuring that 
ABsolute™ QPCR SYBR® mix (Thermo Scientific) had limited exposure to light to 
prevent degradation. The final reaction mix contained 1x ABsolute™ QPCR SYBR® 
Green Mix (Thermo-Start™ DNA Polymerase, 3 mM MgCl2) , 0.35 mM each primer, 
12.5 μg BSA and 5 μl of DNA in a final volume of 25 μl.  
For total bacterial count, the cycling conditions used as 1 cycle at 95 °C for 3 minutes, 34 
cycles of 95 °C denaturation for 3secs, primer annealing at 65 °C for 3secs, and DNA 
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extension at 72 °C for another 3secs, then a final extension cycle step at 72 °C for 6 
minutes. 
Furthermore, to generate the standard for the Lactobacillus acidophilus and 
Bifidobacterium bifidum specific analysis during the probiotic studies, conventional end 
point PCR was carried out on the extracted DNA using 5 μL of X10 EX-Taq Buffer, 2.5 
μL each primer, 4 μL each dNTPs, 0.25 μL each Ex-Taq, 1 μL DNA template and 34.75 
μL sterile 18.2 MΩ H2O to made up to 50 μL. PCR amplification was carried out by 
applying the following PCR temperature profiles: After an initial denaturation step of 1 
cycle at 94 °C for 5 minutes, followed by 35 cycles of 95 °C for 30s, primer annealing at 
60 °C for 30s, and DNA extension at 72 °C for 30s, then a final extension cycle step at 
72 °C for 10 min (Tabasco et al., 2007). The protocol was the same for both Lactobacillus 
acidophilus and Bifidobacterium bifidum with minor modifications, for Bifidobacterium 
bifidum; annealing temperature was increased to 62 °C (Bielecka et al. 2003) and the 
number of cycles were reduced from 35 to 30. The target copy numbers for each reaction 
were calculated from the standard curve and were used to ascertain the number of copies 
per g of stool then log transformed. Standard deviation was determined on the replicate 
threshold cycle (CT) value and reactions repeated if the deviation was above 0.4. Samples 
were considered to be below reasonable limits of detection if the CT value was above 30 
cycles (Karlen et al. 2007). 
 Normalisation of qPCR data 
 
The mean copy numbers from the triplicate reactions were calculated using the qPCR 
standard and the value for the refrigerated samples was paired with the same room 
temperature sample and the two values were added up. The concentrations for the two 
temperatures were then divided by the two added together to normalise the values and 
obtain a value between 0 and 1 to reduce the noise from biological variance. 
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 Analysis of Faecal Lactobacillus acidophilus and Bifidobacterium 
bifidum by Quantitative PCR 
  
Bacterial DNA was extracted from 100 mg of faecal sample for analysis of the total 
community using the PowerLyzer™ PowerSoil® DNA Isolation Kit (MoBio) and 
performed according to manufacturer’s instructions. To generate the standard for the 
Lactobacillus acidophilus  and Bifidobacterium bifidum specific analysis, conventional 
end point PCR was carried out on the extracted DNA using  5 μL of  X10  EX-Taq Buffer 
, 2.5 μL each primer, 4 μL each dNTPs, 0.25 μL each Ex-Taq, 1 μL DNA template and 
34.75 μL  sterile 18.2 MΩ H2O to made up to 50 μL. PCR amplification was carried out 
by applying the following PCR temperature profiles: After an initial denaturation step of 
1 cycle at 94 °C for 5 minutes, followed by 35 cycles of 95 °C for 30s, primer annealing 
at 60 °C for 30s, and DNA extension at 72 °C for 30s, then a final extension cycle step at 
72 °C for 10 min (Tabasco et al., 2007). The protocol same for both Lactobacillus 
acidophilus and Bifidobacterium bifidum with minor modifications, for Bifidobacterium 
bifidum; annealing temperature was increased to 62 °C (this is due to its higher PCR 
product size of 278 bp compared to Lactobacillus that has 227 bp)  (Maria et al. 2003) 
and the number of cycles were reduced to 30 instead of 35. Successful PCR was 
confirmed by 1% agarose gel electrophoresis. The PCR products were cleaned to remove 
unincorporated dNTPs and primers using Exo-SAP-IT and cloned using the p-GEMT 
easy vector cloning kit (Promega). Plasmid DNA was purified using the PureYield™ 
Plasmid Miniprep kit (Promega). The purified plasmids were then pooled into a single 
microcentrifuge tube. Concentration and quality of extracted plasmid DNA was 
determined using a NanoDrop 1000 Spectrophotometer (Thermo Scientific). An average 
of the triplicates was calculated and the concentration adjusted as appropriate for Real –
Time PCR and sequencing. 
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 To achieve absolute quantification of L. acidophilus and B. bifidum; quantitative real-
time polymerase chain-reactions (qPCR) was conducted. For quantification of L. 
acidophilus and B. bifidum, Taqman® methodology using species specific primers for 
each was done at an annealing temperature of 60°C (Tabasco et al. 2007)  and 62 °C 
(Maria et al. 2003) respectively. The whole quantification was done using SYBR green 
methodology as described in qPCR protocol Guide (Illumina). A standard curve with 3 
fold dilutions series was generated. This requires the calculation of plasmid DNA which 
is needed to generate the standards.  
 Quantitative PCR analysis of Eubacteria 
 
To generate the plasmid DNA standard, conventional end point PCR was performed on 
the extracted DNA using 5 μL of X10 EX-Taq Buffer, 2.5 μL each primer, 4 μL each 
dNTPs, 0.25 μL each Ex-Taq, 2.0 μL each mgcl2, 2.5 μL BSA, 0.5 μL DNA template 
and 30.75 μL sterile 18.2 MΩ H2O to made up to 50 μL. DNA amplification was 
performed as follows: 1 cycle at 95 °C for 3                                                                                                                             
minutes, 34 cycles of 95 °C denaturation for 3secs, primer annealing at 65 °C for 3secs, 
and DNA extension at 72 °C for another 3secs, then a final extension cycle step at 72 °C 
for 6 minutes. PCR products were visualised on a 1% agarose gel. The PCR products 
were cleaned using Exo-SAP-IT and cloned using the p-GEMT easy vector cloning kit 
(Promega). Plasmid DNA was purified using the PureYield™ Plasmid Miniprep kit 
(Promega). The purified plasmids were then pooled into a single microcentrifuge tube. 
Concentration and quality of extracted plasmid DNA was determined in triplicate using 
a NanoDrop 1000 Spectrophotometer (Thermo Scientific). An average of the triplicates 
was calculated and the concentration adjusted as appropriate for Real – Time PCR and 
sequencing. 
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To achieve absolute quantification of total microbial load of faecal samples, quantitative 
real-time polymerase chain-reactions (qRT-PCR) was conducted on the extracted DNA 
from the faecal samples from NEC and control patients. The quantification was performed 
using SYBR green methodology with universal 16S primers; EUB 517R and EUB 338 
(forward 5’ ACTCCTACGGGAGGCAGCAG-3’ and reverse 5’- 
ATTACCGCGGCTGCTGG-3’). Theses primers were all ordered (see Table 2.17 for the 
primers detail). A standard curve with a 3 fold dilutions series was generated. With 
plasmid DNA, The relative fluorescence units (RFU) and then relative Ct values (∆Ct) as 
well as cycle threshold (Ct) were obtained, relative to NEC and control samples. Values 
were normalized to 0.1 gram of stool. (Appendix 7 Table for qPCR raw data for total 
bacterial load). 
 Next Generation Sequencing (NGS) Technique 
 
In order to accurately determine the diversity and relative abundance of microbial 
community in the gut of preterm infants, the DNA sample was processed and sequenced 
using the benchtop MiSeq (Illumina) platform. The whole NGS process was carried out 
by the “NUOMICS” facility at Northumbria University.  
 MiSeq  
 
The 16S sequencing on the MiSeq platform was carried out in house, based on the 
‘Schloss wet-lab MiSeq SOP’ (available at - http://www.mothur.org/wiki/MiSeq_SOP),  
(Kozich et al. 2013; Kozich et al. 2014). Paired end indexed reads were used to multiplex 
192 samples per run (188 samples, 2 positive, and 2 negative controls). Briefly, extracted 
DNA from the samples was aliquoted into 96 well plates with the last two wells left empty 
for controls. In a new 96 well plate, 17 μL of Accuprime Pfx Supermix (Life Technologies 
Ltd.) was dispensed into each well, before 1 μL of the DNA template and 2 μL of each 
paired set of index primers was transferred to the corresponding well. 1 μL of PCR grade 
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dH2O was added to the negative control well and 1 μL of a mock community was added 
to the positive control well on each plate. Plates were vortexed briefly and spun down 
before being placed in the thermo cycler (BioRad CFX96 Touch). PCR was carried out 
using the following cycling conditions; initial step at 95 °C for 2 min, then 30 cycles of 
95 °C for 20 seconds, 55°C for 15 seconds, extension at 72 °C for 5 min, and a final 
extension at 72 °C for 10 min. Successful PCR was confirmed by visualising products on 
an agarose gel (1%) on a subset of 12 samples per plate. 
Normalisation was performed by transferring 18 μL of PCR product to the corresponding 
well on a normalisation plate. 18 μL of binding buffer was then transferred and the 
contents mixed by pipetting and vortexing before being spun down. Plates were incubated 
at room temperature for 1 hour. Being careful not to touch the sides of the wells, liquid 
was removed and 50 μL wash buffer was added and briefly mixed by pipetting and 
removed immediately removed leaving no residue. 20 μL of elution buffer was then added 
and mixed by pipetting and vortexed before being spun down. Following incubation at 
room temperate for 5 minutes 5 μl from each well was pooled and the plates frozen for 
later use.  
Library quality control was carried out using a Bioanalyser (Agilent bioanalyser 2100) 
and qPCR using KAPA SYBR FAST qPCR Master Mix (Anachem Ltd.). The pooled 
library underwent serial dilutions to generate the following dilutions; 1:1, 1:10, 1:1000, 
1:2000, and 1:4000. For the Bio analyser, the gel dye mix, ladder, and 1 μL of the 1:1 and 
1:10 dilutions were loaded into the necessary wells of a high sensitivity chip. For Kapa 
qPCR library quantification reactions were carried out in a 10 μL reaction volume with 6 
μL of master mix and 4 μL of standards and library dilutions, in triplicate. qPCR was 
carried out using the following cycling conditions; initial activation step at 95 °C for 5 
min, then 35 cycles of denaturation at 95 °C for 30 seconds and annealing at 60°C for 45 
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seconds. From these results a further dilution was carried out on the median pool dilution 
amongst the standards, as all pools were normalised to the lowest dilution pool selected. 
However, for the sequencing a 500 cycle reagent cartridge and all reagents and samples 
were thawed prior to set up. 3.4 μL of read 1 sequencing primers was placed in well 12, 
3.4 μl of the index primer was placed in to well 13, and 3.4 μl of read 2 sequencing primers 
was placed in well 14. Sampled were prepared by mixing 10 μl of library and 10 μl of 0.2 
NaOH and the PhiX spike was prepared by mixing 2 μl of PhiX, 3 μl PCR grade H2O, 
and 5 μl of NaOH. Following 5 min incubation, samples and PhiX were made up to 1 ml 
with HT1 and then HT1 was used to dilute the library and PhiX to 10 pM. A 5% PhiX 
run was used so 950 μl of 3.5 pM library and 50 μl PhiX were mixed in a tube and 600 μl 
of this mixture was loaded into well 17. The flow cell was rinsed with Milli-Q water, 
wiped with 80% ethanol, and carefully dried prior to placement within the MiSeq 
instrument. The cartridge, flow cell, and PR2 bottle were then loaded and the instruments 
followed accordingly (Kozich et al. 2014; Kozich et al. 2013). 
 Processing the raw sequencing reads  
 
Raw data generated using next generation sequencing technology was bioinformatically 
processed to reduce the error rate by trimming the primer and barcode sequences and 
removing reads with a poor quality score. The Mothur platform was used in the processing 
of raw sequence reads. 
 Mothur 
 
For both the Probiotics and Antibiotics  studies, the fastq files generated were processed 
using Mothur version 1.31.2 (Kozich et al. 2014; Schloss 2009; Schloss et al. 2011). The 
Schloss MiSeq SOP was followed according to the following criteria: 1) no ambiguous 
bases; 2) maximum length of 275 bp; 3) maximum of 8 homopolymers; 4) within 2 
mismatches of the sequence being considered. Detection of potentially chimeric 
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sequences was performed using Chimera uchime and chimeric sequences were removed 
from downstream analysis. Alignment was generated via the Silva database  ( Kozich et 
al. 2013)   (accessed Jan 2015). 
 Metabolomics profiling  
 
Metabolomics analyses were conducted using two main steps: 
- Extraction & preparation of faecal samples and 
- Running the samples (this was conducted by the “NUOMICS” facility at 
Northumbria University. 
Briefly, metabolites were extracted from 100mg stool and homogenised in cold 80% 
methanol by vortexing for 15 min at 4oC. The suspension was then centrifuged at 
10,000×g for 10 min at 4oC, passed through a 0.2 µm cellulose acetate filter (Minisart, 
Sigma-Alrich), and lyophilised in a freeze dryer before storage at -80oC. Samples were 
re-suspended in 1 ml and diluted a further 1:1 in initial start phase buffer (5% ACN). L-
methionyl-arginyl-phenylalanyl-alanine Acetate (MRFA; Sigma-Alrich) was added to 
each sample in a final concentration of 0.5ng/µl to act as an internal standard.  
Stool metabolite profiling was performed using reverse-phase ultra-performance LC-MS 
tandem mass-spectrometry (UPLC-MS/MS). An Accucore C18 column (2.6 µm, 150 × 
2.1 mm) was used at 40 ºC with a 3.0 µl injection and 300 µl/min flow rate throughout. 
A multi-step LC gradient was used with 5% CAN (v/v) increasing to 95% ACN (v/v) 
over 22 minutes, with a further 95% ACN (v/v) for 4 minutes followed by a final 4 
minutes re-equilibration at 5% CAN (v/v). Samples were run in triplicate and the order 
of samples in each triplicate sequence was randomised. A blank consisting of LC-MS 
grade water underwent the same procedure and an aliquot of every sample was used as a 
pool. Prior to each run a blank and 5 pools were processed to equilibrate the system, then 
blanks and pools were processed periodically every 20 samples for background 
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subtraction and quality control, respectively. A Q-Exactive (Thermo) was used for the 
MS and subsequent data dependant MS/MS. Metabolomics profiling was performed 
using HESI with high resolution (70,000) positive and negative switching. The mass 
range was set from 100 – 1000 m/z. MS/MS was subsequently employed with data 
dependency based on the metabolites of interest. 
SIEVE (Version 2.2 beta) was used to process the Thermo RAW files by component 
extraction. The first, middle, and last blank were used in background subtraction. Positive 
and negative data were processed individually and combined prior to downstream 
analysis. An intensity threshold of 1,000,000 was applied detecting a total of 11612 
components (8343 positive and 3269 negative). Putative identification of metabolites was 
based on component mass primarily using the Human Metabolome Database (HMDB). 
Following MS/MS acquisition of significant components identification was performed 
using mz cloud. 
 Analysis of data 
 Statistical analysis of Probiotic study 
 
 The bacterial DGGE and 16S rRNA gene profiles were analysed by multivariate 
partial least squares discriminant analysis (PLS-DA) using SIMCA 13.0 (Umetrics, 
Stockholm, Sweden) (Eriksson et al. 2006) and the results are expressed as copy of 
OTU-matrix and Graphs. All variables, either OTU or component, were automatically 
transformed within SIEVE. Analysis of variance (ANOVA) was used to determine 
whether numbers of L. acidophilus and B. bifidum (qPCR) increased during probiotic 
treatment with post-hoc Tukey’s applied for multiple pairwise comparisons (Minitab 
17), and the results are expressed with means plot and Graphs. 
 
  Diversity indices 
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Diversity indices were calculated for data generated using all techniques to examine the 
structure of the microbial communities present in the preterm gut using PAST (Hammer 
& Harper 2001). Species richness (R) was calculated based on the total number of 
different species present per sample. For culture this was based on the number of different 
isolates, DGGE was based on the total number of distinct bands, and NGS was based on 
the number of unique OTUs. For DGGE and NGS, where abundance information was 
also obtained, Shannon diversity was also calculated. The Shannon diversity index (H’) 
was calculated using the formula;  
 
H’ = -Σ (pilog[pi]) 
 
The symbol pi is the relative intensity of each species. The log of the relative intensity 
was multiplied by the relative intensity for every species in all of the samples (pilog[pi]). 
The sum of these values for each lane was taken and multiplied by -1 (-Σ) which gives 
the Shannon diversity of the sample.  
  Multivariate analysis 
 
OTU matrix files were generated in Microsoft Excel for data generated using all 
techniques. The OTU matrix for culture data contained the identity of all cultured isolates 
and either a 1 or 0 to represent presence or absence, respectively. For DGGE and NGS 
data, where abundance data was obtained, the OTU matrix contained the normalised 
abundance of each band (for DGGE) or OTU (for NGS). Unless otherwise stated, for the 
DGGE analysis, all bands were included based on the Rf value and where possible the 
actual identity of the band replaced the Rf value. 
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  SIMCA 
 
OTU matrices generated from both DGGE and NGS data also underwent multivariate 
partial least squares discriminant analysis (PLS-DA) using SIMCA 13.0 (Eriksson et al. 
2006). OTU matrices were uploaded into SIMCA and each sample in the analysis was 
assigned to a specific group, with the scores of the model visualised in a score plot. The 
loadings plot was used to determine which OTUs were associated with each of the 
variables based on the assigned grouping. To check that data was adhering to multivariate 
normalities, Hotelling’s T2 tolerance limits were calculated and set at 0.95. Plots were 
edited within Windows picture viewer to aid clarity according to important variables. 
  Tukey’s test 
 
Tukey’s test was used to compare the mean bacterial load of both Bifidobacteria spp. and 
Lactobacilli spp. during probiotics study. The samples were analysed based on the 
different treatment (before, during, and after probiotic supplementation and post 
discharge) and compared with controls. This test is a multiple comparisons procedure, 
used in conjunction with one-way analysis of variance (ANOVA), to find means that are 
significantly different from each other. This analysis was computed in Minitab 17 (v. 17) 
with a 95.0 confidence interval and a family error rate of 5. 
 One- Way Analysis of variance (ANOVA) 
 
The normalised concentration from the qPCR data were then put into Minitab 
(version.17) alongside with mean bacterial load and time relative to diagnosis, while for 
probiotics qPCR the data was put in Minitab with different variables as treatment type, 
time and mean load. Minitab was also used during analysis of Antibiotics data. A One-
Way ANOVA was used. This generated a report that contained the mean, standard 
deviation for each treatment as well as a p-value depicting the difference between the two 
means. A p-value of 0.001 – 0.009 shows highly significant relationships and p-value 
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between 0.05 – 0.09 indicated significance while those (that were 0.05 or greater were) 
not deemed to be significant.  
 Ethical Approval 
 
The research studies were carried out after obtaining an ethical approval from NHS via 
National Research Ethics Service, County Durham and Tees Valley Research Ethics 
Committee (Research ethics project number: RE-HLS-13-140303-53143b935c9f8) and 
informed parental consent on behalf of the babies. All the stool samples were collected 
from preterm infants hospitalised in the Neonatal Intensive Care Unit at RVI Newcastle. 
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3 CHAPTER THREE 
 Quantitative analysis of gut microbial flora in preterm infants 
associated with Necrotising enterocolitis  
 
Abstract 
Aims: Necrotising enterocolitis (NEC) is one of the major causes of morbidity and 
mortality in preterm infants. There is no data that shows a particular trend or pattern in 
terms of specific taxa or community structures that are associated with NEC. The aim 
was to identify whether the total bacterial load in the gut of preterm infants is significantly 
correlated with the incidence of NEC. A secondary aim was to quantify the bacterial 
communities’ structure and dynamics over time. It was hypothesized that, if the bacterial 
load in the gut of preterm infants increase over time, it might have an impact on the 
development of NEC and the subsequent clinical management of the disease. 
Methods: Stool samples were collected from 37 preterm infants with confirmed NEC 
plus 35 controls, matched by gestational age, all of which were being treated in the NICU 
at the RVI, Newcastle Upon-Tyne. Bacterial DNA was extracted from 100mg of faecal 
sample for analysis of total bacterial load, using PowerLyzer™ PowerSoil® DNA 
Isolation Kit. Quantitative polymerase chain reaction (qPCR) was used to quantify faecal 
bacterial load using SYBR green with universal 16S rRNA primers. 
Results: The quantification analysis of the total bacterial load over time revealed 
inconsistent patterns. No significant differences were observed between bacterial load at 
1 & 2 week, before diagnosis, on the day of NEC diagnosis and 2 weeks after NEC versus 
controls. However, our study showed a difference in total microbial loads in NEC versus 
control at 1 week after NEC diagnosis (p < 0.05 at 5%). Total bacterial loads between 
control and disease cohorts were also compared which showed no significant difference 
between NEC and control at 5% (p >0.05). 
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Conclusion: There is no distinct trend of total bacterial load associated with NEC over 
time; there are higher bacterial counts at 1 week after NEC diagnosis in control samples. 
Therefore, further work needs to be done in quantifying specific microbial signatures 
associated with NEC based on time intervals as our study applied universal approach. 
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 Background 
 
Necrotising enterocolitis (NEC) affects the gastrointestinal tract of preterm infants and is 
one of the leading causes of morbidity and mortality in preterm babies (Leach et al. 2015; 
Neu 2007; Lagomarcino et al. 2013). It has been reported that there is no consistent trend 
pattern of total microbial load found among the preterm infants with NEC (Singh, Firek, 
Brooks, Castelle1, et al. 2015). But there is variability in the diversity and abundance of 
opportunistic pathogens (Brower-Sinning et al. 2014). However, the evidence suggest 
that bacteria contribute to the pathogenesis of NEC (Leach et al. 2015).  
Studies have been carried out to quantify the bacterial load from different samples 
utilising the real-time polymerase chain reaction (qPCR). Recently, a study was 
conducted to assess the correlation between bacterial load of Clostridium difficile and 
Bristol stool; No relationship was observed between Bristol stool and the bacterial load 
of C. difficile across the time points (Thabit & Nicolau 2015). Another study explored, 
using real-time PCR, the bacterial load of Ureaplasma parvum in amniotic fluid and the 
level of inflammatory responses among the preterm infants, that showed a positive 
correlation between the amount of U. parvum and the magnitude of inflammation (Kasper 
et al. 2010a). The increase in bacterial load was correlated to various factors including; 
premature rupture of the membrane (PROM), preterm labour (PL), early-onset sepsis and 
histologic Chorioamnionitis (Kasper et al. 2010b). Furthermore, the histologic 
Chorioamnionitis (HCA) in women with preterm premature rupture of membrane 
(PPROM), is associated with a higher bacterial load of genital mycoplasmas (Kacerovsky 
et al. 2011). 
Several animal models have been studied to understand physiological and histological 
changes associated with NEC in preterm infants. These animal models have been 
developed to find effective measures and potentialities for the management of NEC (Tian 
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et al. 2010; Sodhi et al. 2008). Work conducted on pups model showed that the presence 
of some Gram negative bacteria (Citrobacter, Klebsiella and Tatumella) was associated 
with NEC (Carlisle et al. 2011). However, a study using preterm pigs with induced NEC 
versus control revealed the colonisation of Clostridium perfringens in high abundance 
among the pigs with NEC which suggests that C. perfringens is an opportunistic 
pathogens associated with NEC (Cilieborg et al. 2012). In addition, another study has 
demonstrated a higher abundance of total microbial load and greater Clostridium 
perfringens densities in piglets with NEC versus healthy controls which suggests their 
positive correlation to be associated with NEC severity (Cathrine et al. 2015).  
Therefore, it was hypothesized that, applying advanced molecular techniques in faecal 
analysis of microbial flora from the gut of preterm infants associated with NEC may show 
the abnormal quantitative colonization and variation based on time and might have some 
implications in the development of NEC (Rougé et al. 2010; Torrazza et al. 2013). 
Therefore, the aim was to quantify the total bacterial load by evaluating the faecal samples 
before, during and after NEC diagnosis. 
 Methods  
 Study design 
 
This study was carried out after obtaining an ethical approval from the NHS via the 
Research Ethics Committee (County Durham and Tees Valley Research Ethics 
Committee) and informed parental consent on behalf of the babies. All the stool samples 
were collected from preterm infants hospitalised in the Neonatal Intensive Care Unit 
(NICU) at the Royal Victoria Infirmary (RVI) Newcastle. The protocols involved in this 
study ensured good sampling based on time intervals from NEC diagnosis (+/-   2 days) 
as well as +/- 2 weeks before and after NEC depending on the availability and suitability 
of the samples obtained. In total, 72 samples were obtained which constituted 37 from 
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confirmed NEC cases and 35 as their corresponding controls from matched infants. 
Controls were selected and matched with NEC cases by gestational age, birth weight, day 
of life and delivery mode. Where the desired sample was not available, then a sample 
from a baby which had the optimal matching characteristics was selected (Table 3.1 – 
3.2). 
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Table 3-1: Clinical Characteristics of the Infants in the cohort study 
(Median) 
 
Characteristic   NEC (n=37) Control   (n=35) 
Birth weight (g)  725(500-1470) 825(570-1455) 
Gestational age (wks) 25(23-30) 25(23-30) 
Delivery mode- no/total 
(%) 
  
        Vaginal  24/37(64.9) 24/35(68.6) 
         C-section 13/37(35.1) 11/35(31.4) 
Sex –no/total no. (%)   
         Male 11/37(29.7) 15/35(42.9) 
         Female 26/37(70.3) 20/35(57.1) 
Day of life of development 
of NEC 
19(5-31) NA 
Day of life for sample 
collected(median value-
lowest to highest) 
  
        2 weeks before  9(4-16)  14(5-20) 
        1 week before  19(9-27) 18(9-27) 
        1 week after 28(21-36) 23(15-36) 
        2 weeks after  37(17-47) 35(16-48) 
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Table 3-2 Summary of the Cohort demographic data 
 
Patient Number of 
samples 
obtained 
Gestational 
Age(wks) 
Birth 
Weight(g) 
Sex Delivery 
Mode 
NEC day 
onset 
Case Total no. of  
antibiotics 
prior to last 
sample 
(days) 
139 5 30 1470 M CS  28 NEC 6 
161 5 25 700 F V 31 NEC 26 
171 5 26 790 F V 19 NEC 26 
180 4 23 500 F V 16 NEC 32 
188 5 24 750 F V 15 P NEC 13 
199 4 25 725 F V 25 NEC 24 
178 3 26 525 F CS  P COMPLX 33 
281 4 25 620 M CS 22 NEC 5 
303 1 25 960 M V 5 NEC 17 
315 1 24  M  10 NEC 21 
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140 3 30 1455 F CS   CON 5 
223 5 25 885 F V  CON 7 
176 5 26 880 M CS  CON 2 
181 4 23 570 F V  CON 14 
222 5 24 620 F V  CON 11 
152 4 25 800 M V  CON 4 
186 3 26 840 F CS  CON 2 
307 4 25 810 M V  CON 10 
229 1 25 910 M V   CON 2 
292 1 24 680 M V  CON 10 
PNEC= potential NEC and P COMPLEX = potential complex cases (see details inappendix 7 A & B- demographic data of Eubacteria qPCR).
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Table 3-3 qPCR based quantification of total bacterial load 
 
The Table below shows the mean copies/g of individual patient between NEC and control 
babies. 
PATIENT COPIES/G AT 0(NEC) CASE 
140 1966376365 CONTROL 
139 149685193.6 NEC 
223 271117654.2 CONTROL 
161 3247230518 NEC 
176 694790839.3 CONTROL 
171 65318060.14 NEC 
181 748408802.9 CONTROL 
180 617695143.9 NEC 
222 3634911474 CONTROL 
188 2082634076 NEC 
152 1096865860 CONTROL 
199 7361043187 NEC 
186 3423746058 CONTROL 
178 768520288.7 NEC 
307 319513441.9 CONTROL 
281 552673102 NEC 
229 142906181.6 CONTROL 
303 14165864.54 NEC 
292 1972369568 CONTROL 
315 187954912.3 NEC 
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Table 3-4 Primers used in the study 
 
The primers used in qPCR assay during this study for the quantification of total bacterial loads are tabulated below: 
Name of 
Primer 
Target 
species 
Sequence (5'-3')       Target 
sequence 
Temperature of 
Annealing(°C) 
Product 
Size (bp) 
Reference 
517R All bacteria ATTACCGCGGCTGCTGG   16S rDNA 65 180 (Muyzer G et al. 1993)  
  
EUB338 All bacteria ACTCCTACGGGAGGCAGCA
G 
16S rDNA 65 180 (Weisburg et al,. 1991)  
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 Statistical analysis 
 
Paired student’s t- test was used for qPCR mean copies data between NEC and control, 
excel and SIMCA-13(Umetrics) were used to analysed the exported qPCR raw data as 
appropriate. Minitab-17 was used to analyse and compared the data between NEC and 
control babies and the results were expressed as one-way analysis of variance (ANOVA) 
with Boxplot of copies/g. Excel was used to evaluate clinical characteristics and 
demographic of the preterm infants in the cohort study. The two-tailed P-values were 
calculated using Mann-Whitney- U Test software (equivalent to the Wilcoxon rank sum 
test) as (p >0.05) which was considered to be not statistically significant between NEC 
and control.’ 
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 Results 
 
A total of 72 faecal specimens from 20 babies were analysed, 37 with NEC and 35 
controls. The total bacterial load present in the samples was estimated by measuring the 
normalised qPCR data (Table 3). 
Boxplot A - bacterial load of disease in NEC babies 
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Boxplot B  - bacterial load of Control  babies 
 
Figure 3-1(A & B): Time relative to diagnosis (wks) of disease in NEC and control 
infants. 
  
Boxplot A is the quantification data for the NEC babies and B for controls. The horizontal 
lines inside the boxes represent the median value of bacterial load. The total bacterial 
loads were determined in NEC patients and matched controls 2 and 1 weeks prior to 
diagnosis in the cohort, then at diagnosis (0) and 1 and 2 weeks following diagnosis of 
NEC. 
However, the above Figures shows the pattern of bacterial load across the time interval 
between NEC cases (A) and control cases (B). both trend shows indefinite distinct pattern 
and variation between within the group, but there is increased in bacterial load at 
diagnosis compared to the time prior to diagnosis in both NEC and control with marginal 
decrease after two weeks of diagnosis in both cases. To make the clear comparison see 
the table below: 
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 Figure 3-2 Combined total bacterial load between and within NEC and control 
samples  
Horizontal lines inside the boxes represent the median; bars indicate upper and lower 
quartiles. Asterisks represent an outlier. * denotes significance. The NEC and Con 
indicates necrotising enterocolitis and control respectively. The number -2 to 2 refer to 
time intervals in week relevant to NEC diagnosis. 
Comparatively, the total bacterial loads between control and disease cohorts were not 
statistically significant (p >0.05) over time, except for values obtained from the samples 
between disease and control at 1 week after NEC diagnosis (p < 0.05) that shows that the 
load is marginally greater in controls (Figure 3.2). 
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Figure 3-3 qPCR for total microbial load in copies/g of 16S gene sequences in NEC 
and control samples 
  
Bars indicate upper and lower quartiles. * Asterisks represent the outlier. The horizontal 
lines inside the boxes represent the median value of bacterial load. The ‘n’ inside the box 
represent the patient number against each case. 
  
However, from the above Figure, the total bacterial load of the entire NEC cases 
irrespective of their group across the time points and the entire controls during the cohort 
study was compared, and the results shows no significant difference between NEC and 
diseases cohorts (P=  0.92). 
  
n=35 n=37 
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 Comparison of bacterial load between NEC and matched control 
based on time intervals 
 
The following Figure  (Figure 3.4) indicates the comparison of bacterial load and analysis 
between individual NEC patients with a corresponding matched control at different time 
intervals. It shows the indefinite pattern of bacterial load across the time interval in the 
cohort, as variability was observed between NEC samples compared to their matched 
control with the exception of patient NO 180 & 181 that depicted a comparable pattern 
of bacterial load at before and after diagnosis (Fig. 3- D). However, in some patients; the 
stool samples not available in the cohort at prior and after diagnosis for both NEC and 
their matched controls as such the graph devoid of bars (Fig. 3- I & J). 
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Figure 3-4 (A-J): Comparison of total bacterial load based on time intervals between 
individual NEC babies with their matched control.  
 
All the bars marked in red and blue colours represent NEC & control respectively. The 
ages attest when samples collected are shown at the bottom of each bar chart in weeks, 
started as -2 , -1 refers to weeks prior to diagnosis, while 0 indicates time at diagnosis and 
1 & 2 refers to week after diagnosis of NEC. 
Time intervals 
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 Discussion 
 
To date, the actual aetiological pathogens if any responsible for NEC are not known. It is 
important therefore, to explore if the total bacterial load irrespective of a particular 
bacterial taxa present might be important etiologically as suggested in studies conducted 
on the resected gut tissue of NEC samples (Brower-Sinning et al. 2014). Therefore, the 
need to accurately quantify the bacterial load in the stool samples of preterm infants with 
confirmed cases of NEC compared with those of matched controls. 
It was hypothesized that an accurate real time-PCR assay for quantification of total 
bacterial load based on time intervals could facilitate the monitoring and management of 
NEC and allow further studies in understanding preterm gut microbiota. This was 
informed by previous work in a pig model that showed a relationship between the total 
bacterial load and the incidence of NEC among preterm pigs (Cilieborg et al. 2012). 
Our data based on stool showed no significant difference (P = 0.92) between NEC and 
matched controls at diagnosis, where the total bacterial load per gram of stool was 1.5 × 
109 (range 1.4 × 107–7.4 × 109) in NEC and 1.4 × 109 (range 1.4 × 108–3.6 × 109) in 
control. 
Furthermore, the analysis showed no significance (P > 0.05)  differences between the 
bacterial load in the stool samples of infants who went on to develop NEC versus control 
based on the time interval studied in our cohort and that the resected gut tissue in NEC 
has a decrease in bacterial load compared to healthy controls. This finding disagrees with 
the previous work that found an increased in total bacterial load of NEC samples than the 
controls (Brower-Sinning et al. 2014). However, another study conducted using an animal 
model indicated that the pathological changes of NEC were noticed from the gut of 
preterm rabbit and there are significant differences between NEC and control (P < 0.0001) 
which showed that the incidence and severity of NEC-like damage increased with time 
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and completeness of gastrointestinal dysfunction (Bozeman et al. 2013). Nevertheless, 
our study is limited as a universal approach was used in quantifying the bacterial loads 
over time intervals; this could detect all the pathogenic and beneficial bacteria associated 
with NEC and other sepsis, as universal primers were used in detecting total bacterial 
count without specification. (Though, in another cohort- probiotic chapter, the qPCR 
technique utilising a specific primers targeting only the beneficial bacteria was explored). 
Furthermore, there is no consistent trend observed in the bacterial load among the 
individual patients as the bacterial load indicated variably intermittent among the NEC 
and control, only that in the Figure 3D (patient No 180 & 181) observed similar pattern 
which goes concurrently, the microbial load increases 2 weeks before NEC and decreases 
significantly at a week before NEC with the loads in NEC infants slightly higher than 
those of the matched control. The pattern continues during and after NEC diagnosis with 
the counts in NEC slightly lower than the control, but generally it shows microbial load 
decreases over time; the reasons behind this could be due to the fact that the patients are 
twin babies which are expected to have similar genetic backgrounds, maternal and other 
clinical exposures associated with their intestinal microbial ecology (See appendix 7 for 
details of their demographic data). Furthermore, no significant difference observed 
between two samples (p >0.05) from the twin babies (patient No 180 & 181). These 
therefore, suggests that, no specific pattern of bacterial load associated with NEC during 
our cohort, this data supports the previous finding that demonstrated no specific trends of 
microbial community associated with NEC (Brower-Sinning et al. 2014). 
Generally, there was no significant difference between bacterial load of NEC and matched 
control during our study. Moreover, our data supports recent reports that found the gut 
microbial communities of preterm infants differ significantly over time and between 
different environments. It was found that individuals exhibited very dynamic gut 
communities while others maintained the same community composition through time. It  
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also  showed these kind of microbial shift and pattern varied widely from one hospital to 
another during within the  cohort (Taft et al. 2014).  
Additionally, qPCR technique was explored in a recent study comparing the bacterial load 
between NEC and non-NEC individuals and the outcomes suggested that; there is no 
single pattern of microbial diversity associated with the NEC (McMurtry et al. 2015; 
Brower-Sinning et al. 2014). This finding supports the findings within our cohort. 
 However, as mentioned earlier that there was no significance difference of total bacterial 
load between NEC and control within our cohort and an increased in bacterial load from 
control with decrease in NEC cases following one week of NEC diagnosis, this finding is 
contrary to a recent study that indicated an increase of bacterial load in both NEC and 
control using intestinal mucosal sample of preterm pigs but irrespective of time interval 
(Cathrine et al. 2015). In contrast, research conducted to determine the level of bacterial 
colonisation on the age of preterm infants showed a distinct bacterial pattern in NEC cases 
during the first two weeks of life prior to NEC diagnosis, with low bacterial population 
(de la Cochetiere et al. 2004). This is contrary to our findings as our data shows no distinct 
pattern and no differences in bacterial load between NEC and control prior to NEC 
diagnosis and after the disease.  
Nevertheless, It has been shown previously in a study conducted on term infants that the 
total bacterial load is stable after the first week of life  (Palmer et al. 2007) and in our 
cohort, the preterm developed NEC at a median postnatal age of 20 days. Fascinatingly, 
the previous study found the copy number per gram in term neonates generally persisted 
in the range of 109 to 1010, an order of magnitude higher than the 108–109 per gram of 
stool in our infants. The time at which the preterm infants increase to a load comparable 
to term is unknown, but appears to be after our study ended at a median postnatal age of 
34 days. 
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 Conclusions 
 
No unique or characteristic trend in microbial signatures that might be responsible for 
causing NEC in preterm infants. Our findings revealed that before and at diagnosis total 
bacterial loads in babies with NEC fluctuating widely over time and were not significantly 
different to bacterial loads in control samples (p >0.05). Although, the overall bacterial 
loads analysed at one week after NEC diagnosis showed that, the load is significant 
different (p < 0.05) between NEC and control. Further work should be conducted utilising 
specific primer set for targeting particular bacteria based on time intervals that were 
suggested as putative pathogens responsible for NEC. 
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4 CHAPTER FOUR 
 Molecular characterisation of Probiotics supplementation from the 
gut of preterm infants and its impacts in the development of NEC 
and sepsis 
 
Abstract 
Probiotics are live microbial supplements that colonize the gut and potentially exert health 
benefit to the host. It was hypothesized that probiotics strains (Infloran: containing two 
species of Lactobacillus acidophilus-NCIMB 701748 and Bifidobacterium bifidum-
ATCC 1569 6) would successfully colonize the gut and protect the infants from 
developing Gastrointestinal tract (GIT) disease. Only a few studies have reported on the 
efficacy of probiotic supplements to reduce late on-set sepsis in Very Low Birth Weight 
(VLBW) infants. 
Aims:  To use high throughput techniques to analyse probiotic diversity and the impact 
it makes in the gut of preterm infants, with its possible effects on Necrotizing Enterocolitis 
(NEC) and late onset sepsis (LOS). Also, quantification of the probiotic strains and its 
relevance in the health and disease was performed.  
Methods: Microbial DNA was extracted from stool samples and further analysed with 
specific primers. Samples were classified into four groups: (i) before, (ii) during and (iii) 
after probiotic intake with matched controls, and (iv) Post discharge samples. The 88 
samples underwent analyses of their bacterial community composition, utilizing 16S 
rRNA gene profiling. A subset of 75 samples underwent quantitative Polymerase Chain 
Reaction (qPCR).  For probiotic diversity, another subset of 85 samples were collected 
and analysed by PCR-DGGE (denaturing gradients gel electrophoresis).  
Results: QPCR analysis showed significant higher numbers of B. bifidum in infants who 
received probiotic treatment compared to controls (p< 0.001), but no significant increase 
was observed for L. acidophilus within the groups (p= 0.575) and also between probiotic 
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and control groups (p= 0.153) in the cohort study. The result from 16S rRNA gene library 
indicated a greater number of Bifidobacteria  in the bacterial community during 
supplementation (15.1%) compared to the control group (4.0%). A small number of 
Lactobacillus (4.2%) was detected in probiotic babies but none (0.0%) or little (1.7%) in 
controls and in groups prior to probiotics administration was detected. There was also 
reduction of Lactobacillus after probiotic was stopped; however, the Bifidobacterium 
contribution to the bacterial community remained in post discharge. The Shannon 
diversity (Hʹ) from the DGGE profiles indicated a significantly reduced diversity 
(p= < 0.001) between the probiotic and non-probiotic babies. Probiotic babies have 
therefore, statistically lower diversity compared to infants not receiving probiotics.  
Conclusions:  Probiotic strains (Bifidobacterium and Lactobacillus) were found to 
colonize the gut of preterm infants with different levels of abundance (15.1% and 4.2%) 
and they all increase with probiotic supplements. B. bifidum was found to colonize the 
gut before administering probiotics and were more prevalent in the gut of preterm infants 
compared to Lactobacilli. Our findings also demonstrated the long term effects of 
Bifidobacterium strain in the preterm gut during post discharge samples. It was therefore 
conclude that, the findings in this study suggest that probiotics have the potentiality to 
alter the gut bacterial community in preterm infants. 
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 Background 
 
Probiotics are live microorganisms which when administered in a controlled amount may 
give health benefits to the recipient (FAO/WHO 2001; de Almada et al. 2015; Wang et 
al. 2015). Probiotics have been shown to affect the composition of gut microbiota which 
may confer health benefits (Villarreal et al. 2013; Herbel et al. 2013; Binns 2013; Picaud 
2013a; Wang et al. 2015). Lactobacillus spp., Bifidobacterium spp. and Staphylococcus 
spp. are the most common types of microbes used as probiotics (Herbel et al. 2013), 
though certain yeasts and bacilli can also be used (Soccol et al. 2013; Julia et al. 2010; 
Binns 2013).  
However, Species of Bifidobacteria and Lactobacilli are the two principal probiotic 
bacteria (Herbel et al. 2013; Chen 2011; de Almada et al. 2015; Alona Bin-Nun et al. 
2005). Probiotics can also increase the population of Lactobacilli and Bifidobacteria  in 
the gut of preterm infant (Christopher J. Stewart et al. 2013).  Probiotics can be taken as 
a food or supplements and are normally administered after antibiotics treatment in certain 
infections (Soccol et al. 2013). The susceptibility of probiotic bacteria to antibiotics has 
been reported; thus suggesting the association of maternal antibiotics to NEC (Beken 
2015). Generally, the gut microbial communities of breast-fed infants are primarily 
composed of Lactic acid bacteria (LAB) including Bifidobacteria and Lactobacilli 
(Turroni et al. 2014), unlike formula-fed infants which is widely diverse of Bacteriodes, 
Clostridium and Enterobacteriaceae (Haarman & Knol 2005; Groer et al. 2014). 
It has been reported that probiotics therapy increases the commensal bacteria and 
promotes human gut health (Saxon 2015). Probiotics compete with pathogenic bacteria 
for host binding sites and nutrients while also stimulating host defence mechanisms and 
enhancing intestinal maturation as well as strengthening the host immune system (Soccol 
et al. 2013). They may also protect against systemic bacterial invasion by decreasing the 
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permeability of the GI wall (Julia et al. 2010; Binns 2013). Some probiotic strains have 
been reported to have an impact in reshaping the gut microbiome on a mice (Wang et al. 
2015). However, for probiotics to work effectively and confer a health benefits to the 
host, it has to be taken regularly (Binns 2013) and with caution more especially in VLBW 
infants (Zbinden et al. 2015), as high doses may be unfavourable to the host (Neu 2007). 
Preterm infants have been shown to have delayed colonisation with potentially important 
‘beneficial bacteria’ such as Bifidobacteria and Lactobacilli (Butel et al. 2007). Some 
evidences shows that probiotics reduce the risk of NEC/Sepsis in preterm infants with 
less than 33 weeks GA and in very low birth weights between 1000-1500g (Deshpande 
& Patole 2013; Picaud 2013b; Alona Bin-Nun et al. 2005; Millar et al. 2003; Yang et al. 
2014; Shlomai et al. 2014; Picaud 2013a; Neu 2007).  Other studies have shown that the 
mortality rate of the preterm infants receiving probiotics was significantly lower than 
controls (P= 0.003) (Yang et al. 2014; Neu 2007).  
Despite the benefits of probiotic administration, there are concerns as some strains of 
probiotics can cause bacteraemia in infants, children, adults and older patients (Singh, 
Firek, Brooks, Castelle, et al. 2015; Picaud 2013a; Herbel et al. 2013). Specifically, 
Bifidobacterium longum was detected in the blood culture of the preterm infants alongside 
probiotics intake (Zbinden et al. 2015). Though, a meta-analysis study of probiotic 
supplementation, showed that probiotics may have no (Costeloe et al. 2015) or minimal 
adverse effect on normal feeding and growth among the preterm infants (Shlomai et al. 
2014; Yang et al. 2014).  
Currently, the routine use of probiotic prophylaxis in clinical practice is still insufficiently 
understood despite it being reported as beneficial in the therapy of NEC (Costeloe et al. 
2015; Zbinden et al. 2015). As such probiotic supplementation should be adopted 
cautiously (Shlomai et al. 2014), as there is no definitive evidence whether different 
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strains of the routinely used probiotics produce variable outcomes in health and diseases 
(Costeloe et al. 2015; Shlomai et al. 2014; Beken 2015). 
Lactobacilli acidophilus has been examined intensively as a probiotic supplement, it was 
found to increase the number of Lactobacilli in an infant gut (Breitbart et al. 2008). When 
combined with Lactitol (beta-galactosido-sorbitol) a non-absorbable disaccharide , it 
increased both the Lactobacilli and Bifidobacteria   numbers (van Zanten et al. 2014; 
Ouwehand et al. 2009; Bjorklund et al. 2012). It was first isolated in 1990 and name 
Bacillus acidophilus. It is part of the normal flora of human GIT and as important 
probiotic strains detected in human breast milk (Cárdenas et al. 2015). 
Bifidobacteria  are residents of the human and animal gastrointestinal tract, dental caries, 
vagina and oral cavity (Barrett & Guinane 2013; Amin et al. 2013). Several 
Bifidobacterium strains are now being used as probiotics including the species of 
Bifidobacterium animalis, B. bifidum, B. breve, B. longum fermentum and some other 
species (Amin et al. 2013). B. bifidum is found to colonize the infant gut more especially 
those receiving breast-milk (Millar et al. 2003; Turroni et al. 2014).  
High through-put NGS techniques have extensively improved our understanding of 
intestinal microbiota and the impact of probiotics  in health and diseases (Villarreal et al. 
2013; de Almada et al. 2015; Herbel et al. 2013; Ju & Zhang 2015). The use of qPCR 
assays and other molecular techniques has identified and quantified the faecal 
Bifidobacterium and Lactobacilli species (Haarman & Knol 2005; van Zanten et al. 2014; 
Wall et al. 2007; Herbel et al. 2013) as well as other probiotic strains (Tobin et al. 2013). 
Here the use of high throughput techniques to study probiotic diversity and babies 
receiving Infloran capsule compared to a control group was explored. Infloran is used as 
a food supplement in some NICUs and contains Lactobacillus acidophilus and 
Bifidobacterium bifidum. The aimed was to investigate the bacterial load in the preterm 
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gut in babies whose diet is supplemented with Infloran and the long term effects of this 
supplementation. There is earlier research that has used Infloran supplementation  (Repa 
et al. 2015), containing different species of Bifidobacterium as  Bifidobacterium longum 
instead of B. bifidum;  but with the same species of Lactobacillus as used in our cohort 
(Zbinden et al. 2015). 
 Methods  
 Study design  
 
Samples Identification for probiotic DGGE study: - Demographic data was provided 
from the infant cohort collected from neonatal intensive care unit of the RVI (Table 4.1). 
A total of 85 samples (57 Probiotic and 28 Non-Probiotic) stool samples were identified. 
(See the demographic data in the appendix 8) 
 Samples identification for NGS and qPCR in probiotics study 
 
The study protocol compared a cohort of preterm infants, who had been admitted in the 
NICU and received probiotics with a control group who did not receive the probiotic. 
Informed consent was obtained from parent as well as ethical approval. Eighty eight 
samples collected from the patients who received Infloran as a prophylactic probiotic 
containing the two species of bacteria: Lactobacillus acidophilus and Bifidobacterium 
bifidum. Bacterial DNA from each samples were subjected to NGS (60 probiotics and 28 
controls). Subsets of 75 samples were subjected to qPCR analysis, (50 from probiotics 
groups and 25 samples from control group). All the stool samples collected were from 
preterm infants born between 27 to 31 weeks gestational age.  The two techniques were 
explored in order to know the relative abundance of the desired organisms (in case of 
NGS data) and the actual bacterial load of those organisms (in case of qPCR data) in the 
gut of preterm infants in our cohort.  
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 Probiotic qPCR and NGS study 
 
Table 4-1: Demographic data for the clinical cohort 
 
 Control  Probiotic 
 
Patient  No. 263 271 272  270 273 274 275 276 277 278 
Gestational Age 27 31 31 25 27 24 28 28 24 24 
Birth weight 550 2030 1535 750 945 700 1100 1150 620 620 
Delivery CS V V V CS V CS CS CS CS 
Sex F F M M F M F M F M 
Total No. of 
Samples 
10 7 8 8 7 12 5 4 3 7 
Post-discharge 
(age in months) 
N N N Y (25) Y Y N N N Y 
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 Characteristics of preterm infants participants 
 
The probiotic supplement was given to preterm infants of less than 32 weeks gestation 
soon after initial introduction of feeds until it reached 34 weeks corrected. The dose 
contain a half of an Infloran capsule which was administered twice a day, equating to 125 
mg b.d at 109 organisms per dose. All the infants received maternal breast milk. All babies 
in this study had a birth weight of less than 1500g. A total of 75 stool samples were 
collected from the cohort, the samples were divided in to the following groups during the 
cohort study: before, during, and after exposure and a control groups as well as post-
discharge (Post discharge is after they leave the NICU as follow up samples) Table 4.2 
and Table 4.3 shows demographic and clinical data for the different groups by which the 
samples were classified in relation to probiotic intake and the number of samples collated 
within each group during the cohort. 
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Table 4-2: Frequency of probiotics groups in the cohort study 
 
Probiotic schedule                                  Number of sample 
Before probiotic                                                     5 
During probiotic                                                    30 
After probiotic                                                       11 
Post-discharged                                                      4 
Control                                                                    25 
Total                                                                        75 
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Table 4-3: Clinical characteristics of preterm infant’s cohort 
 
Characteristics Frequency of Occurrence (Average range) 
 Probiotics Control 
Total stool samples 50 25 
Total samples by Gender:  
Male/Female 
22/28 8/17 
Birth weight (g) 835.6(620-1150) 1371.1(550-2030) 
Gestational age (weeks) 26(24-28) 29(27-31) 
Delivery: Vaginal/ 
Caesarean 
22(44%)/28(56%) 15(60%)/10(40%) 
Feeding: Breast milk/ 
Formula 
50/0 25/0 
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 Results 
 Probiotic and Non-Probiotic diversity study 
 
4.5.1.1  DGGE Analysis of microbial community in Probiotic and non-
probiotic diversity 
 
The Molecular fingerprinting by DGGE analyses of the  10 patients with the total of 85 
samples (57 probiotics and 28 non-probiotics samples) yielded 22 distinct bands for the 
probiotic samples (4-12 bands per lane) (Fig. 4.1) and 36 distinct bands for  non-probiotic 
samples (5-18 bands per lane) (Fig. 4.2) respectively. Each DGGE band was assumed to 
be a single taxon or operational taxonomic unit (OTU) from which measurements of 
species richness and evenness could be derived.  
Qualitative observation from the DGGE profile of probiotic diversity (Fig. 4.1) showed 
that the bands were distributed towards the middle and lower region of the gel in non –
probiotic samples (Fig. 4.2). The band matrix was analysed using PCA (unconstrained) 
which showed that the non-probiotic babies have large variation in the DGGE profiles 
whereas the probiotic babies all develop comparable DGGE profiles (Fig. 4.3). All the 
probiotic babies cluster together while the non-probiotic babies were widely distributed 
with a large variation within and outside the circle. However, the two groups cluster 
independently, indicating distinct DGGE profiles between the treatment groups. To 
determine if there was a statistically significant diversity between treatments, Shannon 
diversity (Hʹ) indices were calculated and showed that probiotics babies have reduced 
diversity when compared to non-probiotics P =  < 0.001) (Fig. 4.4).  
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1          2        3      4       5      6       7       8      9       10    11      12    13 
Enterobacter cloacae 
Serratia marcescens 
Citrobacter freundii 
Staphylococcus epidermidis 
Clostridium perfringens 
Bacteroides fragilis 
Sarcina ventriculi 
The gel contains 13 Lanes. L 1, L 7 and L 13 representing the Bacterial ladder of the isolates, while the remaining 10 
lanes on the image represent the probiotic samples loaded. Lane numbers 2-Probiotic sample (PS-327), 3-PS 3253, 4 
– PS3248, 5 –PS 3242, 6 – PS 3343, 8 – PS 3322, 9 – PS 3310, 10 – PS 3300, 11– PS 3331, - 12 - PS 3263. 
Figure 4-1 representative DGGE profile on 35% - 55% denaturing gradient showing different bands of Probiotic samples 
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Citrobacter freundii
1          2        3      4       5      6       7       8      9       10    11      12    13 
Enterobacter cloacae 
Serratia marcescens 
Staphylococcus epidermidis  
Clostridium perfringens 
Bacteroides fragilis 
Sarcina ventriculi 
The gel contains 13 Lanes. L 1, L 7 and L 13 representing the Bacterial ladder of the isolates, while the remaining 10 lanes on the 
image represent the non- probiotic samples loaded. Lane number: 2-Probiotic sample (PS-3258), 3-PS 3234, 4 – PS 3226, 5 –PS 
3215, 6 – PS 3197, 8 – PS 3174, 9 – PS 3149, 10 – PS 3090, 11– PS 3320, - 12 - PS 3337. 
Figure 4-2: A representative DGGE profile on 35% - 55% denaturing gradient showing different bands of non- probiotic 
samples 
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Figure 4-3: Band Matrix (PCA) of Probiotic and Non-Probiotic DGGE Profiles 
 
Green circles represent Non-probiotic babies and red circles represent probiotic babies. The 
numbers associated with the circles i.e. 263- 278 represents the patient’s unique identification 
number in the cohort study. Thus; 263(a-n), 271(a- g) and 272(a-g) stands for non-probiotic babies 
while, the number 270(a-h), 273(a-i), 274(a-p), 275(a-e), 276(a-g), 277(a-c) and 278(a-i) stands 
for probiotic babies.  
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Figure 4-4: Boxplot of Probiotic and Non-Probiotic data 
Asterisks represent the outlier; the horizontal lines inside the boxes represent the median value of 
diversity indices. + denotes significance (P = <0.001). The ‘n’ inside the box represent the patient 
number. 
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During the research, it was then sought to examine how the bacterial community differed 
between babies receiving probiotic and those that do not during their stay in NICU and 
the impacts on the preterm gut. To achieve this, the data was modelled using PLS analyses 
(Fig. 4.5). 
In PLS analysis, an R value of 0.8 or above is suggestive of securing an adequate 
(comprehensive) set of formative measures assuming (adequate loading), and an R value 
of 0.9 or above indicates an extremely strong result. Q2 >0.5 implies the model has 
predictive relevance, whereas Q2<0.5 represents a lack of predictive relevance (Falfari, 
Alessandro 2010). Forming a model based on the DGGE data shows high predictive 
value, i.e. an unknown sample would be identified as receiving probiotic or not. Well 
modelled variables have high green bars, R2, and high blue bars, Q2, at levels of 0.5 or 
above. Here R2 indicates how well the variation of a variable is explained, while Q2 
indicates how well a variable can be predicted. 
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Figure 4-5: PLS Bar chart model of Probiotic and Non-Probiotic DGGE 
The data showing valid prediction of babies receiving probiotic, the green bars of (A & C) in R2 
imply that receiving probiotic treatment has a significant impact on preterm babies. While the 
blue bars (B & D) in Q2, implies that hypothetical assumption model is valid significantly in 
predictive sense base on the data generated during the analysis. (As all the variables are above 
0.5) 
  
Probiotic 
 
Control 
A 
B 
C 
D 
117 
 
 Quantification of L. acidophilus-(NCIMB 701748) by qPCR in stool samples 
 
The qPCR analysis of the stool samples detected quantifiable numbers of L. acidophilus 
in 2 samples during probiotic administration and 3 in the controls. ANOVA analysis of 
the data shows no significant difference within the groups in the cohort study (Fig. 4.6). 
While, between probiotics and controls (Fig.4.7) displays few outliers in both cases, the 
grouping by Tukey’s family error rate has (p = 0.153) at 95% confidence level. This shows 
no significant difference between the probiotic and control groups in the cohort study 
(mean Log=0.00±0.00).  
However, Lactobacillus species Not detected prior to probiotic intake and after 
administration as well as at post discharge samples, they were only detected in control 
babies and small number during administration (Fig. 4.6). But Lactobacillus species were 
detected higher in control group compared to probiotic samples (Fig. 4.7). 
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Figure 4-6: Boxplot of Lactobacterial load based on time interval to Probiotics 
intake. 
* Asterisks represent the outliers. “a”  represents the grouping by Tukey’s family.  
 
 
 
Figure 4-7: Boxplot of Lactobacterial load between Probiotics and Control group. 
 
* The horizontal lines inside the boxes represent the median value of bacterial load. “a” represents 
the grouping by Tukey’s family.  L. acidophilus was detected in only two samples during probiotic 
administration and in 3 control samples, while absence in the remaining time points during the 
cohort. The numbers  ‘n’ inside the boxes represent the patients number with respect to each goup. 
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 Quantification of B. bifidum-(ATCC 1569 6) by qPCR in stool samples 
 
Quantification results of B. bifidum (ATCC 1569 6) as revealed by Minitab analysis 
showed the mean bacterial load among the groups in the cohort study. The B. bifidum was 
detected in one probiotic baby before administration but was absent in the control cohort. 
B. bifidum load was also significantly (p = <0.001) higher at all-time points following 
administration of probiotic. 
 
Figure 4.8 displays no outliers probiotic supplementation; before, control or in post 
discharge samples. The Bifidobacterial load after probiotic intake has highest median 
with 1 outlier, then decrease a bit during post discharge samples. Also 6 outliers have 
been observed from the load during probiotic intake, it also recorded lower or less at 
before and control respectively, the grouping by Tukey’s family error rate has (P < 0.01) 
at 95% confidence level. This shows that it is highly significant. 
Figure 4.9 displays no box at control group, while observing a reasonable load counts of 
Bifidobacteria  been detected from the gut of infants who received probiotic supplements 
with only few numbers not detected. The grouping by turkey’s family error rate (P < 0.01) 
at 95% confidence level which indicates highly significant difference between probiotic 
and control group in the cohort study. 
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Figure 4-8: Boxplot of Bifidobacterial load based on time to Probiotics intake 
 
* Asterisks represent the outliers, “a & b” = represents the grouping by turkey’s family. The 
horizontal lines inside the boxes represent the median value of bacterial load.  
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Figure 4-9: Boxplot of Bifidobacterial load between Probiotics and Control group. 
 
* Asterisks represent the outliers. The horizontal lines inside the boxes represent the 
median value of bacterial load. The ‘n’ inside the bo0x represent the patient number. 
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 Probiotic Next generation sequencing study 
 
NGS analyses showed significant change in bacterial communities (Fig. 4.10) in the 
different group studied. The most common taxa in the sample are: Enterococcus, 
Escherichia, Enterobacteriaceae, Staphylococcus and Bifidobacterium. Some taxa only 
appear post discharge: Bacteriodes, Proteus and Lachnospiracea , while, the probiotic 
taxa are: Bifidobacterium and Lactobacilli and the most common taxa appear in the 
control group are: Bifidobacterium, Enterobacteriaceae, Enterococcus, Escherichia, 
Staphylococcus, Clostridium and Veillonella . The differences between experimental 
samples and controls are: Lactobacilli, Bacteriodes, Lachnospiracea  and Proteus (Table 
4.4).  
Bifidobacterium spp. increase sequentially with probiotic supplementation with an 11.1% 
contribution before supplementations are given, which grow to 15.0% and 19.3% during 
and after supplementation regimen. But fall down in Post-discharge sample 14.2% and 
remain low in control (4.0%) groups. Lactobacillus taxa contribute 1.7%, 4.8% and 6.1 
% to total bacterial community before, during and after probiotics respectively. Very little 
or no Lactobacillus spp. was found among post-discharged and control groups (Table 
4.4). Therefore, Bifidobacterium species recorded high population numbers from the gut 
of preterm infants. While Lactobacillus taxa detected from the gut of preterm infants (Fig. 
4.10) who received probiotic during the cohort study. The samples in the post discharge 
(PD) group were more diverse (with different bacterial taxa classified as ‘others’ in (Fig. 
4.10) as the babies associate with domestic environment and begins to eat solid food. 
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Figure 4-10: Relative abundance of Bacterial Taxonomy at genera level from 
MiSeq analysis.  
Proportion of OTUs matching the 20 most frequently observed bacteria across the samples. 
Colours on the charts matching with the bacterial taxa on the legend represent the diversity in 
percentage. Sequences matching other bacterial taxa with less abundance OTUs are classified as 
“others” shown on the legend with their matching colour on the chart. The ‘UC’ on the legend 
indicates unclassified OTUs. The final bar labelled as PD represents post discharge samples. (The 
data were sent in to MG-RAST with accession number 4615668.3-4615749.3)  
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Table 4.4: Abundance of Most common taxa in samples 
 
Bacterial Taxa Probiotic 
(%) 
(n=60) 
Control(
%) 
(n=28) 
Before 
(%) 
(n=10) 
During 
(%) 
(n=32) 
After 
(%) 
(n=14) 
Post-
disch. 
(%) 
(n=4) 
Bifidobacteriu
m 
15.1 4.0 11.1 15.0 19.3 14.2 
Lactobacillus 4.2 0.0 1.7 4.8 6.1 0.0 
Enterobacteria
caea 
18.8 37.4 7.9 17.4 31.1 12.8 
Bacteriodes 0.0 0.0 - 0.0 - 10.3 
Enterococcus 17.4 18.4 18.9 24.9 8.2 1.2 
Escherichia 11.9 11.4 2.1 18.4 15.3 14.0 
Lachnospirace
a 
0.0 0.0 0.0 0.0 0.0 5.1 
Proteobacteria 0.7 1.6 1.4 0.5 0.0 0.0 
Proteus 0.0 0.0 0.0 0.0 0.0 5.5 
Staphylococcus 25.2 5.9 53.4 9.6 12.6 0.0 
Clostridium 0.2 3.8 0.0 0.0 0.6 0.0 
Veillonella 1.08 4.0 0.2 2.4 0.7 7.10 
Total 94.58 86.5 96.7 93 93.9 70.2 
 
The probiotic column stand for the entire  babies receiving probiotic supplements during the 
cohort (before, during and after ) to compare them with their healthy matched controls in the 
subsequent column (control), then between the control and the individual groups for easy 
comparison (see the descriptive narration : 4.6, on the previous pages concerning this table: 4.4 
and previous Figure 4.10 under). 
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 Faecal microbial diversity on probiotics babies by MiSeq 
 
The gut microbiome was distinct between preterm infants who received probiotics with 
their healthy control babies (R2Y = 0.85, Q2 = 0.60), the gut bacteria within preterm 
infants receiving probiotic supplement remained relatively comparable (R2Y = 0.36, Q2 
= 0.27), when comparing to sampling point before probiotic supplementation (R2Y = 
0.18, Q2 = 0.02) and after supplementation stopped (R2Y = 0.25, Q2 = 0.09). Therefore, 
R2Y here denotes how well the variable is explained, and Q2 signifies how well the 
variable is predicted as a result of probiotic administration. The PLS-DA matrix 
illustrated the bacterial OTUs associated with each group with different colours that 
cluster separately according to individual groups in the cohort (Fig. 4.12) with the 
exception of post-discharge samples. When the PD samples were included, all NICU 
cluster away from the PD samples (Fig. 4.13); this indicates that bacterial OTUs 
associated with post-discharged are different compared to other groups in the cohort 
study. Nevertheless, PLS-DA analysis of control group compared to other probiotics 
groups revealed that 4x Lactobacillus spp.(otu0007, otu0011, otu0013 & otu0044) were 
detected in probiotic babies and none was detected from the matched control while only 
1x Bifidobacterium species detected from probiotic group (otu0003). Interestingly, 
Streptococcus and Clostridium spp. were increased in controls (Fig. 4.15). The green bar 
in R2 implies that administering probiotic supplement has a significant impact on preterm 
babies (Fig. 4.16). While the blue bars in Q2, implies that hypothetical assumption model 
is valid significantly in predictive sense base on the data generated during the analysis 
(Fig 4.16.). 
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Figure 4-11: Loading plot showing the relationship of bacterial OTUs within the 
groups.  
 
(PLS-DA Coloured according to model terms), the blue circles representing the groups as Control, 
before, during and after. The green circles representing the individual samples during the cohort. 
OTUs associated with during are 3x Lactobacillus spp. (otu 007, otu 0013 & otu 0044) and 1x 
Bifidobacterium spp. (otu 003). The details shown in the Figure 4.12 below: 
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Figure. 4-12: The OTU Matrix showing the relationship of bacterial OTUs 
associated with each group. 
 (PLS-DA Coloured according to classes in M3), the colours indicating the groups but 
post-discharge samples removed. The green = control, blue = before, red = during and 
yellow = after. The numbers attached to each coloured circle representing the actual 
sample & patient numbers from the cohort study. 
 
 
 
 
 
128 
 
 
Figure 4-13: The bacterial samples showing the relationship of each group including 
post-discharge samples. 
 The coloured circles and numbers associated with them represents: 1=Control, 2=before, 
3= during, 4= after and 5= Post-discharged. Most of the samples condensed closely 
related within the circle, while most of the post-discharge samples displaced apart outside 
the circle. 
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Figure 4-14: The OTUs copy shows some few control groups outside the circle.  
The numbers attached to green colour (1) represents control, while those with blue(2) 
represents Probiotics. See the details of their loading plots in the figure below: 
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Figure 4-15: Loading plot showing the relationship of bacterial OTUs between 
probiotics and controls.  
All the OTUs on the blue region (1) associated with control while those on blue region 
(2) with probiotics. Red circles = 4x Lactobacillus spp. (otu 0007, out 0011, otu 0013 and 
otu 0044) and 1x Bifidobacterium spp. (otu 0003).  
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Figure 4-16: PLS Bar chart model of Probiotic and control MiSeq.  
The data showing valid prediction of babies receiving probiotics (R2= 0.9 & Q2 = 0.73). 
Well modelled variables have high green bars, R2, and high blue bars, Q2, at levels of 
0.5 or above. Here R2 indicates how well the variation of a variable is explained, while 
Q2 indicates how well a variable can be predicted. 
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 Discussion 
 
This study explored the impact of routinely used probiotics on the gut bacterial 
communities of preterm infants in the NICU at the RVI, Newcastle upon-Tyne during 
their administration and post- discharge. The application of non-culture base techniques 
was utilised to determine the bacterial diversity in stool sample and to quantify the long-
term effects of probiotic supplementation as well as to determine whether they are 
implicated in microbial dysbiosis of preterm infants gut communities which may impact 
on clinical outcomes.  
The results obtained from DGGE analysis shows that there is a significant reduction in 
diversity between the babies receiving probiotics (P  = <0.001) compared to those babies 
that do not (Fig. 5). This suggests that probiotics have the potential to alter the gut 
microbial community.  This may correlate with earlier work  that shows some groups of 
probiotic significantly reduced NEC in very preterm infants (Jacobs et al. 2013). Also a 
significant decrease in the incidence of sepsis after administering of probiotics to preterm 
infants was noted in several studies (Wang et al. 2009; Lin et al. 2008; Alona Bin-Nun et 
al. 2005; Mai et al. 2011; Mihatsch et al. 2012; Braga et al. 2011; Stenger et al. 2011). 
 
Probiotic strains analysis of B. bifidum and L. acidophilus showed both taxa were detected 
in the stool of preterm infants during the cohort study. There is significant difference seen 
with respect to B. bifidum in the gut of preterm infants when comparing profiles before 
and after probiotics administration (P< 0.005). However, no significant differences was 
observed for L. acidophilus from the stool of probiotics babies in the same time interval 
(P> 0.005).  Nonetheless, the detection of probiotic strains from the preterm gut does not 
necessarily indicate the colonisation of the gut but rather may indicate that the organisms 
were shed after probiotic intake. It has been demonstrated that some probiotics strains 
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were  found to be shed a month after probiotics supplementation was stopped with 
different level of colonisation (Tobin et al. 2013). 
 The results from 16S gene profiling and qPCR assays both agree with one another in 
respect to B. bifidum (Fig. 4.6, 4.8 and 4.10) and for L.acidophilus (Fig. 4.6, 4.7, 4.10 and 
Table 4.4). NGS analyses indicated fewer OTUs reads were detected prior to probiotic 
intake and during the post discharge samples with none detected in control groups (Fig. 
10 & Table 4.4). However, qPCR showed Bifidobacteria  were found to increase during 
and after probiotics were stopped (Fig. 4.8). 
 However, quantitative analysis from our study demonstrated the ability of 
Bifidobacterium to successfully colonise the gut of preterm infants in high numbers even 
during post discharge (Fig. 4.10 and Table 4.4) which is not the case in Lactobacillus. 
This agrees with previous findings that showed an increased in the number of 
Bifidobacterium among breast- fed preterm compare to Lactobacillus (Barrett & Guinane 
2013). However, there are conflicting reports that demonstrate increased colonisation of 
Lactobacillus over Bifidobacterium in the preterm gut in breast-fed infants (Chen 2011).  
Additionally, our research also showed a reduction in the number of Clostridium among 
the preterm babies receiving probiotics (Table 4.4). The role of Clostridium in NEC has 
been identified in recent papers; this finding may suggest by reducing Clostridium, 
probiotics can reduce NEC. Some studies have indicated an association of between 
Clostridia  and the establishment of NEC (Sim et al. 2014; Cassir et al. 2015; Mai et al. 
2013).  Also Clostridium and Streptococcus were increased in control group compared to 
probiotic fed babies (Fig. 4.10). This shows the potential of probiotics to impact on the 
bacterial community in the gut (Table 4.4 shows 3.3% & 0.2% of Clostridium at control 
and probiotic groups respectively). Also Staphylococcus has 53.4% before probiotic start 
and falls down to 12.6% after probiotic stopped. 
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Diversity of bacterial taxa 
Notwithstanding, our study focused on the abundance of Bifidobacterium bifidum and  
Lactobacillus acidophilus from the gut of preterm infant and their effects on the gut 
bacterial community in our cohort; however, other bacterial taxa were detected in high 
abundance which may shed more light on dysbiosis studies associated with preterm 
infants. Our data (Fig. 4.10 and Table 4.4) indicated that the Enterobacteria, 
Enterococcus, Staphylococcus and Escherichia  were frequently detected in the gut of 
preterm babies. This may explain the higher incidence of NEC and sepsis in preterm 
babies as the findings of (Mshvildadze & Neu 2010) showed  high numbers of 
Enterococcus were frequently detected in NEC compared to control groups. Conversely, 
Klebsiella  was frequently detected in control group compared with NEC cases (P=  0.06). 
While, detection of high abundance of Proteobacteria  (61%) and Actinobacteria  (3%) 
before NEC dignosis compared to the control having 19% and 0.4% respectively and less 
abundance of Bifidobacteria and Bacteriodes before NEC (Mai et al. 2013). More 
recently the abundance of Enterobacteriaceae among the NEC babies only has been 
reported (Brower-Sinning et al. 2014).  
 However, many factors are found to be associated with the diversity of microbes in the 
preterm gut  such as mode of delivery, birth weight, feeding habit, gestational age and 
sex (Rigon et al. 2012). These factors may work with and against any impact of probiotic 
supplementation and may be confounders of understanding the impact of such 
supplements on health and disease. 
Delivery mode 
Table 4.3 showed 44% and 56% of babies who received probiotics were delivered through 
vaginal and caesarean respectively. While 60% and 40% of control babies were born via 
vaginal and caesarean section respectively (Table 4.3). A previous study showed that 
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infants delivered through the vaginal canal always harboured a gut microbial community 
similar to that of mother’s vaginal tract. Whereas, caesarean delivered babies had 
communities that resemble the maternal skin microbiota (Dominguez-Bello et al. 2010) 
and gut colonization is delayed (Thompson-Chagoyan et al. 2007). Clostridium, 
Escherichia, Streptococcus and Staphylococcus were found to be prevalent in the gut of 
preterm infants delivered through Caesarean section (Fig. 10) which agrees with the 
previous work (Thompson-Chagoyan et al. 2007).  Likewise different studies were in 
agreement with our finding with some variations in the taxa and level of colonisation 
depending on the delivery mode. Klebsiella, Enterobacter and Clostridium were detected 
after caesarean delivery and high numbers of Bifidobacteria  after vaginal delivery 
(Ventura et al. 2012). Other report showed low number of Bacteriodes and Clostridia  in 
preterm infants delivered by caesarean section (Westerbeek et al. 2006),  and low number 
of Clostridium with high number of Bifidobacteria  and Bacteriodes from the infant 
delivered vaginally (John et al. 2006). Lactobacillus was also found to be dominant 
among the preterm infants who were delivered vaginally (Rougé et al. 2010).  A study 
conducted on microbial diversity based on delivery mode from an animal model showed 
reduction of E-coli, Clostridia  and Lactobacilli among others from Caesarean delivery 
pigs (Cilieborg et al. 2012). 
 In terms of bacterial load, qPCR quantified the Bifidobacteria  and Lactobacilli from the 
stool of breast-fed infants and observed that there is an increased in Bifidobacteria  among 
both vaginally and caesarean delivered groups; this finding comply to the previous study 
(Chen et al. 2007).  
Impact of birth weight  
All the probiotic babies in our cohort weighed less than 1500g, while more than half of 
control group weighed above 1500g (Table 4.1 and 4.3), this may impact on the 
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colonisation of the infant gut, as a more immature GIT may facilitate or confound 
attachment and colonisation by different bacterial taxa. However, a previous work shows 
no significant difference between the bacterial diversity, sex, birth weight & gestational 
age (P=  0.42) (Mshvildadze et al. 2010). 
Breast milk 
In our study, all the babies were breast - fed, this could be why great numbers of 
Bifidobacteria  (11.1%) compare to low Lactobacilli (1.7%) were detected even before 
starting probiotic supplementation (Fig. 10). It was previously reported that the gut of 
breast-fed preterm infants was predominantly colonized by Bifidobacterium and 
Lactobacillus which potentially suppress pathogenic bacteria (Westerbeek et al. 2006). 
However, in case of NGS data, no Lactobacillus and only a small number of 
Bifidobacterium (4.0%) in breast-fed controls and no Lactobacillus in Post-discharge 
babies (Table 5) were detected. This implies that, the feeding alone does not significantly 
increase Lactobacillus and Bifidobacterium but when coupled with probiotic supplements 
it can influence the bacterial colonization in the gut of preterm babies. This finding agreed 
with  previous research which indicated that, the feeding is not significantly related to 
bacterial colonization in the gut of preterm infants (Westerbeek et al. 2006). 
However, the speed at which complete enteral feeding is achieved, or the addition of other 
supplementary dietary inputs may stimulate the gut of preterm infants to function and 
mature more rapidly (Cilieborg et al. 2012; Westerbeek et al. 2006). This could influence 
the colonization of the gut. Bifidobacterial colonization has no significant differences 
associated with birth weight, mode of delivery and feeding habit, but gestational age was 
significantly associated with Bifidobacterial colonization at birth (Butel et al. 2007).  In 
contrast, another study  showed the high abundance number of Lactobacilli and 
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Bifidobacteria  in the gut of preterm infants with decreased number of Clostridium which 
has been associated with maternal breast milk (John et al. 2006).  
However, regardless of probiotics intake, Bifidobacterium was found in our research to 
colonize the gut of preterm infants (4.0% & 11.1% for control and before administering 
probiotic respectively) thus, it concurs with other work that revealed that Bifidobacterium 
is dominant in colonising the infants’ gut more especially those receiving breast milk 
(Turroni et al. 2014). It also support a study that shows that Lactobacillus as common 
beneficial bacteria that is found to colonise the gut of breast-fed infants (Cárdenas et al. 
2015).  
Moreover, the adoption of probiotics prophylaxis routinely in neonatal care units must be 
undertaken with great care in order to reduce the NEC incidence when its properly 
administered (Shlomai et al. 2014). Recently, some research suggested that preterm 
infants with NEC who were fed with breast milk while receiving Infloran as probiotic 
supplements had significantly reduced NEC incidence (P=  0.027) but it did not have a 
similar significant effect on the incidence of  NEC for infants fed entirely with formula 
(P= 0.345) (Repa et al. 2015). It was also reported recently that exposure to maternal 
antibiotics increased the risk of NEC but when followed by post natal probiotics 
supplement, NEC was decreased among the preterm infants (Beken 2015). 
The quantitative analysis of both Lactobacillus and Bifidobacterium comparing between 
probiotics and control groups (Fig. 4.7, 4.9) showed lower detectable levels of 
Lactobacillus in probiotic infants compared to control group (Fig. 4.6). While, for 
Bifidobacterium quantification, we detected reasonable loads among the preterm 
receiving probiotics and none at the control group (Fig. 4.9). A study that compared 
quantitatively, the Bifidobacteria and Lactobacilli load counts between preterm patients 
and their healthy control groups; detected significantly lower Bifidobacteria  and 
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Lactobacilli counts than their healthy control groups and also observed significant 
differences between two groups among intestinal Bifidobacteria and Lactobacilli (Chen 
2011). 
Despite the impact of probiotics intake in reducing the NEC and suppressing some 
potential pathogens (Amin et al. 2013), another viable bacteria (Bifidobacterium longum) 
that was used in the combination of prophylactic probiotics was detected in the blood 
culture of preterm infants who developed NEC (Zbinden et al. 2015). Therefore, care has 
to be taken and other clinical characteristics need to be considered while administering 
the probiotics more especially in VLBW infants to avoid other complications. 
 Conclusions 
 
Our findings demonstrated that Probiotic babies have statistically lower diversity 
compared to non-probiotic. It also revealed Bifidobacterium and Lactobacillus colonize 
the gut of preterm infants at different levels during and after the treatment and they all 
increase with probiotic supplements, which contribute to the decrease of the relative 
abundance of the microbial communities associated with these diseases and hence may 
reduce NEC or LOS in preterm infants. B.bifidum was found to colonize the gut before 
probiotics where administered and Bifidobacteria  are more prevalent in the gut of preterm 
infants and found to proliferate long-term compared to Lactobacilli. Multiple OTUs 
associated with Lactobacillus were detected and qPCR was unable to robustly quantify 
the L. acidophilus used in Infloran raising potential questions about the reported quality 
control of available probiotics. Future studies should explore this concept in advance to 
better understand the systematic role of probiotic supplementation. 
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5 CHAPTER FIVE 
 Systematic functional analysis of the gut of preterm infants by 
probiotic metabolomics profiles 
 
Abstract 
Metabolomics is one of the modern techniques used to study the function of gut microbial 
communities by analysing different metabolites associated with a particular sample. 
Metabolites may have the potential to serve as biomarkers in clinical diagnosis as well as 
determining the nutritional status of an individual in response to clinical interventions.   
Aims 
The aimed was to determine metabolite profile from the gut of preterm infants receiving 
probiotics and any functional changes associated with NEC or sepsis. It was hypothesized 
that probiotics administration may result in functional shifts in the gut microbiome and 
affect the preterm gut metabolites signature. 
Methods 
A robust study of stool metabolomic profiles using ultra-performance liquid 
chromatography mass spectrometry tandem mass-spectrometry (UPLC-MS/MS) 
technique was performed. 
Results 
Exploring the samples showed each group of metabolites to cluster discretely. Groups of 
metabolites were found specifically in controls. While the samples taken during 
probiotics administration, showed distinct metabolites associated with probiotic 
supplements. Therefore, the metabolomic profiles showed variable composition 
associated with probiotics administration compared to that of control samples.  
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Conclusions 
Metabolite profiles clustered separately, with distinct metabolites associated with 
probiotic administration, but their identification was not available. Our findings also 
suggest that probiotics have some systemic functions and may play a significant role in 
the gut microbial communities. 
 Background 
 
Metabolomics involves a comprehensive analysis and systematic identification of 
different metabolites and their physiological changes in a particular sample (Inna et al. 
2010). The metabolome refers to the complete set of small-molecule metabolites in a 
biological system (Xie et al. 2013). The study of low-weight molecules (< 1,500 Da) 
which are the intermediates or end products of metabolism may serve as biomarkers for 
common infections and disease states affecting human population including preterm 
infants (Ganna et al., 2014). A previous study  showed that metabolomic fingerprints of 
some early microbial dysbiosis may serve as a biomarker for predicting NEC among 
preterm infants (Lagomarcino et al. 2013). A recent study also demonstrated the 
usefulness of metabolomics analysis as a biomarker in determining the nutritional value 
and predicting the health status as well as in the management of diseases  affecting 
neonate in clinical practices (Dessì et al. 2014; Marincola et al. 2012; Ganna et al. 2014).  
Metabolomics study serve as a mirror image of the genome and its interaction with its 
ecological environment (Xie et al. 2013). Evaluation at the metabolomics level would 
allow us to determine functional changes as a result of antibiotics therapy, probiotics 
supplementation and other physiological conditions (Dessì et al. 2014). Recent advances 
in metabolomics helps us to study the small complex molecules present in metabolome 
and have shown that intestinal microbiome can influence the metabolomics profiles of 
the individual host (Lagomarcino et al. 2013; Del Chierico et al. 2015; Antunes et al. 
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2011; Jansson et al. 2009). Moreover, the application of high-throughput metabolomics 
technique was used by a previous study to demonstrate the interaction between the 
intestinal microbiome and the individual host (Antunes et al. 2011).  
Metabolomics data are mostly analysed conveniently using principal component analysis 
(PCA) or partial least square (PLS) as part of a multivariate analysis (Trivedi 2012; 
Worley & Powers 2012). Although a recent study demonstrated that univariate analysis 
such as t –test or ANOVA are starting to become prominent in metabolomics data 
analysis. This is due to the need to test the significant differences among different 
metabolites within a particular biological sample (Saccenti et al. 2013). In order to have 
a comprehensive biological  mechanism of a given metabolomics sample, the data 
obtained should be integrated in a pathway analysis for proper comparison with other 
‘omics’ studies (Zhou et al. 2013). 
Most of the metabolites identification techniques involve: matching spectral features of 
the unknown compounds to curated spectral database of reference compounds (known as 
‘identification of known unknowns’), identification of truly novel compounds 
(identification of unknown unknowns) is more difficult and requires advanced 
computational approaches (Wishart 2009; Waterman et al. 2009). Metabolites 
identification is one of the major challenges facing metabolomics studies due to the 
diverse structure of different metabolites alongside with diversity in their physical and 
chemical properties (Zhou et al. 2013; Becker et al. 2012). 
The choice of method (LC/MS)  in the analysis of metabolites from faecal samples of 
probiotic infants is one of the most promising techniques used for the detection of large 
number of compounds in biological samples (Ganna et al. 2014). LC/MS is a robust 
techniques that has been proven in the analysis of the complex compound in biological 
samples (Becker et al. 2012; Ogura & Sakamoto 2007). LC-MS approaches provide an 
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accurate quantitation and identification of metabolites by evaluating the metabolic 
changes in a given sample (Zhou et al. 2013). However, there are difficulties faced during 
compound detection by MS technique at very low concentration is due to ion suppression. 
Though, it is easy to measure the mass of metabolites detected in LC-MS base technique, 
the ability to identify compounds is  hindering the application of the approach (Zhou et 
al. 2013). 
 Methods  
 Study design 
 
A Probiotic supplement was given to preterm infants of less than 32 weeks gestation. All 
had received some maternal breast milk during their stay at neonatal intensive care unit 
(NICU) of the RVI, Newcastle upon-Tyne. All the infants were born within a 3 month 
period.  Overall, 60 stool samples were analysed from 9 patients (6 probiotics and 3 
control babies). 40 are the study samples while 20 are the trial samples. The 20 trial 
samples involved only probiotic babies and were only used to optimise the extraction 
protocols as such were not involved in the analysis.  
The 40 study samples were further divided in to probiotics (28 samples) and their matched 
controls (12 samples). All the 40 study samples underwent metabolomics profiling and 
further analysis (the data presented in this chapter is based on these 40 samples). The 
patient’s clinical demographics data are summarised in Table 5.1- 5.2. 
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Table 5-1: Demographic data for the clinical cohort 
 
 Control  Probiotic 
Patient  No 263 271 272   270 273 274 275 276 278  
Gestational 
Age 
27 31 31 25 27 24 28 28 24  
Birth 
weight 
550 2030 1535 750 945 700 1100 1150 620  
Delivery CS V V V CS V CS CS CS  
Sex F F M M F M F M M  
Total NO. 
of Samples 
4 4 4 5 4 5 4 4 6  
Post dis 
(age in 
months) 
N N N Y 
(25) 
Y Y N N Y  
Feed All  BM           
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Table 5-2: Frequency of probiotic metabolomics groups 
 
The Table below shows different groups on which the entire samples were classified in 
relation to probiotics intake and the number of samples collated within each group during 
the cohort study: 
 Group                                                 Number of stool samples 
Before probiotic     1 
During probiotic     17 
After probiotic     6 
Post-discharge     4 
Control (pre-discharge)              12 
Overall total                                                               40 
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 Trial test of metabolomics analysis 
 
Twenty metabolomics stool samples were sorted out from seven babies receiving 
probiotic supplementation - the probiotic supplementation was given to preterm infants 
of less than 32 weeks gestational age immediately after initial introduction of feeds until 
it reached 34 weeks corrected. The dose contain a half of an Infloran capsule which was 
administered twice a day, equating to 125 mg b.d at 109 organisms per dose -  (see the 
appendix for demographic data of metabolomics trial test) to test the protocols as a trial 
for optimisation of the metabolite extraction/preparation stage. The samples were 
extracted in triplicate and analyses using the LCMS concurrently (see the methods chapter 
for the detail metabolomics protocols). The samples were marked A, B and C to identify 
the modified preparation protocols. The results are in Table 5.3. 
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Table 5-3: Trial test for stool metabolomics technique 
 
Sample groups Remarks 
Procedure Test A Test B Test C Experimental 
samples 
 
 
Homogenisation 50% 
MeoH 
80% 
MeoH 
80% 
MeoH 
80% MeoH 80% gives better 
result 
Vortexing 15 mins 
at 4oc 
15 mins 
at 4oc 
15 mins 
at 4oc 
15 mins at 
4oc 
Adapter was taken 
to cold room 
Centrifugation 500g/15 
mins at 
4oc 
500g/15 
mins at 
4oc 
3,000g/10 
mins at 
4oc 
3,000g/10 
mins at 4oc 
In the cold room or 
using thermos 
centrifuge  
Filtration No 
Filtration 
No 
Filtration 
Filtered 
with 0.2 
whatsize 
No Filtration No filtration gives 
better result 
Lyophilisation Speed 
vac at 
1,1/2hr 
for 30oc 
Speed 
vac at 
1,1/2hr 
for 30oc 
Freeze 
drying 
over night 
Freeze 
drying over 
night 
Freeze drying work 
better 
Re-suspension 1000 µl 
of 5% 
ACN 
1000 µl 
of 5% 
ACN 
1000 µl 
of 5% 
ACN 
1000 µl of 
5% ACN 
95% A (water):  5%  
B (ACN) 
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 Statistical analysis 
 
The bacterial profiles were analysed by multivariate partial least squares discriminant 
analysis (PLS-DA) and the metabolite profiles underwent orthogonal PLS-DA (OPLS-
DA) using SIMCA 13.0 (Umetrics, Stockholm, Sweden) - (Eriksson et al. 2006). All 
variables, either operational taxonomic unit (OTU) or component, were automatically 
transformed within SIEVE. To check that data was adhering to multivariate normalities, 
Hotelling’s T2 tolerance limits were calculated and set at 0.95. To remove the high 
amounts of noise from the metabolomics dataset, only variables >1 in the variable 
importance plot (VIP) were included from the important variables plot (Trivedi 2012). 
 Results 
 Metabolomics profiling of the gut microbiome 
 
 Metabolite profiles demonstrated uniformity among the study group in the cohort. The 
loadings plot showed a cluster of metabolites associated with samples during probiotic 
intake (Fig. 5.1). The post-discharge (PD) samples were found to have a distinct 
metabolite profile when compared with NICU samples by OPLS-DA (R2Y = 0.99, Q2 = 
0.8), with a strong association of unique metabolites and metabolites present in much 
greater abundance compared with NICU samples (Fig. 5.2). Due to low amount of sample 
in the ‘before’ samples (and the skew caused by the PD samples), these 2 groups were 
omitted from OPLS-DA of the probiotic and control groups. Due to the inherently similar 
metabolomics profiles, OPLS-DA was unable to robustly separate samples taken during 
or after probiotic administration, and control groups (Figure 5.2: R2Y = 0.62, Q2 = 0.31). 
However, following removal of metabolites with a VIP of <1 (leaving only significant 
metabolites with large differences in the relative intensities), the groups could be 
separated more robustly (Figure 3B: R2Y = 0.80, Q2 = 0.56).  
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  Figure 5-1 PLS-DA of metabolite profiles  
The data comparing samples collected on the NICU and post discharge. R2Y = 0.99, Q2 
= 0.8. A) Score scatter plot. B) Loadings plot. The green circles in ‘A’ represent the 
samples collected during post discharge period, while the orange circles in ‘A’ represent 
A 
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also the samples collected at NICU. All the samples associated with each group cluster 
separately. 
 
 
 
 
Figure 5-2: PLS-DA of the metabolite profiles 
Before and post discharge not included. A) Raw core scatter plot of the showing the 
relationship of samples associated with each group (R2Y = 0.62, Q2 = 0.31).The colours 
assigned in the Figure represent; Blue= control, Yellow= during & Purple= after. The 
numbers associated with each circle represents the patient and sample number during the 
cohort study.  B) Loading plot of detected metabolites associated with each group (during, 
after and control) to cluster separately with distinct metabolites following VIP removal 
A 
B 
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of noise (R2Y = 0.80, Q2 = 0.56). Red metabolites associated with probiotic 
administration. 
With regards to relative abundance of the OTUs metabolites (Fig. 3), because of the low 
amounts of samples involved in the group before probiotic supplementation, the ‘before’ 
not included during the analysis. However, the metabolites are more diverse in control 
group followed by during probiotic intakes and then after supplementation. While post 
discharge metabolites are less in abundance compared to other groups. Moreover, despite 
the detection and distinct separation of the metabolites during the analysis, their 
identification is challenging in the human metabolome data base (HMDB) library, hence; 
the matched colour numbers in the legend key, represent the samples number in the cohort 
(Fig. 3). 
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Figure 5-3: Relative abundance of metabolomics profiles from MiSeq analysis. 
 
 Proportion of OTUs matching the 200 most frequently observed metabolites across the 
samples. Colours on the chart matched with the metabolites data abundance in percentage. 
Sequences matching other metabolites with less frequently observed in the samples are 
not shown on the chart and represents minor and unclassified OTUs. 
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 Discussion  
 
In order to expand our understanding of the impact of probiotics on the preterm gut 
microbiome function, the metabolomic profiles was analysed to obtain a snapshot of the 
effect of probiotics before, during and after supplementation. A metabolomic profiles 
utilising UPLC-MS from preterm stool sample to determine how functional metabolites 
shift are associated with the intervention and to begin to elaborate the mechanistic role of 
probiotics in neonates was explored. This study is unique as most of the previous studies 
utilising same technique have exploited human biological samples such as serum and 
urine rather than stool (Ganna et al. 2014; Ogura & Sakamoto 2007). Other work has 
utilised urine sample to performed metabolomic profiling in preterm infants and how it 
could be used clinically in neonatal disorders  (Antonucci et al. 2009). 
As our study utilised the stool samples by exploring LC-MS approach to analyse the 
metabolite shifts and its relation with OTUs bacterial profiles. Other study utilised H-
NMR approach to determine the preterm stool and its correlation with OTUs  microbial 
profiles and metabolomic changes (Del Chierico et al. 2015). unlike one of  the previous 
study that focussed on the blood metabolites and showed the great effects of gut 
microbiota on the human blood metabolites (Wikoff et al. 2009). 
In accordance with a small number of published studies related to preterm cohorts, the 
metabolomics profiles were more comparable and stable than bacterial profiles 
(Turnbaugh et al. 2009; Morrow et al. 2013), and were comparable to those of controls, 
as certain metabolites were detected with an increased abundance during probiotic 
administration.  
However, a previous study showed that metabolic pathways were affected by 
antimicrobial agents and altered systematic functions of the gut (Antunes et al. 2011). It 
was also reported that antibiotics treatment affects a  high percentage of detectable 
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metabolites from the human gut demonstrating the impact of antibiotic therapy on the 
function of the intestinal metabolome (Antunes et al. 2011).  
Here, the relationship between gut microbial communities and stool metabolites in 
preterm infants was explored and the result showed that distinct metabolites cluster 
independently between the samples collected in the NICU and during post-discharge (Fig. 
5.2). This could be attributed to many factors including nutrition, environment and 
maturity of the microbiome associated with probiotics metabolites. During PD (post 
discharge), the preterm gut matures and consumption of solid food begins. Environment 
may also contribute as the NICU is more hygienically managed than a domestic milieu. 
Moreover, the gut microbiome becomes more diverse during PD as antibiotics therapy 
and pre and probiotics supplements are removed.  
None of the metabolites detected within our cohort could be matched with the existing 
ones and hence could not be identified based on the reference sample library available. 
This is one of the limitations of our study as further work will be needed to identify these 
compounds, and identifying whether they may be connected with potential regulatory 
pathways. Thus, our detectable metabolites fall under the metabolomics analysis term 
‘unknown unknowns compounds’  (Wishart 2009) and highlights the limitations of this 
technique.  
Previous studies have shown that > 70 % of detected ions in LC-MS analyses were either 
unidentified or had multiple putative identification making it difficult to identify a 
particular metabolite (Zhou et al. 2013). Therefore, identification of metabolites is one of 
the challenges in the field of metabolomics analysis (Zhou et al. 2013). However, due to 
recent advances in technologies, more techniques are being introduced and applied that 
is making metabolite identification simpler more robust (Becker et al. 2012; Wishart 
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2011; Marincola et al. 2012). These techniques include NMR and MS approaches 
(Wishart 2009; Xie et al. 2013; He et al. 2014). 
 Conclusions  
  
It was demonstrated that metabolites increased during probiotics supplementation, but the 
identity of these metabolites was not achieved. Further study will be required to robustly 
identify these and other metabolites of interest using additional techniques or known 
standards. And also exploring functional metabolite changes may provide important 
information on mechanisms of action of interventions such as probiotics, and should be 
considered for inclusion into future interventional trials. 
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6 CHAPTER SIX 
 Impact of antibiotics course combination on the gut microbial 
community in preterm infants 
 
Abstract                                                    
Antibiotics are usually prescribed to preterm infants during their early days of life in 
neonatal intensive care units (NICU). The effects of this intervention on the developing 
gut microbiome are poorly understood, but might have important consequences for 
health. 
Aim: The aimed was to explore how routinely used antibiotics in a neonatal intensive 
care units impacts on the preterm gut microbiome.  
Methods: The three most commonly prescribed antibiotic combinations were analysed 
VCM (Vancomycin, Ceftazidine and Metronidazole), VC (Vancomycin and Ceftazidine) 
and AFG (Amoxicillin, Flucloxacillin, and Gentamicin). Sampling was performed at four 
time points: 2-3 days before the course started (Pre), the last day of administration 
(During), 1-2 days after antibiotic was given (After), and one week later than or as late as 
possible before next antibiotic course. In total, 141 stool samples were collected from 38 
patients and bacterial profiling was performed by 16S rRNA gene sequencing (Miseq, 
Illumina) 
Results: Bacterial diversity increased after the VC and VCM course were stopped 
.Diversity was reduced for all antibiotic treatment during their administration (P >  0.05).  
Generally, VCM and VC were comparable with lower bacterial taxa when compared to 
AFG which recorded higher bacterial taxa.  
Conclusion: The three antibiotics courses differentially affected the preterm gut 
microbiome, causing reductions in the diversity. Further work is necessary to determine 
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the contribution of these changes to health and how medical intervention can be tailored 
to achieve optimal outcomes for preterm infants. 
 Background 
 
Preterm infants are typically treated with antibiotics during the early days of life. 
Antibiotics produce short- and long-term impacts on the gut microbial communities  
(Jernberg et al. 2010; Jernberg et al. 2007), though the long-term health implications are 
still not clear (Fouhy et al. 2012). The impact of antibiotics on the gut microbiome are 
manifested during the early days of an infant’s life through decreases in the number of 
Bifidobacterium and Bacteriodes as well as general decrease in bacterial diversity (John 
et al. 2006; Johnson & Versalovic 2012). 
Some studies showed that preterm gut microbiota contain; more pathogens than healthy 
term infants; few numbers of beneficial bacteria and low bacterial diversity (Mai et al. 
2011; Morowitz et al. 2011) but the extent to which this observation can be attributed to 
antibiotics exposure is not clear (Greenwood et al. 2014). It was therefore, sought to 
explore the impact of commonly prescribed antibiotic combinations on preterm infant’s 
gut microbiome. Antibiotics affect the intestinal microbial composition depending on a 
number of factors including: drug combination, mode of delivery, treatment time and 
dosage (Jernberg et al. 2010). Intestinal antibiotics may cause dysbiosis  (Johnson & 
Versalovic 2012; Dethlefsen & Relman 2010; Jernberg et al. 2007; Jernberg et al. 2010), 
as well as affecting the host-microbe’s interaction and intestinal homeostasis (Antunes et 
al. 2011). It has been recently reported that antibiotic therapy during pregnancy influence 
the gut microbial colonisation of maternal mothers and infants (Gonzalez-Perez et al. 
2016). 
The routine antibiotic exposure of preterm infants is one of the factors influencing the 
colonisation of gut bacteria in the early days of life that affects the community 
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composition and structure (Ward et al., 2014). Early exposure to antibiotics by preterm 
infants may lead to increases in the incidence of morbidity and mortality when compare 
to those not receiving antibiotics (Greenwood et al. 2014). Furthermore, antibiotics are 
routinely prescribed to very extremely preterm (less than 34 weeks GA) infants within 
the first two days of life without symptoms of infection and then may subsequently be 
administered later if symptoms of infection were manifested (Gosalbes et al. 2016; 
Greenwood et al. 2014).  Antibiotics in the gut of preterm infants has been linked to the 
pathogenesis of NEC (Torrazza et al. 2013). Furthermore, care has to be taken when 
prescribing antibiotics to both preterm infants and pregnant women in order to avoid their 
detrimental effects on the bacterial gut community (Johnson & Versalovic 2012). A recent 
study demonstrated how certain antibiotics resistance genes present among the pregnant 
women can be transmitted and established in the gastrointestinal tract of infants (Gosalbes 
et al. 2016). Moreover, antibiotics resistance genes were reported to persist in the human 
intestinal microbiome after antibiotic administration for up to two years after treatment 
stopped (Jernberg et al. 2007; Jernberg et al. 2010). It has been reported that the alteration 
of gut microbiota due to antibiotic treatment may cause immune dysregulation leading to 
autoimmune disorders (Willing et al. 2011; Wu & Wu 2012).  
The application of molecular techniques may help in understanding the gut microbiome 
better and the impact of clinical interventions (Willing et al. 2011). Studying the effects 
of antibiotics using molecular techniques illustrates how antibiotics affect the intestinal 
physiology and its interactions with gut microbiota resulting in significant impacts on the 
intestinal metabolites (Antunes et al. 2011a). 
Some routinely used antibiotic courses with and without metronidazole were selected and 
looked at their impact on preterm gut microbiology over time. Metronidazole was the key 
antibiotic that our study focussed on which when combined with other antibiotics is 
instrumental in the management of NEC/Sepsis during infants stay at NICU. Identifying 
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the best antibiotic course could lead to better outcome in the treatment of mixed 
infections. Metronidazole is the antibiotic of choice globally in clinical practice against 
anaerobic infections and, is commonly used in the treatment of severe complications of 
prematurity, such as NEC, (Löfmark et al, 2010). Metronidazole has previously been 
shown to alter the rat intestinal microbial community by significantly increasing the 
number of Bifidobacterium and Enterobacteria  (Pélissier et al. 2010). Different clinical 
trials have been carried out using probiotics strains to test the clinical responses of 
infections to metronidazole either alone or combined with other antimicrobial agents 
(Löfmark et al., 2010; Zar et al., 2007). 
To further explore the effects of antibiotics in preterm infants, three different antibiotic 
combinations were analysed, which were the most frequently prescribed in the NICU: 
VCM (Vancomycin, Ceftazidine and Metronidazole), VC (Vancomycin and Ceftazidine) 
and AFG (Amoxicillin, Flucloxacillin, and Gentamicin). It was hypothesise that distinct 
changes in the gut microbiota will occur as a direct result of antibiotic administration, 
which may have important consequences for the short and long term outcomes of 
premature infants. 
 Methods 
 
 Ethical approval 
 
Ethical approval was obtained from the County Durham and Tees Valley Research Ethics 
Committee. The consent form was duly processed and endorsed by parents facilitating 
sample collection. 
 Study design 
 
All the preterm infants in the cohort study were cared for in the neonatal intensive care 
unit (NICU) of the Royal Victoria Infirmary Newcastle upon Tyne. There is a standard 
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feeding practice in the unit; antibiotics, antifungal as well as probiotics were used 
depending on the clinical diagnosis.  All the infants in the cohort were <30 weeks 
gestational age and <1500g birth weight with the exception of patients 207 who was 
1580g and patient 294 who was 1650g (Appendix 13). Babies were grouped into before, 
during and after antibiotic treatment and 1 week post antibiotics treatment (Table 6.1). 
Overall 141 stool samples and clinical data were collected from 38 infants, out of which 
12 preterm infants received VCM (41 samples), 13 VC (51 samples) and 13 (49 samples) 
AFG course. Three different antibiotic combinations were identified during the studies 
as:  VCM (Vancomycin, Ceftazidine and Metronidazole), VC (Vancomycin and 
Ceftazidine) and AFG (Amoxicillin, Flucloxacillin & Gentamicin).  
Table 6-1: Antibiotics sampling at different time points 
 
Sampling was undertaken at four time points.  
Time points                              Description 
     I                                2-3 days before course started 
    II                                last day of administration 
    III                              1-2 days after antibiotic was given 
    IV                 1 week after last antibiotic treatment, or as late as possible before next 
antibiotic    course  
  
I = Pre  
II = During 
III = After 
IV = Post antibiotics               
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The study involved 38 patients from which 141 samples were collected (See the summary 
in Table 6.1 and the details in the appendix 13 for clinical characteristics and demographic 
data during the antibiotics cohort study).  
 Sample analysis 
 
 Next Generation sequencing (NGS) 
 
16S rRNA gene bacterial profiling was performed on all samples in the study. The entire 
stool samples underwent nucleic acid extraction on 100 mg of stool sample using the 
PowerLyzer™ PowerSoil® DNA Isolation Kit (MoBio) following the manufacturer’s 
guidelines. After DNA extraction, the NGS analysis was carried out by NU-OMICS 
(Northumbria University) based on the Schloss wet-lab MiSeq standing operating 
protocol (available at - http://www.mothur.org/wiki/MiSeq_SOP). Raw fastq data were 
processed using Mothur (version 1.31.2) as described in the MiSeq SOP. Chimeric 
sequences were detected by Chimera.uchime and removed from downstream analysis. 
Alignment was generated via the Silva database. The data obtained was subjected further 
to statistical analysis using SIMCA, Minitab, and past.exe and excel. 
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Table 6-2: Demographic data of cohort infants (Average Mean)  
 
Antibiotic
s course 
No of 
Patie
nt 
No of 
Samp
le 
GA 
(weeks) 
BW 
(weeks) 
 
Antibiotics Time points 
(No of Pt.) 
     I II III IV 
 
VCM 12 41 24.6(24
-27) 
777.1(620-
1180) 
12 7 12 10 
VC 13 51 25.9(24
-28) 
922.5(790-
1310) 
10 11 13 17 
AFG 13 49 26.0(23
-29) 
1013.8(69
5-1650) 
13 12 13 11 
TOTAL 38 141   35 30 38 38 
 
*The alphabets represent the name of antibiotics course given as:  VCM (Vancomycin, 
Ceftazidine and Metronidazole), VC (Vancomycin and Ceftazidine) and AFG (Amoxicillin, 
Flucloxacillin, and Gentamicin). 
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Table 6-3: Antibiotics and their Target Microorganisms 
 
The Table below shows the individual antibiotic used to treat infants during the cohort 
study alongside their usual bacterial targeted. 
Antibiotics Target Microorganisms 
1 Vancomycin Listeria monocytogenes, Streptococcus pyogenes, 
Streptococcus pneumoniae , Streptococcus agalactiae, 
Actinomyces spp., and Lactobacillus spp., Enterococci. 
2 Ceftazidine  Pseudomonas, Lactobacillus and Enterobacteriaceae, with 
intermediate activity versus  Veillonella  
3 Metronidazole Anaerobic bacteria, Helicobacter pylori, and Veillonella. 
4 Amoxicillin Streptococcus pyogenes, S. pneumoniae, Staphylococcus spp., 
H. influenzae, E. coli, P. mirabilis, or E. faecalis. , Veillonella . 
5 Flucloxacillin Anaerobic bacteria and aerobic bacteria, Staphylococcus spp., 
and Streptococci, Clostridia spp. 
6 Gentamicin Proteus spp., E. coli, Klebsiella-Enterobactor-Serratia  spp., P. 
aeruginosa , Citrobacter spp. and Staphylococcus spp. 
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 Results 
 Comparison of most abundant taxa over time  
 
It was observed that Staphylococcus had a significantly higher (P =  0.004) number of 
OTU in the VCM treatment across the early time points but this was reduced 1 week after 
treatment stopped and showed no significant difference (P =  0.157) compared to other 
taxa except with E. coli (P =  0.006) (Fig. 6.1). However, the other taxa (Pseudomonas, 
Enterococcus and Enterobacteriaceae) increased at 1 week after VCM regimen stopped 
but not reached significantly so (Fig. 6.1). 
Staphylococcus and Enterococcus OTUs were high in the VC regimen across all the time 
points when compared to other taxa (Fig. 6.2). All taxa increased at 1 week after VC 
regimen was stopped except Enterococcus, (Fig. 6.2).  Pseudomonas OTUs were lower 
in AFG treatment across the time points when compared to other taxa (Fig. 6.3). All taxa 
have stable OTUs in AFG treatment at 1 week after treatment stopped except 
Enterococcus OTUs that increased significantly (P =  0.02) (Fig. 6.3).The other most 
abundant taxa showed inconsistent patterns across the time points between the different 
the entire antibiotic courses (Fig. 6.1- 6.3 and Table 6.4). 
Generally, Staphylococcus was the most abundant taxa with high OTUs in almost all the 
antibiotic mixtures in the cohort. Also there is overall increase in OTUs number with 
antibiotic treatment at 1 week after regimens were stopped with the exception of 
Staphylococcus (in VCM treatment) and Enterococcus (in VC treatment) Figure 6.1- 6.3. 
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Figure 6-1: The most abundant organisms over time for VCM regimen. 
 
Figure 6.1 above indicates the average OTUs of the highest relative abundance OTUs and 
the effect of antibiotic treatment to microbial community in the cohort study. Proportion of 
OTUs matching the 5 most frequently observed taxa over time among the antibiotic course. 
Colours on the charts matching with the bacterial taxa on the legend represent the diversity 
in percentages. While the letters I, II, III and IV on the bottom of each chart representing 
different sampling points of the antibiotics I, II, III and IV represents pre, during, after and 
week after respectively.  
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Figure 6-2: The most abundant organisms over time for VC regimen. 
 
Figure 6.2 above indicates the average OTUs of the highest relative abundance OTUs and 
the effect of antibiotic course to microbial community in the cohort study. Proportion of 
OTUs matching the 5 most frequently observed taxa over time among the antibiotic 
course. Colours on the charts matching with the bacterial taxa on the legend represent the 
diversity in percentages. While the letters I, II, III and IV on the bottom of each chart 
representing different sampling points of the antibiotics I, II, III and IV represents pre, 
during, after and 1 week after respectively.  
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Figure 6-3: The most abundant organisms over time for AFG regimen. 
 
Figure 6.3 above indicates the average OTUs of the highest relative abundance OTUs and 
the effect of antibiotic course to microbial community in the cohort study. Proportion of 
OTUs matching the 5 most frequently observed taxa over time among the antibiotic 
course. Colours on the charts matching with the bacterial taxa on the legend represent the 
diversity in percentages. While the letters I, II, III and IV on the bottom of each chart 
representing different sampling points of the antibiotics I, II, III and IV represents pre, 
during, after and 1 week after respectively.  
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Table 6-4: Average OTUs of the bacterial community in patients treated with VCM, VC & AFG at different time 
points 
 
 VCM VC AFG 
Organisms I II III IV   I II III IV I II III IV 
Staphylococcus 3280± 3285± 3118± 1162 2798± 2365± 2023± 2335 1138± 814± 518± 467 
Pseudomonas 1560± 1186± 1100± 1371 16± 14± 6943± 751 0.307± 226± 211± 31 
E. coli 305± 444± 628± 352 384± 615± 136± 538 1283± 2092± 1856± 1547 
Enterococcus 356± 559 ± 714± 1816 2004± 2359± 2192 1280 1945± 904± 728± 2018 
Enterobacteriaceae 665± 1400± 448± 874 1332± 1105± 612± 902 497± 1102± 1957± 1569 
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 Shannon diversity for antibiotic courses over time 
 
Shannon diversity did not significantly change across different sampling points in stools 
from infants treated with VCM, VC or AFG (Fig. 6.4 – 6.6). The median value was 
decreased during antibiotic administration while there is an increase after VC treatment 
was stopped (Fig. 6.5). A comparable pattern was observed between VCM (Fig.6.4) and 
AFG (Fig. 6.6) with general decreased in diversity across the time points.  
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Figure 6-4:  Shannon diversity for VCM course combination across the antibiotic 
time points  
 
The letters below on the X axis represent time points; where I = pre, II = during, III = after, IV-1 
= 1 week after and IV-2 = more than 1 week before next antibiotic course.  * Asterisks represent 
the outliers, horizontal lines in the boxes represent the median value, shade boxes indicates upper 
and lower quartiles and the vertical lines extending from the boxes represent highest and lower 
whiskers. Diversities not significantly different between time points (P = 0.3).  The ‘n’ inside the 
bos represent the patient number that received AFG regime in the cohort. 
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Figure 6-5: Shannon diversity for VC course combination across the antibiotic time 
points.  
 
The letters below on the X axis represent time points; where I = pre, II-1 = 1-2 day during 
antibiotics administration, III = after, IV-1 = 1 week after and IV-2 = more than 1 week before 
next antibiotic course. The horizontal lines in the boxes represent the median value, shade boxes 
indicates upper and lower quartiles and the vertical lines extending from the boxes represent 
highest and lower whiskers. Diversities were not significantly different between time points (P- 
value 0.1). The ‘n’ inside the bos represent the patient number that received AFG regime in the 
cohort. 
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Figure 6-6:  Shannon diversity for AFG course combination across the antibiotic 
time points.  
 
The letters below on the X axis represent time points; where I = pre, II-1 = 1-2 day during 
antibiotics administration, III = after, IV-1 = 1 week after and IV-2 = more than 1 week before 
next antibiotic course. * Asterisks represent the outliers, horizontal lines in the boxes represent 
the median value, shade boxes indicates upper and lower quartiles and the vertical lines extending 
from the boxes represent highest and lower whiskers. Diversities are not significantly different 
between time points (P- value 0.9). The ‘n’ inside the bos represent the patient number that 
received AFG regime in the cohort. 
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 Average Shannon diversity of microbial taxa 
 
Although, there was a general trend of decreased diversity, this was not significant 
between treatment time points for any antibiotic mixture (Fig. 6.4 – 6.6). Overall average 
diversity between antibiotic mixtures was calculated, the mean, standard deviation and 
mean error was also calculated (Fig. 6.7). A comparable pattern was observed between 
VCM and VC treatment across the time points with VC lower in diversity than VCM and 
AFG (Fig. 6.7). Generally, there is decrease in microbial diversity with all treatment 
during antibiotics administration and increase after the treatment was stopped except in 
AFG regimen (Fig. 6.7).  
  
173 
 
 
Figure 6-7: Comparison of the overall Antibiotics combination with respects to their 
microbial diversity over time. 
 
A comparison of the gut community diversity measured in stool in response to the three 
antibiotic treatments (Fig. 6.7). Although there was a general trend to decreased diversity, 
this was not significant between treatment time points for each antibiotic mixture as 
illustrated in Figs 6.4 – 6.6.  
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Figure 6-8: Individual effects of VCM antibiotics with microbial diversity over time 
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Figure 6-9: Individual effects of VC antibiotics with microbial diversity over time 
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Figure 6-10: Individual effects of AFG antibiotics with microbial diversity over time 
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Figures 6.8 - 6.10 above indicates the individual data for each patient treated with the 
antibiotic course VCM, VC and AFG respectively showing the microbial diversity 
alongside with time points during the analysis 
 
However, the Figures 6.8 – 6.10 illustrated the proportion of OTUs matching the 12 most 
frequently observed taxa across individual patients treated with VCM, VC and AFG in 
our cohort. Sequences matching other bacterial taxa represent less frequently (< 1 %) in 
the samples are not shown on the legend. The alpha-numeric numbers on the bottom of 
each figure represent the time point on which antibiotic course was given. PA indicates 
pre antibiotic, DA indicates during antibiotic and AA indicating after antibiotic. 
Numerical numbers on the top of each line chart represents the patient number in the 
cohort. 
The data shows that specific taxa varied widely across the time course for each antibiotic 
regimen. The individual variation suggests no coherent trends and highlights the fact that 
bacterial gut communities are very variable from one baby to another and significantly 
affected by host factors. 
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 Discussion 
 
The faecal samples derived from 38 premature infants were robustly explored by subjecting 
them to 16S rRNA sequencing and further statistical analysis. A comparison was made 
between three antibiotic regimens which including one incorporating metronidazole to look 
at their impact on bacterial community in the gut of these infants. Our hypothesis was that 
certain antibiotic regimen may alter the preterm gut microbiota. 
Overall comparison between antibiotic courses: The result from average Shannon 
diversity showed the following distinct points: 
i-  There is general decrease in microbial diversity across the entire course during the 
antibiotics administration and increase after the treatment stopped except in AFG, 
but these differences are not significant (P =  0.9). 
ii- The overall response of the gut bacterial communities showed comparable patterns 
between VCM and VC regimen. However, the VC regimen had a lower diversity, 
but not significantly so (P =  0.1).  
iii- The, AFG regimen had a higher diversity at sampling points when compared to 
other treatments, but this decreased after treatment was stopped though no statistical 
difference between the means was found (P =  0.5) (Fig. 6.7). 
Moreover, with regards to the most abundant taxa, Staphylococcus had a high OTU number 
in VCM and VC regimens across the sampling points with a decrease one week after VCM 
treatment was terminated. Enterococcus also decreased in VC one week after treatment but 
with no significant difference (P =  0.181) when compared with other abundant taxa. 
Pseudomonas was lower in AFG regimen with a significant difference between its mean 
value and that of Enterococcus, E. coli and Enterobacteriaceae across the time points (P 
=  0.02). Staphylococcus was significantly different when compared with Pseudomonas (P 
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=  0.05) at point 1, but statistically not different at remaining sampling points (P =  0.27) 
(Fig. 6.3). 
Our findings are closely related to previous study which observed a significant reduction 
in the diversity of bacterial populations within the gut of preterm infants  (Greenwood et 
al. 2014). That study  showed a reduction in bacterial diversity during antibiotic intake with 
an increased contribution of Enterobacter in to the community (Greenwood et al. 2014). 
Other studies have reported low microbial diversity with an increase in Proteobacteria in 
the preterm infants associated with NEC (Wang et al. 2009), and that the abundance of 
Bifidobacterium in the gut is reduced as a result of antibiotic usage which may result in 
dysbiosis (Kheadr et al., 2007). Similarly, the effect of antibiotics treatment in reducing the 
bacterial diversity as well as that of Bifidobacterium and Bacteriodes among infants of less 
than 12 month of age (Johnson & Versalovic 2012) has been reported. It has also been 
shown that the pattern of bacterial colonisation after one week of antibiotics treatment 
resemble that of at the initial point of administration (Dethlefsen & Relman 2010). 
Furthermore, our research demonstrated how certain antibiotics combinations altered the 
composition and structure of the bacterial communities from the gut of preterm infants 
during the early days of life (Fig. 6.2 – 6.4 and Table 6.4). This supports with work 
reporting the use of antibiotics course combination within the 48 hrs of birth among preterm 
infants significantly altered the gut microbial community (Fouhy et al. 2012). 
 Previous work has demonstrated that the intestinal microbiome of infants who received 
antibiotics treatment had high percentage of Proteobacteria and lower percentages of 
Actinobacteria , Bifidobacterium and Lactobacillus than infants that did not, even after the 
antibiotic dose was stopped. However, two month later, Actinobacteria, Bifidobacterium 
and Lactobacillus recovered to levels observed before the antibiotic treatment (Fouhy et 
al. 2012). Similarly, a commensal microbiome in the human gut were shown to stabilised 
a few weeks after antibiotics treatment ceased (Jernberg et al. 2010). 
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During this study, some bacterial taxa (Fig. 6.1 & Table 6.3) were detected differentially 
in high abundance prior to antibiotics administration; these might be passed across from 
the maternal microbiota during birth or acquired immediately after delivery as it is 
recognised previously that the preterm GIT often harbour a microbiota resembling that of 
mother’s skin or vaginal community dependent on the mode of delivery  (Nyangale et al. 
2012; Mshvildadze et al. 2010). However, it has been reported that preterm gut microbiome 
consists of more pathogens when compared to healthy term infants (Greenwood et al. 2014; 
Mai et al. 2011; Morowitz et al. 2011). 
Metronidazole was described as one of the most commonly used antibiotics for the 
treatment of pathogenic anaerobic bacteria. Its clinical importance relates to it being cheap, 
its mechanisms of action being against anaerobic infections, that it had less adverse effects 
than many alternating and ease of application (Löfmark et al. 2010). However, combining 
it with other antibiotics is clinically important during the therapy of both aerobic and 
anaerobic infections (Zar et al. 2007; Löfmark et al. 2010). In our cohort, it was observed 
that when metronidazole was added to the VC course, a distinct bacterial community 
pattern was found enriched in Staphylococcus with fewer Enterococcus, compared to VC 
treatment alone. Also, there is significant (P =  0.02) increase in Pseudomonas in VC versus 
VCM regimen after treatment stops. This signifies that metronidazole when combine with 
ceftazidine has a great effect against Pseudomonas. Moreover, Staphylococcus and E. coli 
were reduced in VCM versus VC regimens after treatment stops which imply the effects 
of Metronidazole against anaerobic bacteria (Table 6.3). However, in AFG regimen, 
Staphylococcus decrease across the time points indicating the effect of antibiotics mixture 
against Staphylococcus as one of the  target organism (Table 6.3). With regards to 
Lactobacilussus, Veillonella, Bifidobacterium, Acinetobacter and Enterobacteriacaea; 
there is an inconsistent trend across all the sample points during the cohort study which 
indicates a large amount of variation within individuals in term of their gut bacterial 
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community and how it responds to antibiotic treatment (Berrington et al. 2014) (Fig. 9.8, 
6.9 and 6.10). 
Microbial diversity: Generally, AFG recorded higher diversity, followed by VCM and 
then VC with least diversity in the cohort study (Fig. 6.7). While with respect to sampling 
points, microbial diversity was higher prior to antibiotics intake and reduced during the 
antibiotics intake in the entire courses with variation after the dose was finished. For VCM 
and AFG, it was decreased across the time points but increased after VC course was 
stopped (Fig. 6.1 to 6.5). 
Though, a short-term recovery of some bacteria was noticed from the preterm gut after 
antibiotics treatment, it varied and were inconsistent depending on the antibiotic 
combination. There is limited published data reported on the short-term recovery of 
microbiome from the infant’s gut after antibiotics therapy (Fouhy et al. 2012) although 
some studies demonstrated both short and long term impacts of antibiotics treatment on gut 
microbiome (Jernberg et al., 2010 & Jansson et al., 2007) with also few studies on long-
term impacts (Jernberg et al. 2007). However, a lack of a definite pattern of bacterial 
recovery after antibiotics treatment has also been reported (Johnson & Versalovic 2012). 
Our study involved cross sectional samples from preterm infants receiving different 
antibiotics combinations. However, the limitations of our study include the low number of 
the preterm infants who received different antibiotics regimen and the limited antibiotics 
combination that could be studied. In future, it will be necessary to explore more antibiotic 
regimen in larger cohorts and compare that data with the present study.  
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 Conclusions 
 
Generally, there is decrease in microbial diversity during antibiotics intake for the entire 
course and an increased at one week after the treatment terminated in all the antibiotic 
mixture with the exception of AFG regimen. VCM and VC showed similar pattern of 
microbial diversity across the time points. It was therefore conclude that antibiotics 
administration may alter the microbial diversity from the gut of preterm infants. Further 
study is necessary on other antibiotic regimens that are routinely given to preterm infants 
and their clinical impacts in health and disease as our study is limited to particular course 
due to unavailability of the desired samples from other combinations. 
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7 CHAPTER SEVEN: Concluding remarks 
 
 Summary  
 
The study focused on the development of the preterm gut microbiome and its response to 
therapeutic and nutritional interventions. These multi-disciplinary studies explored the 
use of culture and non-culture fingerprinting and molecular profiling to determine 
microbial colonisation and metabolomics to determine overall functional changes 
resulting from microbial-host interaction in the preterm gut environment. This study 
utilised the ecological theory and statistical modelling to identify the assembly, functional 
and phylogenetic diversity and contribution these communities make to the disease state. 
It was also aimed to study the impacts of clinical and dietary interventions on the 
community structure, function and how it alter the preterm gut microbiota by using a 
robust approach to analyse stool before diagnosis, at diagnosis, and after onset of NEC. 
However, sampling in different time points including post discharge pave way toward 
better understanding, comparisons and observing the long term effects of these 
interventions and how it can be tailored accordingly.  
The bacterial mediated pathogenesis of NEC remains elusive, but several studies 
including our own demonstrated some potential bacteria to be associated as the 
aetiological pathogens of NEC (Clostridium, Klebsiella, Bacteroides and 
Gammaproteobacteria). However, our qPCR study to determine the stool bacterial load 
from preterm infants with NEC matched to healthy controls demonstrated the bacterial 
load is not associated with NEC in preterm infants. Probiotic supplementations and 
antibiotics therapy are found to be promising interventions in the management of NEC 
and alter dysbiosis as well as the functional shifts in the preterm gut microbiome. 
Administration of probiotics in this breast fed population was not sufficient for 
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eradicating NEC or LOS, but a reduction in the relative abundance of organisms 
previously associated with these diseases was observed. Thus therapeutics should be 
tailored to optimise healthy microbial communities, rather than suppressing and 
potentially limiting microbial diversity through the use of broad-spectrum antibiotics.  
Exploring the function metabolites in conjunction with microbial profiling may offer 
important information on how the probiotic strains are interacting with the gut ecosystem, 
both with other microbes and with the host. 
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   Table 7-1– Summary of the bacterial species select from OTUs  
 
  
Control  
NICU Probiotic 
PD 
Before During After 
Acinetobacter 1.38 0.02 0.00 0.00 0.00 
Actinomyces 2.36 0.00 0.00 0.00 0.00 
Anaerostipes 0.00 0.00 0.00 0.00 4.37 
Bacteroides 0.00 0.00 0.03 0.00 10.36 
Bifidobacterium 4.02 11.06 15.03 19.10 14.16 
Clostridium1 3.84 0.03 0.02 0.47 0.00 
Clostridium2 0.81 0.00 0.00 0.00 0.08 
Enterococcus 18.41 18.93 24.38 12.04 1.16 
Escherichia 11.44 2.06 19.66 23.77 14.02 
Klebsiella 37.41 7.93 16.54 23.92 12.84 
Lachnospiracea 0.00 0.00 0.00 0.00 5.10 
Lactobacillus1 0.00 1.73 4.81 4.77 0.00 
Lactobacillus2 0.00 0.77 5.80 0.08 0.00 
Lactobacillus3 0.00 0.73 0.20 2.32 0.01 
Lactobacillus4 0.00 0.06 0.19 0.24 0.00 
Proteus 0.00 0.00 0.00 0.00 5.53 
Pseudomonas 1.58 1.44 0.49 0.03 0.01 
Staphylococcus 5.86 53.49 9.73 10.52 0.02 
Streptococcus1 3.09 0.01 0.01 0.00 1.04 
Streptococcus2 1.00 0.00 0.00 0.00 0.00 
Veillonella 0.00 0.00 0.00 0.00 4.47 
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The above table suggest a summarized bacterial species associated with  NEC and how 
these change with time or intervention during the cohort study. The bold numbers in the 
table indicate the OTUSs associated with sampling time according to PLS-DA loading 
plot. From the previous findings and as confirmed by our research study, the following 
bacteria were reported to be associated with the development of NEC in preterm infants: 
Clostridium spp., Klebsiella spp., and Bacteriodes spp. which were all detected in our 
cohort study. 
 Archeal/Fungal PCR-DGGE study 
 
Following the stool analysis from the gut of preterm infants by exploring PCR-DGGE 
fingerprinting of the archeal16S rRNA and fungal 28S rRNA fragments revealed low 
diversity of archaeal and fungal communities in preterm stool samples. Both archaeal and 
fungal microbial communities were found to colonize the gut of preterm infants in low 
abundance compare to that of bacterial microbiota with archaea in less abundance than 
fungi.  
  Stool bacterial load study 
 
Resected gut tissue is not valuable as a diagnostic tool and is only taken from the most 
severe NEC cases, but stool bacterial load has not been explored before.  If the results 
from stool matched to those from resected gut tissue then there is the potential for this 
finding to be exploited in clinical diagnostics. The aimed was to determine changes in 
bacterial load in preterm infant stool to determine if the onset of NEC is associated with 
alterations in the structure and bacterial load of the preterm gut community. Quantitative 
PCR (qPCR) was carried out on longitudinal stool samples from preterm infants with 
established NEC cases and matched to healthy control infants to accurately quantify the 
total bacterial copy number (bacterial load). The stool was analysed before and after the 
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onset on NEC. The outcome of this study showed that no unique or characteristic trend 
in microbial signatures that might be responsible for causing NEC in preterm infants. Our 
findings also revealed that before and at diagnosis total bacterial loads in babies with NEC 
fluctuated widely over time and were not significantly different to bacterial loads in 
control samples (p >0.05). Although, the overall bacterial loads analysed at one week 
after NEC diagnosis showed that, the load is significant lower (p < 0.05) between NEC 
and control, this is most likely due to clinical intervention with antibiotics. It was 
therefore conclude that more work needs to be done in quantifying specific microbial 
signatures associated with NEC based on time intervals as our study applied universal 
approach. 
 Probiotics study 
 
Our findings demonstrated that Probiotic babies have statistically lower diversity 
compared to non-probiotic. It also revealed Bifidobacterium and Lactobacillus colonize 
the gut of preterm infants at different levels during and after the treatment and they all 
increase with probiotic supplements, which contribute to the decrease of the relative 
abundance of the microbial communities associated with these diseases and hence may 
reduce NEC or LOS in preterm infants. B.bifidum was found to colonize the gut before 
probiotics where administered and Bifidobacteria  are more prevalent in the gut of preterm 
infants and found to proliferate long-term compared to Lactobacilli. Multiple OTUs 
associated with Lactobacillus were detected and qPCR was unable to robustly quantify 
the L. acidophilus used in Infloran raising potential questions about the reported quality 
control of available probiotics. It was conclude that, the findings in this study suggest that 
probiotics have the potentiality to alter the gut bacterial community in preterm infants and 
further work should explore this concept in advance to better understand the systematic 
role of probiotic supplementation. 
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 Metabolomics study 
 
To achieve the above recommendation, the LC-MS metabolomics approach was 
explored. The results showed that metabolite profiles clustered separately, with distinct 
metabolites associated with probiotic administration, but their identification was not 
available. It was suggest that probiotics have some systemic functions and play significant 
role in the gut microbial communities. It was demonstrated that metabolites increased 
during probiotics supplementation, but the identity of these metabolites was not achieved.  
 Antibiotics study 
 
In order to explore the routinely used antibiotics that are usually prescribed to preterm 
infants in a neonatal intensive care unit and to what extent this intervention alters the 
preterm gut microbiome. The 16S rRNA gene profiling was utilised to analyse three 
commonly antibiotics course given to preterm infants in our cohort study (VCM, VC and 
AFG).These three antibiotics courses differentially affected the preterm gut microbiome, 
causing reductions in the diversity. Generally, there is decrease in microbial diversity 
during antibiotics intake for the entire course and an increased at one week after the 
treatment terminated in all the antibiotic mixture with the exception of AFG regimen. 
VCM and VC showed similar pattern of microbial diversity across the time points. It was 
therefore conclude that antibiotics administration may alter the microbial diversity from 
the gut of preterm infants.  
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 Future work 
 
Based on the findings in our study, the following recommendations and projections can 
be considered into future study: 
 Sampling from other NICUs for comparisons of different clinical and nutritional 
intervention can be tailored accordingly. 
 Further molecular studies exploring metabolomics approach and next generation 
sequencing to investigate systematic functions and genetic profiles of the archeal 
and fungal microbial communities from the gut of preterm infants should be 
employed. 
 Further work should be conducted utilising specific primer set for targeting 
particular bacteria based on time intervals that were suggested as putative 
pathogens responsible for NEC. Future studies should aim to compare resected 
tissue and stool to determine if bacterial load is involved in NEC pathogenesis and 
if stool provides an accurate means of quantification. 
 Exploring functional metabolite changes may provide important information on 
mechanisms of action of interventions such as probiotics, and should be 
considered for inclusion into future interventional trials. Future studies should 
explore this concept further to better understand the mechanistic role of probiotics 
supplementation 
 Further study is necessary on other antibiotic regimens that are routinely given to 
preterm infants and their clinical impacts in health and disease as our study is 
limited to particular course due to unavailability of the desired samples from other 
combinations. Also future work is necessary to determine the contribution of these 
changes to health and how medical intervention can be tailored to achieve optimal 
outcomes for preterm infants.   
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Appendices 
 
Appendix 1- Dyes 
 
Bromophenol blue (6x concentrate)  
 
Preparation: Bromophenol blue was prepared at 6× concentrate and diluted 
appropriately with the sample as required as follows: 
0.025g Bromophenol blue  
4.0g Sucrose   
dH2O to 1 L  
DCode Dye  
 
DCode dye was added to the „high‟ denaturing solution so that the efficacy of mixing  
between the low and high solutions when pouring the gradient for the DGGE gel could 
be established. The solution was prepared as follows;   
0.05g    Bromophenol blue  
0.05g     Xylene cyanol  
1x TAE up to 10 ml 
DGGE loading dye (2× concentrate)  
 
DGGE loading dye was prepared at 2× concentrate and diluted appropriately with the 
sample as required. The solution was prepared as below: 
 
Step 1 - 2% (w/v) solution of bromophenol blue and xylene cyanol 
A 2% (w/v) solution of bromophenol blue and a 2% (w/v) solution of xylene cyanol were 
prepared by dissolving 0.002g of each solid in 1 mL dH2O.  
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Step 2 – Make up to 10 mL 
 
0.25ml 2% (w/v) bromophenol blue  
0.25ml 2% (w/v) xylene cyanol  
7.0ml 100% glycerol  
2.5ml dH2O 
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Appendix 2- TAE Buffer   
 
TAE buffer was prepared at 50x concentrate then diluted as required.  
100ml EDTA pH 8.0;  
Step 1  
18.61g EDTA  
100ml dH2O  
The beaker containing the EDTA and 50ml dH2O was placed on to a magnetic stirrer and 
the pH was measured throughout. Sodium hydroxide pellets were added to the solution 
until the solution was at pH 8.0. Addition dH2O was added as required to achieve a final 
volume of 100ml.    
Step 2  
242g Tris base ultrapure  
57.1ml Glacial acetic acid  
100ml EDTA pH 8.0  dH2O to 1L  
The Tris base was weighed and placed into a 1L Duran bottle along with the glacial acetic 
acid and the EDTA which was prepared fresh as described above. The buffer was then 
made up to 1L with dH2O.  
To make 1x TAE dilute 1 part 50x TAE in 49 parts dH2O 
 
200 mL EDTA pH 8.0 
 
Step 1  
37.22 g EDTA 
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200 mL dH2O 
 
A beaker containing the EDTA and ~150 mL dH2O was placed on to a magnetic stirrer 
and the pH was measured throughout. Sodium hydroxide pellets were added to the 
solution until the solution was at pH 8.0. dH2O was added to achieve a final volume of 
200 mL.  
 
Step 2 – Make up 2 L 
 
484g Tris base ultrapure  
114.2 mL Glacial acetic acid  
200 mL EDTA pH 8.0  dH2O to 2L 
 
The Tris base was weighed and placed into a 1L Duran bottle along with the glacial acetic 
acid and the EDTA which was prepared fresh as described above. dH2O was added to 
achieve a final volume of 2 L.  
 
To make 1 L of 1× TAE: dilute 20 mL of 50x TAE in 980 mL dH2O.
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Appendix 3 – DGGE denaturing solutions 
 
Reagent  
Bacterial  Fungal 
34% 55% 40% 60% 
40% (v/v) acrylamide 
(37.5:1 
acrylamide:bisacrylamide)  
30 mL 30 mL 30 mL 30 mL 
50x TAE  2 mL  2 mL  2 mL  2 mL  
Deionised formamide  13.6 mL 22 mL 16 mL 24 mL 
Urea (electrophoresis 
grade)  
14.28 g  23.1 g  16.8 g 25.2 g 
dH2O  To 100 mL  To 100 mL  To 100 mL  To 100m L  
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Appendix 4 – SOC media 
 
Step 1 – Prepare solutions 
Prepare the following solutions: 
1M NaCl  
0.5844 g NaCl  
dH2O to 10 mL 
 
1M KCl  
0.7455 g KCl  
DH2O to 10 mL  
 
2M Mg2+ stock  
2.330 g MgCl2 • 6H2O  
2.465 g MgSO4 • 7H2O  
dH2O to 10 mL filter sterilise with a 0.22 μM filter  
 
2M glucose  
3.603 g Glucose  
dH2O to 10 mL filter sterilise with a 0.22 μM filter  
 
Step 2 – Make the media 
 
To make the media add; 
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2.0 g Tryptone  
0.5 g Yeast extract  
1 mL 1M NaCl  
1 mL 1M KCl  
dH2O to 100 mL 
 
Autoclave and allow to cool to room temperature. Then add;  
 
1 mL 2M Mg2+  
1 mL 2M glucose  
Check the pH is 7.0, adjust accordingly if it is not. 
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Appendix 5 – Luria-Bertani media  
 
Basic recipe (per Litre)  
 
Tryptone 10 g  
Yeast Extract 5 g  
Sodium Chloride 5 g  
Agar 15 g (For broth omit agar from the recipe) 
 
Autoclave at 121°C for 45 minutes and allows cooling to 50 °C and pouring ~ 20 mL in 
to each Petri dish. 
JM109 LB plates (LB/ampicillin/IPTG/X-Gal) 
 
Once the media from the basic recipe has cooled to 50 °C add Ampicillin (100 μg/mL), 
IPTG (0.5 mM), and X-Gal (80 μg/mL) to the media and pour as described above. 
 
Antibiotic selection broth  
 
Omit agar from the basic recipe and then proceed as described above. When the media 
has cooled to 50 °C add Ampicillin (100 μg/mL). For plates pour as described above and 
for broths dispense 5mL aliquots into sterile glass universals. 
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Appendix 6 - The PCR-DGGE Analysis for Archaeal and Fungal 
Microbial diversity from the gut of preterm infants with 
Necrotising enterocolitis and Sepsis  
 
Summary  
 The aim was to compare the archaeal and fungal diversity from patients that have had 
NEC or sepsis compared to healthy controls. Due to the fastidious nature of Archaea and 
their low abundance in most microbial community and the lack of data on archaeal 
communities in relation to preterm infants, it was aimed to map the diversity of Archaea 
in the gut of preterm infants to identify any significant correlation between their presence 
and disease outcomes. 
A total of 43 (NEC, Sepsis and Nec/Sepsis) test DNA samples and 24 Controls (NEC and 
Sepsis) were identified from the demographic data. The parameters used to identify 
infants for the study and controls include: Mode of delivery, Sex, Birth weight, 
Gestational Age. Emphasis was given to samples analysed on two days, one and two 
weeks before and after the occurrence of NEC/Sepsis respectively. DNA extracts were 
analysed by PCR-DGGE for assessment of the total archaeal and fungal communities by 
analysis of 16S bacterial profiling and 28S fungal rRNA genes respectively. Relevant 
Primers were used for the analysis. 
After the analysis, the DGGE data were subjected to statistical software using Phoretix 
ID and Conoco to analyse the association and impact between archeal and fungal 
communities in the cohort study. No significant community profiles for either archeal or 
fungal communities were obtained from the analysis. Sequencing of excised DGGE bands 
from archeal analysis did not yield any recognisable Archaea-like sequences. In the 
analysis of fungal communities, low diversity in the fungal DGGE was found. 
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It was conclude that, DGGE analysis of the archaeal community in the preterm gut 
showed low diversity with no characteristic community profiles distinguishable. The 
fungal DGGE from the preterm cohort study likewise had low diversity. Further work has 
to be done to investigate systematic function molecular analysis of the archaeal and fungal 
microbiota from the gut of preterm infants using other established molecular techniques. 
 
Archaeal PCR- DGGE analysis 
 
After producing the archeal ladder, series of DNA samples from our cohort study were 
selected and undergo PCR-DGGE analysis Most of the gels produce no any desired 
bands. A clean amplified DNA sample produced was selected and prepared for 
sequencing. The results showed no archaeal-like distinguishable profiles. 
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Fungal PCR- DGGE Analysis  
 
After confirming the fungal ladder, the desired amplified DNA samples were loaded 
alongside with the DGGE Ladder. The DGGE analyses of the fungal community 
produced few distinct band positions on some lanes corresponding to the band position 
from the ladder while others produces the bands at the top or below the ladder bands 
(Figure 10). Low diversity of fungal community from the gut of preterm infants after 
DGGE analysis using phoretix ID was observed. 
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Appendix 7 - Quantitative analysis of gut microbial flora in preterm 
infants associated with Necrotising enterocolitis  
 
qPCR raw data for Eubacteria 
 
PATI
ENT 
NO 
SAM
PLE 
ME
AN 
CQ 
ME
AN 
SD 
MEAN 
COPIE
S 
DILU
TION 
1 
DILU
TION 
2 
COPIES 
0.1G 
STOOL 
COPIES 
1G 
STOOL 
139 554 16.7
8263 
0.35
3494 
103187
.6841 
20 5 10318768.
41 
10318768
4.1 
 590 11.9
4395 
0.88
2166 
305501
1.276 
20 5 305501127
.6 
30550112
76 
 619 16.2
2536 
0.28
2551 
149685
.1936 
20 5 14968519.
36 
14968519
3.6 
 678 14.7
5834 
0.40
0781 
411954
.1584 
20 5 41195415.
84 
41195415
8.4 
 716 13.5
4159 
0.12
6836 
924692
.5656 
20 5 92469256.
56 
92469256
5.6 
140 555 13.9
3422 
0.21
3551 
710592
.169 
20 5 71059216.
9 
71059216
9 
 592 16.6
8139 
0.96
8853 
122648
.3069 
20 5 12264830.
69 
12264830
6.9 
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 621 13.0
7236 
2.02
5927 
196637
6.365 
20 5 196637636
.5 
19663763
65 
161 838 16.6
4041 
0.29
9257 
112971
.8903 
20 5 11297189.
03 
11297189
0.3 
 868 17.6
8956 
0.13
4863 
54641.
97324 
20 5 5464197.3
24 
54641973
.24 
 961 11.7
0303 
0.17
2915 
324723
0.518 
20 5 324723051
.8 
32472305
18 
223 2283 16.1
8425 
0.11
1225 
152401
.5905 
20 5 15240159.
05 
15240159
0.5 
 2331 16.8
5005 
0.11
9727 
96812.
28639 
20 5 9681228.6
39 
96812286
.39 
 2442 15.3
3753 
0.05
3719 
271117
.6542 
20 5 27111765.
42 
27111765
4.2 
 2499 13.1
481 
0.06
0106 
120701
5.326 
20 5 120701532
.6 
12070153
26 
 2615 14.7
9711 
0.21
9668 
394693
.8472 
20 5 39469384.
72 
39469384
7.2 
171 1085 15.6
8618 
0.65
1839 
226842
.7872 
20 5 22684278.
72 
22684278
7.2 
 1113 16.0
6468 
0.81
3804 
180619
.6895 
20 5 18061968.
95 
18061968
9.5 
227 
 
 1168 17.4
2679 
0.11
6099 
65318.
06014 
20 5 6531806.0
14 
65318060
.14 
 1272 18.4
9748 
0.12
7985 
31485.
14995 
20 5 3148514.9
95 
31485149
.95 
176 1239 12.1
2836 
0.18
4127 
243129
9.587 
20 5 243129958
.7 
24312995
87 
 1349 12.7
186 
0.27
159 
736064
5.222 
20 5 736064522
.2 
73606452
22 
 1435 13.5
0389 
0.12
5228 
413220
0.925 
20 5 413220092
.5 
41322009
25 
180 1257 13.8
4325 
0.43
6919 
332857
3.342 
20 5 332857334
.2 
33285733
42 
 1293 18.5
5365 
0.22
2149 
108489
.3812 
20 5 10848938.
12 
10848938
1.2 
 1325 16.1
6197 
0.34
3799 
617695
.1439 
20 5 61769514.
39 
61769514
3.9 
 1388 19.7
4462 
0.37
2085 
46579.
90192 
20 5 4657990.1
92 
46579901
.92 
181 1258 13.9
5778 
0.01
9626 
296977
3.325 
20 5 296977332
.5 
29697733
25 
 1299 18.8
9762 
0.37
1241 
85828.
54411 
20 5 8582854.4
11 
85828544
.11 
228 
 
 1327 15.9
1561 
0.44
2012 
748408
.8029 
20 5 74840880.
29 
74840880
2.9 
 1377 18.2
8296 
0.58
2099 
138062
.509 
20 5 13806250.
9 
13806250
9 
188 1394 17.3
8801 
0.15
0232 
250505
.4647 
20 5 25050546.
47 
25050546
4.7 
 1446 14.2
7733 
0.09
7237 
236164
2.697 
20 5 236164269
.7 
23616426
97 
 1476 14.4
5283 
0.12
4016 
208263
4.076 
20 5 208263407
.6 
20826340
76 
 1509 20.3
6723 
0.29
0105 
29450.
62401 
20 5 2945062.4
01 
29450624
.01 
222 2173 19.4
5075 
0.02
6734 
56288.
80227 
20 5 5628880.2
27 
56288802
.27 
 2235 15.7
3972 
0.09
322 
821534
.9019 
20 5 82153490.
19 
82153490
1.9 
 2398 13.6
9541 
0.27
4813 
363491
1.474 
20 5 363491147
.4 
36349114
74 
 2263 14.6
4686 
0.39
5441 
185635
8.558 
20 5 185635855
.8 
18563585
58 
 2301 17.9
8807 
0.32
9352 
165013
.2285 
20 5 16501322.
85 
16501322
8.5 
229 
 
191 1579 17.7
7467 
0.33
6532 
191554
.0296 
20 5 19155402.
96 
19155402
9.6 
 1720 18.2
6061 
0.12
6361 
133183
.1688 
20 5 13318316.
88 
13318316
8.8 
 1776 12.7
1592 
0.25
5265 
736104
3.187 
20 5 736104318
.7 
73610431
87 
 1959 18.7
5103 
0.60
517 
99754.
37561 
20 5 9975437.5
61 
99754375
.61 
152 780 17.4
3428 
0.31
1192 
370479
6.491 
20 5 370479649
.1 
37047964
91 
 850 17.0
4649 
0.91
0074 
542535
3.021 
20 5 542535302
.1 
54253530
21 
 957 19.2
9823 
0.96
4772 
109686
5.86 
20 5 109686586 10968658
60 
178 1268 19.1
8543 
0.93
7519 
120851
8.138 
20 5 120851813
.8 
12085181
38 
 1343 19.7
1087 
0.68
4755 
768520
.2887 
20 5 76852028.
87 
76852028
8.7 
 1376 18.9
8545 
0.11
3309 
120123
1.321 
20 5 120123132
.1 
12012313
21 
186 1421 18.0
7124 
0.85
4738 
263999
8.775 
20 5 263999877
.5 
26399987
75 
230 
 
 1491 17.6
9373 
0.92
379 
342374
6.058 
20 5 342374605
.8 
34237460
58 
 1526 17.0
4032 
0.50
2501 
498657
6.828 
20 5 498657682
.8 
49865768
28 
281 3362 18.8
2548 
1.11
1896 
166434
3.312 
20 5 166434331
.2 
16643433
12 
 3369 17.8
9848 
0.67
491 
280013
8.537 
20 5 280013853
.7 
28001385
37 
 3382 20.0
9416 
0.33
7063 
552673
.102 
20 5 55267310.
2 
55267310
2 
 3407 20.5
2689 
0.61
8198 
422576
.7866 
20 5 42257678.
66 
42257678
6.6 
307 3645 22.1
3913 
0.88
6655 
144023
.2861 
20 5 14402328.
61 
14402328
6.1 
 3667 21.1
2232 
1.23
6884 
319513
.4419 
20 5 31951344.
19 
31951344
1.9 
 3685 20.0
5603 
0.31
8486 
565968
.2699 
20 5 56596826.
99 
56596826
9.9 
229 2472 21.9
6441 
0.21
3252 
142906
.1816 
20 5 14290618.
16 
14290618
1.6 
315 3699 21.8
3649 
1.16
3065 
187954
.9123 
20 5 18795491.
23 
18795491
2.3 
231 
 
292 3450 18.3
1156 
0.29
9822 
197236
9.568 
20 5 197236956
.8 
19723695
68 
176 1250 19.3
1453 
0.45
6952 
279225
.4321 
40 5 55845086.
43 
55845086
4.3 
161 984 16.0
2937 
0.40
3188 
307252
3.619 
40 5 614504723
.8 
61450472
38 
176 1287 19.1
1622 
0.75
3285 
347395
.4197 
40 5 69479083.
93 
69479083
9.3 
307 3589 18.7
9154 
0.14
7156 
396654
.8337 
40 5 79330966.
75 
79330966
7.5 
152 822 18.0
8165 
1.68
7845 
956512
.7024 
40 5 191302540
.5 
19130254
05 
171 1183 21.3
63 
0.51
8433 
63359.
90589 
10 5 3167995.2
95 
31679952
.95 
161 1081 23.0
327 
1.26
4422 
24114.
74707 
10 5 1205737.3
54 
12057373
.54 
188 1615 25.5
922 
2.22
6755 
5274.0
85298 
10 5 263704.26
49 
2637042.
649 
303 3590 22.6
5555 
1.14
3021 
28331.
72908 
10 5 1416586.4
54 
14165864
.54 
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Demographic data of Eubacteria qPCR 
A - NEC Babies 
 
 
Samples StorenumbeJohnptnumbAgeattest DeliverymodBirthweightGA Reviewed byNEC NECdayonset
90015518 554 139 14 CS Breeh poo 1470 30 JB Y (medical) 28
90015518 590 139 21 CS Breeh poo 1470 30 JB Y (medical) 28
90015518 619 139 27 CS Breeh poo 1470 30 JB Y (medical) 28
90015518 678 139 36 CS Breeh poo 1470 30 JB Y (medical) 28
90015518 716 139 42 CS 1470 30 JB Y (medical) 28
90016504 838 161 16 V 700 25 JB Y (Sx) 31
90016504 868 161 19 V 700 25 JB Y (Sx) 31
90016504 961 161 32 V 700 25 JB Y (Sx) 31
90016504 984 161 35 V 700 25 JB Y (Sx) 31
90016504 1081 161 47 V 700 25 JB Y (Sx) 31
90017219 1085 171 9 V 790 26 JB Y 19
90017219 1113 171 12 V 790 26 JB Y 19
90017219 1168 171 19 V 790 26 JB Y 19
90017219 1183 171 21 V 790 26 JB Y 19
90017219 1272 171 36 V 790 26 JB Y 19
91169570 1257 180 7 V 500 22 JB Y(sx_) 16
91169570 1293 180 11 V 500 23 JB Y(sx_) 16
91169570 1325 180 15 V 500 23 JB Y(sx_) 16
91169570 1388 180 23 V 500 23 JB Y(sx_) 16
90018108 1394 188 4 V 750 24 JB Possible 15
90018108 1446 188 10 V 750 24 JB Possible 15
90018108 1476 188 15 V 750 24 JB Possible 15
90018108 1509 188 19 V 750 24 JB Possible 15
90018108 1615 188 29 V 750 24 JB Possible 15
90018699 1579 199 11 V 725 25 JB Y (Sx) 25
90018699 1720 199 19 V 725 25 JB Y (Sx) 25
90018699 1776 199 24 V 725 25 JB Y (Sx) 25
90018699 1959 199 38 V 725 25 JB Y (Sx) 25
90017650 1268 178 14 CS 525 26 JB P (complex!))
90017650 1343 178 24 CS 525 26 JB P (complex!))
90017650 1376 178 28 CS 525 26 JB P (complex!))
90029077 3362 281 8 CS 620 25 N 22
90029077 3369 281 21 CS 620 25 N 22
90029077 3382 281 28 CS 620 25 N 22
90029077 3407 281 37 CS 620 25 N 22
90031153 3590 303 17 V 960 25 N 5
90032123 3699 315 9 24 N 10
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B  Control Babies 
 
Samples StorenumbeJohnptnumbAgeattest DeliverymodBirthweightGA Reviewed byNEC
90015519 555 140 14 CS poor GIT 1455 30 JB N
90015519 592 140 21 CS poor GIT 1455 30 JB N
90015519 621 140 27 CS 1455 30 JB N
90019862 2283 223 15 V 885 25 N
90019862 2331 223 20 V 885 25 N
90019862 2442 223 31 V 885 25 N
90019862 2499 223 36 V 885 25 N
90019862 2615 223 48 V 885 25 N
90017582 1239 176 10 CS 880  JB N
90017582 1250 176 12 CS 880 26 JB N
90017582 1287 176 16 CS 880 26 JB N
90017582 1349 176 25 CS 880 26 JB N
90017582 1435 176 35 CS 880 26 JB N
91169448 1258 181 8 V 570 23 JB N
91169448 1299 181 12 V 570 23 JB N
91169448 1327 181 17 V 570 23 JB N
91169448 1377 181 23 V 570 23 JB N
90019802 2173 222 5 V 620 24 JB N
90019802 2235 222 11 V 620 24 JB N
90019802 2398 222 28 V 620 24 JB N
90019802 2263 222 15 V 620 24 JB N
90019802 2301 222 19 V 620 24 JB N
780 152 14 V 800 25 JB N
822 152 20 V 800 25 JB N
850 152 24 V 800 25 JB N
957 152 39 V 800 25 JB N
90017984 1421 186 14 CS 840 26 JB N
90017984 1491 186 23 CS 840 26 JB N
90017984 1526 186 28 CS 840 26 JB N
90031465 3589 307 #VALUE! V 810 25 JB N
90031465 3645 307 #VALUE! V 810 25 JB N
90031465 3667 307 #VALUE! V 810 25 JB N
90031465 3685 307 #VALUE! V 810 25 JB N
90020240 2472 229 16 V 910 25 JB N
90029891 3450 292 9 V 680 24 JB N
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Appendix 8 -   Molecular characterisation of Probiotics supplementation from the gut of preterm infants and its 
impacts in the development of NEC and sepsis 
A – Probiotics NGS Demographic data 
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Probiotic 
Start 
Probiotic 
Stop Sample 
Patient 
number 
Age 
attest Remark Delivery mode Sex 
Birth 
weight GA 
Control Control 3090 263 12 Control CS F 550 27 
Control Control 3094 263 13 Control CS F 550 27 
Control Control 3099 263 15 Control CS F 550 27 
Control Control 3106 263 16 Control CS F 550 27 
Control Control 3108 263 17 Control CS F 550 27 
Control Control 3120 263 19 Control CS F 550 27 
Control Control 3127 263 20 Control CS F 550 27 
Control Control 3134 263 22 Control CS F 550 27 
Control Control 3140 263 23 Control CS F 550 27 
Control Control 3149 263 26 Control CS F 550 27 
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Control Control 3153 263 27 Control CS F 550 27 
Control Control 3159 263 28 Control CS F 550 27 
Control Control 3162 263 29 Control CS F 550 27 
Control Control 3168 263 32 Control CS F 550 27 
31 61 3191 270 9 Before V M 750 25 
31 61 3230 270 28 Before V M 750 25 
31 61 3262 270 39 During V M 750 25 
31 61 3278 270 46 During V M 750 25 
31 61 3299 270 59 During V M 750 25 
31 61 3309 270 65 After V M 750 25 
31 61 3328 270 71 After V M 750 25 
238 
 
31 61 3338 270 77 After V M 750 25 
31 61 PD 270 PD After V M 750 25 
Control Control 3224 271 3 Control V F 2030 31 
Control Control 3240 271 9 Control V F 2030 31 
Control Control 3250 271 11 Control V F 2030 31 
Control Control 3255 271 14 Control V F 2030 31 
Control Control 3267 271 18 Control V F 2030 31 
Control Control 3282 271 26 Control V F 2030 31 
Control Control 3295 271 35 Control V F 2030 31 
Control Control 3225 272 3 Control V  1535 31 
Control Control 3232 272 6 Control V  1535 31 
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Control Control 3245 272 10 Control V  1535 31 
Control Control 3254 272 14 Control V  1535 31 
Control Control 3266 272 18 Control V  1535 31 
Control Control 3281 272 25 Control V  1535 31 
Control Control 3290 272 31 Control V  1535 31 
14 28 3231 273 9 Before CS F 945 27 
14 28 3238 273 12 Before CS F 945 27 
14 28 3273 273 25 During CS F 945 27 
14 28 3276 273 27 After CS F 945 27 
14 28 3300 273 40 After CS F 945 27 
14 28 3310 273 47 After CS F 945 27 
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14 28 3322 273 50 After CS F 945 27 
14 28 3331 273 54 After CS F 945 27 
14 28 3343 273 63 After CS F 945 27 
14 28 3347 273 66 After CS F 945 27 
12 70 3235 274 9 Before V M 700 24 
12 70 3242 274 12 During V M 700 24 
12 70 3248 274 13 During V M 700 24 
12 70 3253 274 16 During V M 700 24 
12 70 3263 274 20 During V M 700 24 
12 70 3269 274 23 During V M 700 24 
12 70 3274 274 25 During V M 700 24 
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12 70 3279 274 27 During V M 700 24 
12 70 3284 274 31 During V M 700 24 
12 70 3288 274 33 During V M 700 24 
12 70 3298 274 38 During V M 700 24 
12 70 3305 274 43 During V M 700 24 
12 70 3316 274 48 During V M 700 24 
12 70 3333 274 53 During V M 700 24 
12 70 3339 274 59 During V M 700 24 
12 70 3345 274 64 During V M 700 24 
12 70 PD 274 PD During V M 700 24 
3 12 3236 275 6 During CS  1100 28 
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3 12 3244 275 9 During CS  1100 28 
3 12 3247 275 10 During CS  1100 28 
3 12 3268 275 19 After CS  1100 28 
3 12 3271 275 21 After CS  1100 28 
8 26 3302 276 37 After CS  1150 28 
8 26 3237 276 7 Before CS  1150 28 
8 26 3243 276 9 During CS  1150 28 
8 26 3259 276 15 During CS  1150 28 
8 26 3270 276 21 During CS  1150 28 
8 26 3280 276 24 During CS  1150 28 
8 26 3286 276 29 After CS  1150 28 
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14 26 3296 277 6 Before CS  620 24 
14 26 3318 277 16 During CS  620 24 
14 26 3340 277 27 After CS  620 24 
5 73 3301 278 7 During CS  620 24 
5 73 3307 278 13 During CS  620 24 
5 73 3315 278 15 During CS  620 24 
5 73 3317 278 16 During CS  620 24 
5 73 3326 278 19 During CS  620 24 
5 73 3330 278 20 During CS  620 24 
5 73 3341 278 29 During CS  620 24 
5 73 3348 278 35 During CS  620 24 
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5 73 3350 278 38 During CS  620 24 
5 73 PD 278 PD During CS  620 24 
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B – Probiotics Diversity Demographic data 
 
Sample Patient 
Number 
Age attest Probiotic 
Start 
Probiotic 
Stop 
Remark 
3090 263 12 Control Control Control 
3094 263 13 Control Control Control 
3099 263 15 Control Control Control 
3106 263 16 Control Control Control 
3108 263 17 Control Control Control 
3120 263 19 Control Control Control 
3127 263 20 Control Control Control 
3134 263 22 Control Control Control 
3140 263 23 Control Control Control 
3149 263 26 Control Control Control 
3153 263 27 Control Control Control 
3159 263 28 Control Control Control 
3162 263 29 Control Control Control 
3168 263 32 Control Control Control 
3191 Patient 270 9 31 61 Before 
3230 Patient 270 28 31 61 Before 
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3262 Patient 270 39 31 61 During 
3278 Patient 270 46 31 61 During 
3299 Patient 270 59 31 61 During 
3309 Patient 270 65 31 61 After 
3328 Patient 270 71 31 61 After 
3338 Patient 270 77 31 61 After 
3224 Patient 271 3 Control   Control 
3240 Patient 271 9 Control   Control 
3250 Patient 271 11 Control   Control 
3255 Patient 271 14 Control   Control 
3267 Patient 271 18 Control   Control 
3282 Patient 271 26 Control   Control 
3295 Patient 271 35 Control   Control 
3225 Patient 272 3 Control   Control 
3232 Patient 272 6 Control   Control 
3245 Patient 272 10 Control   Control 
3254 Patient 272 14 Control   Control 
3266 Patient 272 18 Control   Control 
3281 Patient 272 25 Control   Control 
3290 Patient 272 31 Control   Control 
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3231 Patient 273 9 14 28 Before 
3238 Patient 273 12 14 28 Before 
3273 Patient 273 25 14 28 During 
3276 Patient 273 27 14 28 During 
3300 Patient 273 40 14 28 After 
3310 Patient 273 47 14 28 After 
3322 Patient 273 50 14 28 After 
3331 Patient 273 54 14 28 After 
3343 Patient 273 63 14 28 After 
3235 Patient 274 9 12 70 Before 
3242 Patient 274 12 12 70 During 
3248 Patient 274 13 12 70 During 
3253 Patient 274 16 12 70 During 
3263 Patient 274 20 12 70 During 
3269 Patient 274 23 12 70 During 
3274 Patient 274 25 12 70 During 
3279 Patient 274 27 12 70 During 
3284 Patient 274 31 12 70 During 
3288 Patient 274 33 12 70 During 
3298 Patient 274 38 12 70 During 
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3305 Patient 274 43 12 70 During 
3316 Patient 274 48 12 70 During 
3333 Patient 274 53 12 70 During 
3339 Patient 274 59 12 70 During 
3345 Patient 274 64 12 70 During 
3236 Patient 275 6 3 12 During 
3244 Patient 275 9 3 12 During 
3247 Patient 275 10 3 12 During 
3268 Patient 275 19 3 12 After 
3271 Patient 275 21 3 12 After 
3302 Patient 276 37 8 26 After 
3237 Patient 276 7 8 26 Before 
3243 Patient 276 9 8 26 During 
3259 Patient 276 15 8 26 During 
3270 Patient 276 21 8 26 During 
3280 Patient 276 24 8 26 During 
3286 Patient 276 29 8 26 After 
3296 Patient 277 6 14 26 Before 
3318 Patient 277 16 14 26 During 
3340 Patient 277 27 14 26 After 
249 
 
3301 Patient 278 7 5 73 During 
3307 Patient 278 13 5 73 During 
3315 Patient 278 15 5 73 During 
3317 Patient 278 16 5 73 During 
3326 Patient 278 19 5 73 During 
3330 Patient 278 20 5 73 During 
3341 Patient 278 29 5 73 During 
3348 Patient 278 35 5 73 During 
3350 Patient 278 38 5 73 During 
 
  
250 
 
C - Probiotics QPCR Demographic data 
  
Sampl
e 
Patient 
Number 
Age attest GA Probiotic 
Start 
Probiotic 
Stop 
Remark 
3090 263 12 27 Control Control Control 
3149 263 26 27 Control Control Control 
3197 263 41 27 Control Control Control 
3215 263 48 27 Control Control Control 
3221 263 53 27 Control Control Control 
3226 263 57 27 Control Control Control 
3258 263 69 27 Control Control Control 
3297 263 89 27 Control Control Control 
3320 263 100 27 Control Control During 
3337 263 108 27 Control Control Control 
PD 270 PD 25 PD PD PD 
3230 270 28 25 31 61 Before 
3262 270 39 25 31 61 During 
3278 270 46 25 31 61 During 
3299 270 59 25 31 61 During 
3309 270 65 25 31 61 After 
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3328 270 71 25 31 61 After 
3338 270 77 25 31 61 After 
3224 271 3 31 Control Control Control 
3240 271 9 31 Control Control Control 
3250 271 11 31 Control Control Control 
3255 271 14 31 Control Control Control 
3267 271 18 31 Control Control Control 
3282 271 26 31 Control Control Control 
3295 271 35 31 Control Control Control 
3225 272 3 31 Control Control Control 
3232 272 6 31 Control Control Control 
3245 272 10 31 Control Control Control 
3254 272 14 31 Control Control Control 
3266 272 18 31 Control Control Control 
3281 272 25 31 Control Control Control 
3294 272 35 31 Control Control Control 
PD 273 PD 27 PD PD PD 
3231 273 9 27 14 28 Before 
3238 273 12 27 14 28 Before 
3276 273 27 27 14 28 During 
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3300 273 40 27 14 28 After 
3310 273 47 27 14 28 After 
3330 273 40 27 14 28 After 
3331 273 54 27 14 28 After 
PD 274 PD 24 PD PD PD 
3235 274 9 24 12 70 Before 
3242 274 12 24 12 70 During 
3248 274 13 24 12 70 During 
3253 274 16 24 12 70 During 
3263 274 20 24 12 70 During 
3279 274 27 24 12 70 During 
3284 274 31 24 12 70 During 
3298 274 38 24 12 70 During 
3305 274 43 24 12 70 During 
3316 274 48 24 12 70 During 
3333 274 53 24 12 70 During 
3345 274 64 24 12 70 During 
3236 275 6 28 3 12 During 
3244 275 9 28 3 12 During 
3247 275 10 28 3 12 During 
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3268 275 19 28 3 12 After 
3271 275 21 28 3 12 After 
3243 276 9 28 8 26 During 
3259 276 15 28 8 26 During 
3280 276 24 28 8 26 During 
3286 276 29 28 8 26 After 
3296 277 6 24 14 26 Before 
3318 277 16 24 14 26 During 
3340 277 27 24 14 26 After 
PD 278 PD 24 PD PD PD 
3301 278 7 24 5 73 During 
3307 278 13 24 5 73 During 
3315 278 15 24 5 73 During 
3317 278 16 24 5 73 During 
3326 278 19 24 5 73 During 
3341 278 29 24 5 73 During 
3348 278 35 24 5 73 During 
3350 278 38 24 5 73 During 
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Appendix 9 : Lactobacillus spp. qPCR raw data in the cohort 
 
Sample Patient 
number 
SQ Mean SQ Std. Dev mean 
(Log) 
Standard 
deviation 
(log) 
Age 
attest 
Probiotic 
Start 
Probiotic 
Stop 
Remark 
270-PD  0.000 0.000 0.00 0.00 PD PD PD PD 
273-PD  0.000 0.000 0.00 0.00 PD PD PD PD 
274-PD  0.000 0.000 0.00 0.00 PD PD PD PD 
278-PD  0.000 0.000 0.00 0.00 PD PD PD PD 
3090 263 0.000 0.000 0.00 0.00 12 Control Control Control 
3120 263 0.000 0.000 0.00 0.00 19 Control Control Control 
3149 263 0.000 0.000 0.00 0.00 26 Control Control Control 
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3197 263 0.000 0.000 0.00 0.00 41 Control Control Control 
3215 263 0.000 0.000 0.00 0.00 48 Control Control Control 
3221 263 0.000 0.000 0.00 0.00 53 Control Control Control 
3224 271 0.000 0.000 0.00 0.00 3 Control Control Control 
3225 272 0.000 0.000 0.00 0.00 3 Control Control Control 
3226 263 0.000 0.000 0.00 0.00 57 Control Control Control 
3230 270 0.000 0.000 0.00 0.00 28 31 61 Before 
3231 273 0.000 0.000 0.00 0.00 9 14 28 Before 
3232 272 0.000 0.000 0.00 0.00 6 Control Control Control 
3235 274 0.000 0.000 0.00 0.00 9 12 70 Before 
3236 275 0.000 0.000 0.00 0.00 6 3 12 During 
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3238 273 0.00000 0.00000 0.00 0.00 12 14 28 Before 
3240 271 7921483.09259 832340.32746 6.90 5.92 9 Control Control Control 
3242 274 80452.99627 8736.04045 4.91 3.94 12 12 70 During 
3243 276 0.000 0.000 0.00 0.00 9 8 26 During 
3244 275 0.000 0.000 0.00 0.00 9 3 12 During 
3245 272 0.000 0.000 0.00 0.00 10 Control Control Control 
3247 275 0.000 0.000 0.00 0.00 10 3 12 During 
3248 274 0.000 0.000 0.00 0.00 13 12 70 During 
3250 271 0.000 0.000 0.00 0.00 11 Control Control Control 
3253 274 0.00000 0.00000 0.00 0.00 16 12 70 During 
3254 272 0.00000 0.00000 0.00 0.00 14 Control Control Control 
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3255 271 0.00000 0.00000 0.00 0.00 14 Control Control Control 
3258 263 0.00000 0.00000 0.00 0.00 69 Control Control Control 
3259 276 347925.46389 40255.21687 5.54 4.60 15 8 26 During 
3262 270 0.00000 0.00000 0.00 0.00 39 31 61 During 
3263 274 0.00000 0.00000 0.00 0.00 20 12 70 During 
3266 272 1707784.44464 106561.73176 6.23 5.03 18 Control Control Control 
3267 271 787843.16177 118520.59161 5.90 5.07 18 Control Control Control 
3268 275 0.00000 0.00000 0.00 0.00 19 3 12 After 
3271 275 0.00000 0.00000 0.00 0.00 21 3 12 After 
3276 273 0.00000 0.00000 0.00 0.00 27 14 28 During 
3278 270 0.00000 0.00000 0.00 0.00 46 31 61 During 
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3279 274 0.00000 0.00000 0.00 0.00 27 12 70 During 
3280 276 0.00000 0.00000 0.00 0.00 24 8 26 During 
3281 272 0.00000 0.00000 0.00 0.00 25 Control Control Control 
3282 271 0.00000 0.00000 0.00 0.00 26 Control Control Control 
3284 274 0.00000 0.00000 0.00 0.00 31 12 70 During 
3286 276 0.00000 0.00000 0.00 0.00 29 8 26 After 
3294 272 0.00000 0.00000 0.00 0.00 35 Control Control Control 
3295 271 0.00000 0.00000 0.00 0.00 35 Control Control Control 
3296 277 0.00000 0.00000 0.00 0.00 6 14 26 Before 
3297 263 0.00000 0.00000 0.00 0.00 89 Control Control Control 
3298 274 0.000 0.000 0.00 0.00 38 12 70 During 
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3299 270 0.000 0.000 0.00 0.00 59 31 61 During 
3300 273 0.000 0.000 0.00 0.00 40 14 28 After 
3301 278 0.000 0.000 0.00 0.00 7 5 73 During 
3305 274 0.00000 0.00000 0.00 0.00 43 12 70 During 
3307 278 0.000 0.000 0.00 0.00 13 5 73 During 
3309 270 0.000 0.000 0.00 0.00 65 31 61 After 
3310 273 0.000 0.000 0.00 0.00 47 14 28 After 
3315 278 0.000 0.000 0.00 0.00 15 5 73 During 
3316 274 0.000 0.000 0.00 0.00 48 12 70 During 
3317 278 0.000 0.000 0.00 0.00 16 5 73 During 
3318 277 0.000 0.000 0.00 0.00 16 14 26 During 
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3320 263 0.000 0.000 0.00 0.00 100 Control Control Control 
3326 278 0.000 0.000 0.00 0.00 19 5 73 During 
3328 270 0.000 0.000 0.00 0.00 71 31 61 After 
3330 273 0.000 0.000 0.00 0.00 40 14 28 After 
3331 273 0.000 0.000 0.00 0.00 54 14 28 After 
3333 274 0.000 0.000 0.00 0.00 53 12 70 During 
3337 263 0.000 0.000 0.00 0.00 108 Control Control Control 
3338 270 0.000 0.000 0.00 0.00 77 31 61 After 
3340 277 0.000 0.000 0.00 0.00 27 14 26 After 
3341 278 0.000 0.000 0.00 0.00 29 5 73 During 
3345 274 0.000 0.000 0.00 0.00 64 12 70 During 
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3348 278 0.000 0.000 0.00 0.00 35 5 73 During 
3350 278 0.00000 0.00000 0.00 0.00 38 5 73 During 
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Appendix 10: Bifidobacterium spp. qPCR raw data in the cohort 
 
Sample Patient 
Number 
SQ Mean Mean 
(Log) 
SQ Std. Dev St 
deviation 
(Log) 
Age 
attest 
Probiotic 
Start 
Probiotic 
Stop 
Remark 
3268 275 225,888 5.35 166168.86969 5.22 19 3 12 After 
3271 275 15,511,928 7.19 40323.43811 4.61 21 3 12 After 
3286 276 487,850,010 8.69 3033391.64732 6.48 29 8 26 After 
3300 273 25,168,965 7.40 123291.04233 5.09 40 14 28 After 
3309 270 658,850 5.82 112250.62990 5.05 65 31 61 After 
3310 273 17,346,830 7.24 82069.08700 4.91 47 14 28 After 
3328 270 6,292,852 6.80 3206394.42357 6.51 71 31 61 After 
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3330 273 52,193,995 7.72 10559838.49398 7.02 40 14 28 After 
3331 273 32,034,908 7.51 484526.82979 5.69 54 14 28 After 
3338 270 76,263 4.88 7062.52023 3.85 77 31 61 After 
3340 277 0 0.00 0.000 0.00 27 14 26 After 
3230 270 0 0.00 0.000 0.00 28 31 61 Before 
3231 273 0 0.00 0.000 0.00 9 14 28 Before 
3235 274 133,105 5.12 3694.96386 3.57 9 12 70 Before 
3238 273 0 0.00 0.000 0.00 12 14 28 Before 
3296 277 130,002 5.11 9758.40879 3.99 6 14 26 Before 
3090 263 0 0.00 0.000 0.00 12 Control Control Control 
3120 263 0 0.00 0.000 0.00 19 Control Control Control 
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3149 263 0 0.00 0.000 0.00 26 Control Control Control 
3197 263 0 0.00 0.000 0.00 41 Control Control Control 
3215 263 0 0.00 0.00000 0.00 48 Control Control Control 
3221 263 0 0.00 0.000 0.00 53 Control Control Control 
3224 271 0 0.00 0.000 0.00 3 Control Control Control 
3225 272 0 0.00 0.000 0.00 3 Control Control Control 
3226 263 0 0.00 0.000 0.00 57 Control Control Control 
3232 272 0 0.00 0.000 0.00 6 Control Control Control 
3240 271 0 0.00 0.000 0.00 9 Control Control Control 
3245 272 0 0.00 0.000 0.00 10 Control Control Control 
3250 271 0 0.00 0.000 0.00 11 Control Control Control 
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3254 272 0 0.00 0.000 0.00 14 Control Control Control 
3255 271 0 0.00 0.000 0.00 14 Control Control Control 
3258 263 0 0.00 0.000 0.00 69 Control Control Control 
3266 272 0 0.00 0.000 0.00 18 Control Control Control 
3267 271 0 0.00 0.000 0.00 18 Control Control Control 
3281 272 0 0.00 0.000 0.00 25 Control Control Control 
3282 271 0 0.00 0.000 0.00 26 Control Control Control 
3294 272 0 0.00 0.000 0.00 35 Control Control Control 
3295 271 0 0.00 0.000 0.00 35 Control Control Control 
3297 263 0 0.00 0.000 0.00 89 Control Control Control 
3320 263 0 0.00 0.000 0.00 100 Control Control Control 
266 
 
3337 263 0 0.00 0.000 0.00 108 Control Control Control 
3236 275 74,894 4.87 9075.33954 3.96 6 3 12 During 
3242 274 79,564 4.90 2895.98919 3.46 12 12 70 During 
3243 276 90,437 4.96 18702.04048 4.27 9 8 26 During 
3244 275 1,568,726 6.20 5198.74564 3.72 9 3 12 During 
3247 275 1,950,779 6.29 8983.19734 3.95 10 3 12 During 
3248 274 0 0.00 0.00000 0.00 13 12 70 During 
3253 274 2,419,817 6.38 3352.21227 3.53 16 12 70 During 
3259 276 4,964,745 6.70 495588.53475 5.70 15 8 26 During 
3262 270 2,021,199 6.31 2369.52959 3.37 39 31 61 During 
3263 274 0 0.00 0.000 0.00 20 12 70 During 
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3276 273 23,436,334 7.37 75084.95157 4.88 27 14 28 During 
3278 270 1,162,462 6.07 123695.73014 5.09 46 31 61 During 
3279 274 207,123 5.32 19579.01791 4.29 27 12 70 During 
3280 276 22,512,857 7.35 137823.45821 5.14 24 8 26 During 
3284 274 17,761,359 7.25 23096.25195 4.36 31 12 70 During 
3298 274 163,703 5.21 21220.29048 4.33 38 12 70 During 
3299 270 1,537,540 6.19 522465.01326 5.72 59 31 61 During 
3301 278 91,554 4.96 11387.16884 4.06 7 5 73 During 
3305 274 682,730 5.83 26010.93129 4.42 43 12 70 During 
3307 278 73,497 4.87 1487.58565 3.17 13 5 73 During 
3315 278 82,420 4.92 1475.16989 3.17 15 5 73 During 
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3316 274 0 0.00 0.000 0.00 48 12 70 During 
3317 278 431,310 5.63 31263.95858 4.50 16 5 73 During 
3318 277 0 0.00 0.000 0.00 16 14 26 During 
3326 278 0 0.00 0.00000 0.00 19 5 73 During 
3333 274 222,935 5.35 30407.54183 4.48 53 12 70 During 
3341 278 1,095,837 6.04 2284.43704 3.36 29 5 73 During 
3345 274 1,946,796 6.29 7938.05726 3.90 64 12 70 During 
3348 278 0 0.00 0.00000 0.00 35 5 73 During 
3350 278 3,000,712 6.48 83442.00484 4.92 38 5 73 During 
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Appendix 11: MG-RAST Accession number for Probiotic data 
Your MG-RAST IDs: 4615661.3, 4615662.3, 4615663.3, 4615664.3, 4615665.3, 
4615666.3, 4615667.3, 4615668.3, 4615669.3, 4615670.3, 4615671.3, 4615672.3, 
4615673.3, 4615674.3, 4615675.3, 4615676.3, 4615677.3, 4615678.3, 4615679.3, 
4615680.3, 4615681.3, 4615682.3, 4615683.3, 4615684.3, 4615685.3, 4615686.3, 
4615687.3, 4615688.3, 4615689.3, 4615690.3, 4615691.3, 4615692.3, 4615693.3, 
4615694.3, 4615695.3, 4615696.3, 4615697.3, 4615698.3, 4615699.3, 4615700.3, 
4615701.3, 4615702.3, 4615703.3, 4615704.3, 4615705.3, 4615706.3, 4615707.3, 
4615708.3, 4615709.3, 4615710.3, 4615711.3, 4615712.3, 4615713.3, 4615714.3, 
4615715.3, 4615716.3, 4615717.3, 4615718.3, 4615719.3, 4615720.3, 4615721.3, 
4615722.3, 4615723.3, 4615724.3, 4615725.3, 4615726.3, 4615727.3, 4615728.3, 
4615729.3, 4615730.3, 4615731.3, 4615732.3, 4615733.3, 4615734.3, 4615735.3, 
4615736.3, 4615737.3, 4615738.3, 4615739.3, 4615740.3, 4615741.3, 4615742.3, 
4615743.3, 4615744.3, 4615745.3, 4615746.3, 4615747.3, 4615748.3, 4615749.3 
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Appendix 12 - Systematic functional analysis of the gut of preterm infants by probiotic metabolomics profiles 
 
 
 Demographic data of probiotics metabolomics study 
  
Sample Patient Number Age attest Probiotic Start Probiotic Stop Remark 
4289 273 PD PD PD PD 
4324 274 PD PD PD PD 
5086 278 PD PD PD PD 
8975 270 PD PD PD PD 
3197 263 41 Control Control Control 
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3215 263 48 Control Control Control 
3226 263 57 Control Control Control 
3297 263 89 Control Control Control 
3262 270 39 31 61 During 
3299 270 59 31 61 During 
3309 270 65 31 61 After 
3338 270 77 31 61 After 
3224 271 3 Control Control Control 
3255 271 14 Control Control Control 
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3282 271 26 Control Control Control 
3295 271 35 Control Control Control 
3245 272 10 Control Control Control 
3254 272 14 Control Control Control 
3281 272 25 Control Control Control 
3294 272 35 Control Control Control 
3276 273 27 14 28 During 
3300 273 40 14 28 During 
3331 273 54 14 28 After 
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3235 274 9 12 70 Before 
3263 274 20 12 70 During 
3305 274 43 12 70 During 
3345 274 64 12 70 During 
3236 275 6 3 12 During 
3247 275 10 3 12 During 
3268 275 19 3 12 After 
3271 275 21 3 12 After 
3243 276 9 8 26 During 
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3259 276 15 8 26 During 
3280 276 24 8 26 During 
3286 276 29 8 26 After 
3301 278 7 5 73 During 
3315 278 15 5 73 During 
3317 278 16 5 73 During 
3341 278 29 5 73 During 
3348 278 35 5 73 During 
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Demographic data of metabolomics trial samples 
 
Sample No Pt NO. Age attest Probiotic Start Probiotic Stop Remark 
3328-A 270 71 31 61 After 
3328-B 270 71 31 61 After 
3328-C 270 71 31 61 After 
3322-A 273 54 14 28 After 
3322-B 273 54 14 28 After 
3322-C 273 54 14 28 After 
3321-A 274 49 12 70 During 
3321-B 274 49 12 70 During 
3321-C 274 49 12 70 During 
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3244-A 275 9 3 12 During 
3244-B 275 9 3 12 During 
3244-C 275 9 3 12 During 
3237-A 276 7 8 26 Before 
3237-B 276 7 8 26 Before 
3237-C 276 7 8 26 Before 
3340-A 277 27 14 26 After 
3340-B 277 27 14 26 After 
3350-A 278 38 5 73 During 
3350-B 278 38 5 73 During 
3350-C 278 38 5 73 During 
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Appendix 13: Impact of antibiotics course combination on the gut microbial community in preterm infants 
 
Table: Demographic data of Antibiotics course combination  
 
Pts 
No 
GA (weeks) BW (g) Antibiotics 
course 
 Antibiotics course combination* 
222 24 620 VCM 0(G6M6A6) 15(V5C5) 26(V4M4C4) 
188 24 750 VCM 0(P2G2) 12 (A2F2G2) 14 (M9V9C9) 
270 25 750 VCM 0(P,G2) 3 (C5,V7,M8) 14 (C5,V5,M5) 28 (C2,V2) 33 (C2,V2) 
215 27 1180 VCM 0(P2G2) 3(v5C5M5) 
163 24 760 VCM 0(P2,G2)8(M7,V7,C7)20(A2,F2,G2)22(V3,C5)42(V7,M7,C7)69(V2,C2)77(
V2,C2,M2)86(F2,G2) 
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163 24 760 VCM 0(P2,G2)8(M7,V7,C7)20(A2,F2,G2)22(V3,C5)42(V7,M7,C7)69(V2,C2)77(
V2,C2,M2)86(F2,G2) 
277 24 620 VCM 0(P2G2) 12(V7,C7,M7) 
287 24 670 VCM 0 (P6G5Cx6) 4(F7) 17 (A1G1F1) 18(C2M6V6) 19(mero4) 
335   VCM 0(P5G5) 21(A5F5) 26(C6V6M6) 48(C13F13)61(L33) 
336   VCM 0(P2G2) 7(C3V3) 12(C2V2) 14(A8) 28(V15C15M4) 31(A6) 
337   VCM 0(P2G2) 4(V5C5M5) 44 (V3C3M3) 63 (V7C7M7) Y 
356   VCM 0(P2G2) 4(F4G4A4) 27(V10C10M10) 60(A3F3G3) 87 (F2) 
130 27 1000 VC 0(P2G2)1(A7,M7)8(V3,C3)21(V2,C2)23(F14)31(G6)63(A2,F2,G2) 
130 27 1000 VC 0(P2G2)1(A7,M7)8(V3,C3)21(V2,C2)23(F14)31(G6)63(A2,F2,G2) 
153 28 1310 VC 8(C2,V2) 
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161 25 700 VC 0(P2,G2)6(A3,F3,G3)19(V6,C6)20(M5)27(A10,G10,M10)61(A5) 
163 24 760 VC 0(P2,G2)8(M7,V7,C7)20(A2,F2,G2)22(V3,C5)42(V7,M7,C7)69(V2,C2)77(
V2,C2,M2)86(F2,G2) 
171 26 790 VC 0(P3,G3)9(V2C2)13(A3,G3,F3)17(A4,G5,F4)19(M8)21(V6C6) 
228 25 910 VC 0(P2,G2,M2)7(V2,C5)98(A2,F2,G2)118(A5,F6,G5) 
229 25 910 VC 0(P2,G2,M2)3(V6,C8)11(Mer6)20(F3,A3,G3)25(T6)27(M5)38(F1,A1,G1)4
6(Trimethoprim prophylaxis) 
303 26 990 VC 0 (P2G2) 5 (M8A8G7) 14 (A1) 15 (V6C6) 
307 25 810 VC 0 (P2G2) 2(A3F3) 32 (C5V5) 
330 26 990 VC 0(P5G5) 2(F5) 7(V5C5) 16 (A3F3G3) 24 (V2C2) 37 (taz5) 
336   VC 0(P2G2) 7(C3V3) 12(C2V2) 14(A8) 28(V15C15M4) 31(A6) 
336   VC 0(P2G2) 7(C3V3) 12(C2V2) 14(A8) 28(V15C15M4) 31(A6) 
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152 25 800 AFG 0(P2,G2)5(F2,G2,A2) 
167 27 1290 AFG 0(P2,G2)43(A2,F2,G2) 
171 26 790 AFG 0(P3,G3)9(V2C2)13(A3,G3,F3)17(A4,G5,F4)19(M8)21(V6C6) 
181 23 570 AFG 0(P2,G2)13(V3)14(F9)27(T1,C1,V2,G4,Mer17)33(G3)37(G3)41(G3)53(A2, 
F2,G2)61(A2,F2,G2) 
203 26 1130 AFG 0(P2,G2)4(F3,A3,G2) 
206 28 1255 AFG 0(P1,G2)5(A2,F2,G2)13(A3,F3,G3) 
207 29 1580 AFG 0(P2,G2)10(A3,F3,G3) 
232 24 695 AFG 0(P2,G2)7(G2,F6,A2)14(G3,F3,A3)24(A2,F2,G2)31(A5,F5,G5) 
284 25 710 AFG 0(P2G2) 2(C10V10) 27(A3F12G5) 
294 30 1650 AFG 0(P2G2) 28(A2F7G2) 
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313 28 1120 AFG 0 (P2G2) 10 (A2 F2G2) 21 (A4G2M9) 24(V7 C7) 34 (V3C2M3) 43 
(mero2V2) 54 (Mero7 V7) 56 (M5) 
317 28 780 AFG 0(P2G2) 21 (A2F2G2) 
330 26 990 AFG 0(P5G5) 2(F5) 7(V5C5) 16 (A3F3G3) 24 (V2C2) 37 (taz5) 
 
*Antibiotic course combination with the number inside the bracket indicating how many times (days) each specific antibiotic was given, while the 
number outside the bracket indicates the day of life during which antibiotic was given. The alphabets represent the name of antibiotics as:  A – Amoxicillin, 
C – Ceftazidine, F – Flucloxacillin, G – Gentamicin, L – Linezolid, M – Metronidazole, Me – Meropenem, P – Penicillin, T – Tazocin, and V – 
Vancomycin. 
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Table: Clinical characteristics of the infants in Antibiotics cohort study 
 
Patient 
Number 
Frequency of 
occurrence 
Sample 
Number 
Day 
Of 
Life 
Gestational 
Age (weeks) 
Birth 
Weight 
(g) 
Sex Delivery 
Mode 
Antibiotics 
Age (days) 
Antibiotics 
Course 
Duration of 
Antibiotics 
Treatment (days) 
222 4 2362 25 24 620 F V 26 VCM 4 
 
 2411 29        
 
 2429 32        
 
 2475 36        
188 2 1459 12 24 750 F V 14 VCM 9 
 
 1578 39        
270 3 3191 9 25 750 M V 14 VCM 5 
 
 3230 28        
 
 3262 39        
215 4 1984 10 27 1180 M FD 3 VCM 5 
 
 2013 13        
 
 2047 16        
 
 2054 17        
283 
 
163 4 1109 40 24 760 M CS 42 VCM 7 
 
 1188 50        
 
 1227 58        
 
 1238 60        
163 3 1362 76 24 760 M CS 77 VCM 2 
 
 1383 78        
 
 1409 81        
277 3 3296 6 24 620 M CS 12 VCM 7 
 
 3318 16        
 
 3340 27        
287 4 3390 16 24 670 M V 18 VCM 6 
 
 3421 23        
 
 3430 25        
 
 3445 30        
335 4 3899 22     26 VCM 6 
 
 3919 30        
284 
 
 
 3936 33        
 
 3945 39        
336 4 3922 26     28 VCM 15 
 
 3975 42        
 
 4010 46        
 
 4020 50        
337 3 3974 40     44 VCM 3 
 
 4029 49        
 
 4037 51        
356 3 4228 26     27 VCM 10 
 
 4244 35        
 
 4261 44        
130 4 429 8 27 1000 F CS 8 VC 3 
 
 435 11        
 
 439 13        
 
 453 18        
285 
 
130 4 454 19 27 1000 F CS 21 VC 2 
 
 461 22        
 
 467 26        
 
 474 28        
153 4 736 5 28 1310 M CS 8 VC 2 
 
 763 11        
 
 775 13        
 
 803 17        
161 4 849 17 25 700 F CS 19 VC 6 
 
 868 19        
 
 869 20        
 
 961 32        
163 4 867 9 24 760 F CS 22 VC 5 
 
 1010 27        
 
 1089 35        
 
 1109 40        
286 
 
171 4 1085 9 26 790 M V 9 VC 2 
 
 1106 11        
 
 1125 13        
 
 1149 16        
228 4 2378 6 25 910 M V 7 VC 5 
 
 2435 12        
 
 2467 15        
 
 2521 19        
229 4 2348 3 25 910 M V 3 VC 6 
 
 2413 10        
 
 2449 14        
 
 2488 17        
303 4 3568 4 25 960 M V 15 VC 6 
 
 3597 22        
 
 3599 23        
 
 3608 27        
287 
 
307 4 3677 30 25 810 F V 32 VC 5 
 
 3685 37        
 
 3689 39        
 
 3697 41        
330 4 3794 5 26 990 M V 7 VC 3 
 
 3805 11        
 
 3813 13        
 
 3829 18        
336 3 3842 6   M  7 VC 3 
 
 3869 12        
 
 3887 16        
336 4 3881 7   M  7 VC 3 
 
 3878 14        
 
 3880 15        
 
 3906 21        
152 4 731 4 25 800 F V 5 AFG 2 
288 
 
 
 739 6        
 
 750 9        
 
 778 13        
167 4 1228 40 27 1290 F CS 43 AFG 2 
 
 1265 45        
 
 1286 48        
 
 1320 52        
171 4 1113 12 26 790 M V 13 AFG 3 
 
 1142 15        
 
 1168 19        
 
 1183 21        
181 4 1643 54 23 570 M V 61 AFG 2 
 
 1693 66        
 
 1719 68        
 
 1746 71        
203 4 1690 2 26 1130 M V 4 AFG 3 
289 
 
 
 1761 7        
 
 1767 9        
 
 1824 14        
206 4 1736 4 28 1255 M V 5 AFG 2 
 
 1766 7        
 
 1790 9        
 
 1834 13        
207 4 1806 9 29 1580 M CS 10 AFG 3 
 
 1831 12        
 
 1885 16        
 
 1930 19        
232 4 2469 6 24 695 M V 7 AFG 2 
 
 2517 10        
 
 2539 12        
 
 2561 14        
284 4 3398 25 25 710 M CS 27 AFG 3 
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 3422 29        
 
 3426 30        
 
 3435 34        
294 3 3479 26 30 1650 M CS 28 AFG 2 
 
 3483 29        
 
 3488 36        
313 3 3668 9 28 1120 F CS 10 AFG 2 
 
 3678 12        
 
 3683 18        
317 3 3704 20 28 780 F CS 21 AFG 2 
 
 3707 22        
 
 3712 31        
330 4 3815 14 26 990 M V 16 AFG 3 
 
 3829 18        
 
 3846 21        
 
 3867 26        
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Comparison between Mean, Standard Deviation and Standard 
Error of the Most Abundance Taxa 
 
 
Comparison between Mean, Standard deviation and Standard error of the VCM course 
among the most abundance taxa, the colour at the chart matched with the Roman numerals 
colour of the time points, where I =prior to antibiotic intake, II = during, III = immediately 
after and IV = one week after administration. M = OTUs mean, SD = standard deviation 
and SE = standard error. 
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 Comparison between Mean, Standard deviation and Standard error of the VC course in 
the most abundance taxa, the colour at the chart matched with the Roman numerals colour 
of the time points, where I =prior to antibiotic intake, II = during, III = immediately after 
and IV = one week after administration. M = OTUs mean, SD = standard deviation and 
SE = standard error. 
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Comparison between Mean standard deviation and standard error of the AFG course in 
the most abundance taxa, the colour at the chart matched with the Roman numerals colour 
of the time points, where I =prior to antibiotic intake, II = during, III = immediately after 
and IV = one week after administration. M = OTUs mean, SD = standard deviation and 
SE = standard error. 
 
